

What is the effectiveness of community diagnostic centres: a rapid review

Authors: Alesha Wale¹, Chukwudi Okolie¹, Jordan Everitt¹, Amy Hookway¹, Hannah Shaw¹, Kirsty Little¹, Ruth Lewis², Alison Cooper², Adrian Edwards²

¹ Public Health Wales, Wales, United Kingdom

² Wales COVID-19 Evidence Centre, Wales, United Kingdom

Abstract: The COVID-19 pandemic directly impacted diagnostic services in the UK and globally. This exacerbated the rapid rise in demand for diagnostics that existed before the pandemic, resulting in significant numbers of patients requiring various diagnostic services and increased waiting times for diagnostics and treatment. In 2021, community diagnostic centres were launched in England. As diagnostic services account for over 85% of clinical pathways within the NHS and cost over six billion pounds per year, diagnostic centres across a broader range of diagnostic services may be effective, efficient, and cost-effective in the UK health sector.

This rapid review aimed to identify and examine the evidence on the effectiveness of community diagnostic centres. A prior Research Evidence Map was used, along with the stakeholder input, to select a substantive focus for the rapid review. Comparative studies examining community diagnostic centres that accept referrals from primary care as a minimum were included. Prioritised outcomes included those relating to impact on capacity and pressure on secondary care, ensuring equity in uptake or access, and economic outcomes


The review included evidence available up until August 2022. Twenty primary studies were included. Twelve individual diagnostic centres were evaluated across the 20 studies. Most studies evaluated diagnostic centres located within hospital settings. One study evaluated a mobile diagnostic ultrasound service. Most studies were specific to cancer diagnoses. Six studies covered multiple health conditions, which will have also included cancer. Other conditions reported included: severe anaemia, fever of uncertain nature, and multiple sclerosis. A range of outcomes was identified. 11 studies conducted in Spain evaluated the same type of clinic i.e. Quick Diagnostic Unit and seven studies evaluated the same centre at different time intervals. No evidence relating to equity of access was identified.

The evidence relating to effectiveness appeared mixed. There is evidence to suggest that diagnostic centres can reduce various waiting times, including time to surgical consultation, time from consultation to treatment, time from cancer suspicion to treatment, time from diagnosis to specialist consultation and time from diagnosis to treatment. Diagnostic centres could help reduce pressure on secondary care by avoiding hospitalisations in stable patients.

Cost-effectiveness may depend on whether the diagnostic centre is running at full capacity. Factors that could determine the costs incurred by a centre include the diagnostic and clinical complexity of patients, and the characteristics of the unit including the number of staff and contribution of staff time.

Funding statement: Public Health Wales was funded for this work by the Wales COVID-19 Evidence Centre, itself funded by Health & Care Research Wales on behalf of Welsh Government.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.



Wales COVID-19 Evidence Centre (WCEC) Rapid Review

What is the effectiveness of community diagnostic centres: a rapid review Report number – RR00043 (November 2022)

Rapid Review Details

Review conducted by: Public Health Wales (PHW)

Review Team:

- Alesha Wale, Public Health Wales, Alesha.Wale@wales.nhs.uk
- Chukwudi Okolie, Public Health Wales, Chukwudi.Okolie@wales.nhs.uk
- Jordan Everitt, Public Health Wales, Jordan.Everitt2@wales.nhs.uk
- Amy Hookway, Public Health Wales, amy.hookway2@wales.nhs.uk
- Hannah Shaw, Public Health Wales, Hannah.Shaw@wales.nhs.uk
- Kirsty Little, Public Health Wales, Kirsty.Little@wales.nhs.uk

Review submitted to the WCEC: November 2022

Stakeholder consultation meeting: 22nd November 2023

Rapid Review report issued by the WCEC: December 2022

WCEC Team:

Ruth Lewis, Adrian Edwards, Alison Cooper involved in drafting the Topline Summary and editing.

This review should be cited as: RR00043_Wales COVID-19 Evidence Centre_What is the effectiveness of community diagnostic centres: a rapid review. November 2022

Disclaimer: The views expressed in this publication are those of the authors, not necessarily Health and Care Research Wales. The WCEC and authors of this work declare that they have no conflict of interest.

What is the effectiveness of community diagnostic centres: a rapid review

Report number – RR00043 (November 2022)

TOPLINE SUMMARY

What is a Rapid Review?

Our rapid reviews (RR) use a variation of the systematic review approach, abbreviating or omitting some components to generate the evidence to inform stakeholders promptly whilst maintaining attention to bias. They follow the methodological recommendations and minimum standards for conducting and reporting rapid reviews, including a structured protocol, systematic search, screening, data extraction, critical appraisal, and evidence synthesis to answer a specific question and identify key research gaps. They take 1- 2 months, depending on the breadth and complexity of the research topic/ question(s), extent of the evidence base, and type of analysis required for synthesis.

This report is linked to a **rapid evidence map** published as: [REM00043 Wales COVID-19 Evidence Centre](#). A rapid evidence map of what evidence is available on the effectiveness of community diagnostic centres. September 2022

Who is this summary for?

Diagnostics Strategy Board

Background / Aim of Rapid Review

The COVID-19 pandemic directly impacted diagnostic services in the UK and globally. This exacerbated the rapid rise in demand for diagnostics that existed before the pandemic, resulting in **significant numbers of patients requiring various diagnostic services and increased waiting times for diagnostics** and treatment. **In 2021, community diagnostic centres were launched in England.** As diagnostic services account for over 85% of clinical pathways within the NHS and cost over £6 billion per year, **diagnostic centres across a broader range of diagnostic services may be effective, efficient, and cost-effective** in the UK health sector. This rapid review aimed **to identify and examine the evidence on the effectiveness of community diagnostic centres.** The prior REM was used, along with the stakeholder input, to select a substantive focus for the RR. It was decided that only **comparative studies** examining **community diagnostic centres that accept referrals from primary care as a minimum** would be included. Prioritised **outcomes included those relating to impact on capacity and pressure on secondary care, ensuring equity in uptake or access, and economic outcomes.**

Key Findings

Extent of the evidence base

- Twenty **primary studies** were included: 16 quasi-experimental studies (all comparative studies using cross sectional post-test only designs), three economic evaluations and one randomised controlled trial (the latter published in 1998, and now superseded by more recent research).
- Twelve individual diagnostic centres were evaluated across the 20 studies.
- Most studies (n=19) evaluated diagnostic centres **located within hospital settings**. One study evaluated a mobile diagnostic ultrasound service.
- Most studies (n=10) were specific to **cancer diagnoses**. Six studies covered **multiple health conditions**, which will have also included cancer. Other conditions reported

included: **severe anaemia** (n=1), **fever of uncertain nature** (n=1), and **multiple sclerosis** (n=1). **One study did not report a particular health condition of interest.**

- A range of outcomes was identified from studies conducted in Canada (n=4), UK (n=5), and Spain (n=11). The 11 studies conducted in Spain evaluated the same type of clinic – Quick Diagnostic Unit (QDU), and seven of these studies evaluated the same centre at different time intervals.
- **No evidence relating to equity of access** was identified.
- **No comparative ongoing studies** were identified.

Recency of the evidence base

- The review included evidence available up until August 2022. Included studies were published between 1998 and 2021, with data collection between 1995 and 2018.

Evidence of effectiveness

- **The evidence relating to effectiveness appeared mixed.**
- There is evidence to suggest that diagnostic centres can reduce various waiting times, **including time to surgical consultation, time from consultation to treatment, time from cancer suspicion to treatment, time from diagnosis to specialist consultation and time from diagnosis to treatment.**
- Diagnostic centres could help reduce pressure on secondary care by **avoiding hospitalisations in stable patients, reducing the number of visits required to receive a definite diagnosis, and increasing the number of patients in whom a definite outcome (discharged or scheduled for surgery) was reached.**
- Cost-effectiveness may depend on whether the diagnostic centre is running at full capacity. Factors that could determine the costs incurred by a diagnostic centre include **the diagnostic and clinical complexity of patients, and the characteristics of the unit including the number of staff and contribution of staff time.**

Best quality evidence

- All studies had considerable methodological limitations. The three economic evaluation studies (Bosch et al 2021, Sewell et al 2020, Sanclemente-Ansó et al 2016) were considered the most robust.

Policy Implications

- This rapid review highlighted **possible benefits of diagnostic centres**, particularly with regards to **reducing waiting times and pressure on hospitals.**
- As the data collection dates of included studies are wide-ranging, and many of the diagnostic centres included were from other countries where the healthcare system is different to that of the UK, **the results may not be generalisable.**
- Further research is needed to determine the optimum location for diagnostic centres.
- Further research is required to evaluate the effectiveness of diagnostic centres for conditions other than cancer.
- Further well-designed robust research from the UK and other comparable countries is needed to better understand the effectiveness and accessibility of diagnostic centres within Wales. (Only one UK study was published after 2013)
- Comparative impact evaluations should be incorporated into service development plans from the onset, to assess the effectiveness of newly opened diagnostic centres in the UK over time.

Strength of Evidence

Most study designs used weak methods that may be less appropriate for inferring effectiveness. Studies varied by countries, designs, definitions and often had inconsistent findings, so results should be interpreted with caution.

TABLE OF CONTENTS

TABLE OF CONTENTS.....	5
1. BACKGROUND	8
1.1 Who is this review for?.....	8
1.2 Purpose of this review	8
1.3 Definition of community diagnostic centres.....	9
2. RESULTS.....	9
2.1 Overview of the Evidence Base.....	9
2.2 Impact of diagnostic centres on waiting times.....	10
2.2.1 Bottom line results for the impact of diagnostic centres on waiting times	14
2.3 Impact of diagnostic centres on capacity and pressure on secondary care.....	14
2.3.1 Bottom line results for the impact of diagnostic centres on capacity and pressure on secondary care	16
2.4 Economic impact of diagnostic centres and other economic outcomes.....	16
2.4.1 Economic evaluations.....	17
2.4.2 Generic economic outcomes derived from quasi-experimental studies.....	17
2.4.3 Bottom line results for the economic effectiveness of diagnostic centres	20
3. DISCUSSION.....	56
3.1 Summary of the findings.....	56
3.2 Limitations of the available evidence.....	56
3.3 Implications for policy and practice	57
3.4 Strengths and limitations of this rapid review.....	57
4. REFERENCES	59
5. RAPID REVIEW METHODS.....	60
5.1 Eligibility criteria	60
5.2 Literature search.....	60
5.3 Study selection process.....	61
5.4 Data extraction.....	61
5.5 Study design categorisation	61
5.6 Quality appraisal	61
5.7 Synthesis.....	62
6. EVIDENCE	62
6.1 Study selection.....	62
6.2 Study selection flow chart.....	63
6.3 Quality appraisal tables	64
7. ADDITIONAL INFORMATION.....	66
7.1 Conflicts of interest	66
7.2 Information available on request	66
7.3 Acknowledgements.....	66

8.	ABOUT THE WALES COVID-19 EVIDENCE CENTRE (WCEC)	67
9.	APPENDIX	68

Abbreviations:

Acronym	Full Description
2WW	Two-Week Wait
COVID-19	Coronavirus Disease 2019
CMV	Cytomegalovirus
CNS	Clinical Nurse Specialist
CT	Computed Tomography
DDC	Demyelinating Disease Diagnostic Clinic
DES	Discrete-Event Simulation
D.F.	Degrees Of Freedom
EBV	Epstein–Barr Virus
ED	Emergency Department
EUS	Upper Gastrointestinal Endoscopic Ultrasound
FDG-PET	Fluorodeoxyglucose-Positron Emission Tomography
FNA	Fine-Needle Aspiration
FUN	Fever of Uncertain Nature
HCSW	Healthcare Support Worker
JB	Joanna Briggs Institute
LRDC	Lymphoma Rapid Diagnosis Clinic
MS	Multiple Sclerosis
PHC	Primary Healthcare Centres
RABC	Rapid Access Breast Clinic
RADS	Rapid Diagnosis And Support
RCT	Randomised Controlled Trial
RDC	Rapid Diagnostic Centre/clinic
RDU	Rapid Diagnostic Unit
REM	Rapid Evidence Map
RO	Radiation Oncology
RR	Rapid Review
RT	Radiotherapy Treatment
SD	Standard Deviation
TAC	Technical Advisory Cell
TS	Traditional System
QALYs	Quality Adjusted Life Years
QDU	Quick Diagnostic Unit
UHN	University Health Network
UK	United Kingdom
WCEC	Wales COVID-19 Evidence Centre

1. BACKGROUND

1.1 Who is this review for?

This Rapid Review (RR) was conducted as part of the Wales COVID-19 Evidence Centre Work Programme (WCEC). The above question was suggested by the Welsh Government Technical Advisory Cell (TAC) to inform the Diagnostics Strategy Board and support the implementation of community diagnostic centres across Wales.

1.2 Purpose of this review

The COVID-19 pandemic has had a direct impact on diagnostic services in the United Kingdom (UK) and globally. This, in addition to the rapid rise in demand for diagnostics that existed prior to the pandemic, has resulted in a significant backlog of patients requiring various diagnostic services and increased waiting times for diagnostics and treatment. The most recently published data shows that in Wales, the number of patients waiting longer than the target of eight weeks for diagnostics rose from 10.8% (7,964) in March 2020 to 41.5% (44,489) in August 2022 (StatsWales 2022). An Independent Review of Diagnostic Services for NHS England chaired by Professor Sir Mike Richards, called for significant reform and investment in diagnostic services, and recommended the establishment of community diagnostic centres to aid in tackling the backlog and delays to diagnostic services (National Health Service England 2020). Community diagnostic centres aim to provide patients with quicker and more convenient direct access to diagnostic services than is currently available, and reduce pressure on hospitals (Department of Health and Social Care 2021). With an emphasis on direct patient access to services from primary care, these centres can be located within hospital settings or within the community. In Wales, community diagnostic centres are generally referred to as **Regional Diagnostic Hubs** (but are referred to here as Community Diagnostic Centres, for the purpose of this report).

In England, community diagnostic centres were first launched in 2021 in a range of settings including hospitals, football stadiums, and repurposed retail outlets (Department of Health and Social Care 2021). At present, over 90 community diagnostic centres have been opened, with plans to open up to 160 centres by 2025 (National Health Service England 2022). In Wales, a plan to create a network of community diagnostic centres was outlined by the Welsh Government in April 2022 (Welsh Government 2022). As diagnostic services currently account for over 85% of clinical pathways within the NHS and cost over £6 billion a year (National Health Service 2022), community diagnostic centres across a broader range of diagnostic services may be an effective, efficient, and cost-effective introduction to the UK health sector. These services could ensure timely diagnoses and reduced waiting times in a convenient location, ensuring people receive the treatment they need. Furthermore, community diagnostic centres could help address inequalities by providing accessible diagnostic services to people from particular social groups who may be less likely to engage with the healthcare system (The King's Fund 2022).

The purpose of this RR is to draw on the earlier work undertaken to identify and examine the evidence on the effectiveness of community diagnostic centres. This preliminary work included a rapid evidence map (REM) that identified a large body of evidence relevant to community diagnostic centres: REM00043 Wales COVID-19 Evidence Centre. A rapid evidence map of what evidence is available on the effectiveness of community diagnostic centres. September 2022. In order to measure effectiveness as part of the current RR, stakeholders prioritised outcomes, identified during the REM, that evaluated whether community diagnostic centres can impact capacity and pressure on secondary care, as well as ensuring equity in uptake or access as most important, along with economic outcomes. Therefore, our RR focussed on outcomes that were best able to demonstrate this. Due to the

large number of studies identified during the initial investigation into this topic, **only comparative studies examining community diagnostic centres that accept referrals from primary care as a minimum, were included in this RR.** Comparative studies are defined here as studies that investigated some aspect of a diagnostic centre and compared it with usual care, another diagnostic centre or some other service.

1.3 Definition of community diagnostic centres

Community diagnostic centres are described within the international literature using a variety of terms and definitions. For the purposes of this RR, community diagnostic centres are defined as health services aimed at improving population health outcomes by providing quicker and easily accessible diagnostic services in the community, which are accessible to primary care practitioners/services, thereby relieving pressure on secondary care services. In Wales, community diagnostic centres are generally referred to as Regional Diagnostic Hubs to avoid confusion with the descriptors or acronyms used for other similar services. For the purposes of this RR, we use the descriptor 'community diagnostic centres' to incorporate the range of terms used for these services. However, the different descriptors used within individual studies are also outlined and discussed in this report.

2. RESULTS

2.1 Overview of the Evidence Base

A total of 20 primary studies met our inclusion criteria. Sixteen of these were quasi-experimental studies comprising cross sectional post-test only designs, three were economic evaluations and one was a randomised controlled trial (RCT). Included studies were conducted in Spain (n=11), UK (n=5), and Canada (n=4), and were published between 1998 and 2021. Ten studies were specific to cancer diagnoses, six studies reported on multiple health conditions (rather than a specific condition) and three studies covered a single health condition including severe anaemia (n=1), fever of uncertain nature (FUN) (n=1), and multiple sclerosis (MS) (n=1). One study did not report a particular health condition of interest. Included studies varied in their reporting of outcomes, with some being purely descriptive and others offering inferential statistical findings. A detailed matrix of the outcomes reported by each study presented in this RR can be found in Figure 1. A detailed summary of included studies organised by country, diagnostic centre and comparator, can be found in Table 1.

Twelve individual diagnostic centres were assessed across the 20 included studies.

Details on the characteristics of each diagnostic centre can be found in Appendix 1. The majority of studies reported on diagnostic centres located within hospital settings (n=19). Only one study (Pallan et al 2005) reported findings from a diagnostic service located within the community setting. As outlined in our eligibility criteria (Table 2 in Section 5), all diagnostic centres accepted referrals from primary care as a minimum. The diagnostic centres in five studies accepted referrals solely from primary care while the remaining 15 studies accepted referrals from primary care and other referral sources such as emergency departments (ED) and hospital outpatient clinics.

The methodological quality of the included studies was assessed using the appropriate Joanna Briggs Institute (JBI) critical appraisal tool (for quasi-experimental studies, RCTs and economic evaluations) (see Tables 3, 4, 5). The JBI tool contains a set of signalling questions for particular domains of bias, including bias in selection of participants, bias in measurement of outcomes, and bias in selection of the reported results. Critical appraisal of the economic evaluation studies showed that all three studies measured outcomes and costs accurately. However, appraisal determined that none reported results that were

generalisable to the setting of interest in our review. The single RCT measured all outcomes in a reliable way across groups but had issues with blinding of participants and outcome assessors. In the quasi-experimental studies, participants received similar treatment/care however, there appeared to be differences between participants included in compared groups. While all studies had some methodological issues, none were excluded from the review after quality appraisal.

2.2 Impact of diagnostic centres on waiting times

Nineteen included studies reported a range of outcomes relevant to waiting times. These included outcomes such as time to first visit, time to examination and time to diagnosis. In addition, some outcome measures relating to waiting times were specific to cancer studies, such as time from cancer suspicion to diagnosis, and time to surgical/specialist consultation. Some outcome measures relating to waiting times may have been measured at the same time intervals across the diagnostic pathway, but as they were often poorly defined across the studies, we have reported them separately.

Time to first visit

Time to first visit (the interval between referral and first visit to the diagnostic centre) was reported in 10 studies covering five diagnostic centres (three from Spain and two from the UK). The findings from the most recent studies are reported below for each diagnostic centre. Two studies covered the same diagnostic centre (Montori-Palacín et al 2017; Bosch et al 2020). However, one of these compared outcomes between patients referred to the diagnostic centre and patients hospitalised in inpatient wards (Bosch et al 2020), while the other compared the diagnostic performance of two diagnostic centres of different levels of complexity (secondary vs tertiary) (Montori-Palacín et al 2017). The findings of both studies are reported below. Study findings were generally mixed.

- A reduction in time to first visit was reported in two studies (Choudhury et al 2013, Porter et al 2003). Choudhury et al (2013) assessed the efficacy of a newly established rapid diagnostic clinic (RDC) for patients with suspected head and neck cancer by conducting an audit of new referrals made to a head and neck clinic during a six-month period before the new clinic was established (pre-RDC) and compared this with findings from the RDC period. The study reported a **statistically significant reduction in the time from referral to the patients being seen between pre-RDC period and RDC period** for both patients referred via the two-week wait (2WW) source (11.2 vs 9.2 days; $p = 0.0002$) and for patients referred via all other referral sources (33.5 vs 23.3 days; $p = 0.0015$).
- Porter et al (2003) compared a newly established demyelinating disease diagnostic clinic (DDC) with two existing clinical settings in the management of MS and reported that **the mean waiting time to first visit was shorter for the patients attending the DDC** (5.9 weeks) compared to the general neurology clinic (7.7 weeks) and the inpatient investigation unit (10.0 weeks) operating within the same hospital.
- Bosch et al (2020) compared outcomes between patients referred to a quick diagnostic unit (QDU) and patients hospitalised in inpatient wards and reported that **the time to first QDU visit (outpatients) was found to be significantly longer than the time to admission in hospitalised patients** (1.2 vs 0.7 days; $p < 0.001$).
- Bosch et al (2018) compared outcomes between patients referred to two QDUs and patients hospitalised in inpatient wards and reported that **the time to first QDU visit (outpatients) was found to be significantly longer than the time to admission in hospitalised patients** (1.7 vs 0.6 days; $p < 0.001$). It should be noted that two QDUs were combined and analysed as a single outpatient unit in this study.

- Montori-Palacín et al (2017) compared the diagnostic performance of two QDUs of different levels of complexity (secondary vs tertiary) and found that **the median time to first visit was longer in the QDU of a secondary hospital than that of the QDU of its reference general tertiary hospital** (5 vs 3 days; $p=0.008$). The study authors suggested that this difference could be due to direct appointments to the tertiary hospital QDU from the ED and a lack of administrative support of the secondary hospital QDU. This study, however, did not provide any non-QDU comparator data.

Time to diagnostic examination

Time to examination (the interval between diagnostic centre physician's order and the examination being actually performed) was reported in four studies covering four different diagnostic centres (three from Spain and one from the UK). Two studies reported findings from the same diagnostic centre (Bosch et al 2012c; Bosch et al 2018), however one of these studies compared outcomes between patients referred to the diagnostic centre and patients hospitalised in inpatient wards (Bosch et al 2012c), while the other study combined two diagnostic centres into a single unit and compared outcomes with patients hospitalised in inpatient wards (Bosch et al 2018). The findings of both studies are therefore reported below. Similarly, Montori-Palacín et al (2017) and Bosch et al (2018) reported findings from the same diagnostic centre. However, unlike the latter, Montori-Palacín et al (2017) compared the diagnostic performance of the diagnostic centre with that of another diagnostic centre of a different level of complexity. Study findings were generally mixed.

- Pallan et al (2005) assessed the effectiveness of a primary care-based mobile diagnostic ultrasound service provided by an independent radiographer compared to an NHS Trust diagnostic ultrasound service and found that **the mean waiting time for an ultrasound scan appointment was shorter for the community service than for the hospital service** (17.44 days vs 44.53 days).
- Bosch et al (2018) compared waiting times of patients attending two outpatient QDUs versus conventional hospitalisation for the diagnosis of lymphoma and found that **the mean time to biopsy was significantly longer in the outpatient QDUs than in inpatient settings** (7.4 vs 3.5 days; $p<0.001$). Two QDUs were combined and analysed as a single outpatient unit in this study.
- Bosch et al (2012c) compared waiting times of patients attending a QDU versus conventional hospitalisation for those with severe anaemia and found that the mean waiting time to gastroscopy was shorter in the QDU than in inpatient settings (3.23 vs 3.47 days) while the mean waiting time to colonoscopy was longer in the QDU than in inpatient settings (4.45 vs 4.24 days). However, these differences were not statistically significant.
- Montori-Palacín et al (2017) compared waiting times of two QDUs of different levels of complexity. **Significant differences were observed in the waiting times to computed tomography (CT) scan (2 vs 3 days; $p=0.03$) and cytology/biopsy studies (3 vs 4 days; $p=0.03$), which were longer in patients attending the QDU of the tertiary hospital, and in the waiting times to ultrasonography (3 vs 2 days; $p=0.04$), endoscopy (12 vs 5 days; $p<0.001$), scintigraphy (7 vs 2 days; $p<0.001$), and body fluorodeoxyglucose-positron emission tomography (FDG-PET) (6 vs 3 days; $p<0.001$), compared to patients attending the QDU of the secondary hospital.** However, this study did not provide non-QDU comparator data.

Time to diagnosis

Time to diagnosis (the time elapsed between the request of the decisive diagnostic procedure and the cyto/pathological diagnosis) was reported in 14 studies covering six diagnostic centres (three from Spain, two from Canada, and one from the UK). The findings from the most recent studies for each diagnostic centre are reported below. Two studies reported findings from the same diagnostic centre (Bosch et al 2020; Bosch et al 2021), however the former compared outcomes between patients referred to the diagnostic centre and patients hospitalised in inpatient wards, while the latter compared the diagnostic performance of two diagnostic centres of different levels of complexity. Both studies are reported below. Findings were generally mixed.

- Nixon et al (2020) examined the impact of a nurse practitioner-led lymphoma rapid diagnosis clinic (LRDC) by comparing findings from the initial 30-month experience of the LRDC with those prior to its implementation. **The time from initial assessment to lymphoma diagnosis was found to be significantly shorter for the patients attending the LRDC** compared to historical controls (16 vs 28 days; $p < 0.001$).
- Sethukavalan et al (2013) compared wait time intervals for patients with prostate cancer diagnosed at a rapid diagnostic unit (RDU) versus the usual community process. The results showed **that time from urologist visit to diagnosis was significantly shorter in the RDU patients** compared to community patients (29 vs 100 days; $p = 0.0094$).
- Sewell et al (2020) found **that patients diagnosed directly at a RDC had a shorter time to diagnosis than patients receiving usual care** (5.9 days vs 84.2 days). However, this study was conducted using patient-level discrete-event simulation (DES) and decision analytic modelling.
- Bosch et al (2020) found **no significant differences** between admission time to diagnosis (hospitalised patients) and the QDU time to diagnosis (4.1 vs 4.3 days; $p = 0.163$).
- Bosch et al (2018) found that the **time to diagnosis of QDU outpatients was significantly longer than the admission time to diagnosis among inpatients** (hospitalised) (16.2 vs 12.3 days; $p < 0.001$). Two QDUs were combined and analysed as a single outpatient unit in this study.
- Bosch et al (2021) compared the diagnostic performance of two QDUs of different levels of complexity (secondary vs tertiary) and found that the **time to diagnosis was significantly longer in the QDU of a secondary hospital than in QDU of its reference general tertiary hospital** (12 vs 8 days; $p < 0.0001$). This study, however, does not provide any non-QDU comparator data.

Wait time from abnormal imaging to biopsy and from biopsy to pathology verification

One study conducted in Canada reported on the wait time from abnormal imaging to biopsy and from biopsy to pathology verification.

- Arnaout et al (2013) assessed the impact of a Rapid Diagnosis and Support (RADS) programme on diagnostic and treatment wait times for patients with a high probability of breast cancer compared to patients who had BI-RADS 5 diagnostic imaging in the year before the programme (PRE-RADS). **Significant reductions were found in the mean wait time from abnormal imaging to biopsy** (7.1 days vs 3 days; $p < 0.01$) **and from biopsy to pathology verification** (3.9 days vs 3.4 days; $p < 0.01$) **for patients attending the RADS programme** compared to PRE-RADS.

Time to surgical consultation

Time to surgical consultation (the time from presentation to seeing the surgeon/ the interval between pathology verification to surgical consultation) was reported by two Canadian studies investigating two different rapid diagnostic services. It should be noted that these studies use different start points to measure this outcome, as described above. Both studies identified a statistically significant reduction in wait times compared to their comparators.

- McKevitt et al (2017) reported that **patients seen at a Rapid Access Breast Clinic (RABC) had a significantly decreased time from presentation to surgical consultation** (33 vs 86 days; $p < 0.0001$) for both malignant (36 vs 59 days; $p = 0.0007$) and benign diagnoses (31 vs 95 days; $p < 0.0001$) compared to patients diagnosed through the traditional system (TS).
- Arnaout et al (2013) reported that **the time from pathology verification to surgical consultation had been reduced significantly** from 16.1 to 5.9 days ($p < 0.01$) in patients who took part in a **RADS programme** compared to patients who had BI-RADS 5 diagnostic imaging in the year before the programme (PRE-RADS).

Time from cancer suspicion to treatment

One study conducted in Canada reported the time from cancer suspicion to treatment (the time from suspicion of cancer to radiotherapy).

- Sethukavalan et al (2013) compared wait time intervals for patients with prostate cancer diagnosed at a multidisciplinary RDU versus the usual community referral process. The results showed a **statistically significant difference in the time interval from cancer suspicion to treatment** (158 days vs 218; $p = 0.046$) in favour of the patients attending the RDU.

Time from consultation to treatment

Time from consultation to therapy (the time interval from consultation to treatment/surgery) was reported in five studies covering five different diagnostic centres (four from Canada and one from UK). All studies identified a reduction in time from consultation to treatment compared to their comparators, but only two identified a statistically significant difference.

- Nixon et al (2020) found that **the time from initial assessment to treatment of aggressive lymphomas and Hodgkin's lymphoma was significantly shorter for patients attending a LRDC** compared to historical controls (29 days vs 48 days; $p < 0.001$).
- Arnaout et al (2013) reported that **time from surgical consultation to treatment was reduced significantly** from 31.5 to 24.1 days ($p = 0.04$) **for patients who took part in a RADS programme** compared to patients who had BI-RADS 5 diagnostic imaging in the year before the programme (PRE-RADS).
- McKevitt et al (2017) reported that patients seen at a RABC had a **decreased time from surgical consultation to surgery** compared to patients diagnosed through the TS (31 days vs 33 days). However, this difference was not statistically significant ($p = 0.78$).
- Choudhury et al (2013) reported that patients seen during the RDC period had a **decreased time from initial consultation to date of surgery** compared to patients seen during the pre-RDC period (32.5 vs 38.9 days) however this difference was not statistically significant ($p = 0.307$).

- Sethukavalan et al (2013) found **the time from consultation to treatment to be shorter for patients attending a RDU compared to the usual community referral process** (60 vs 62 days), however this difference was not statistically significant ($p = 0.52$).

Time from diagnosis to specialist consultation

One study conducted in Canada reported the outcome time from diagnosis to specialist consultation (the time from diagnosis to radiation oncology consult).

- Sethukavalan et al (2013) found the **time from diagnosis to specialist consultation was significantly shorter for patients attending a RDU** compared to the usual community referral process (27 days vs 49 days; $p=0.0019$).

Time from diagnosis to treatment

One study conducted in Canada reported the outcome time from diagnosis to treatment.

- Sethukavalan et al (2013) found the **time from diagnosis to treatment was significantly shorter for patients attending a RDU** compared to the usual community referral process (mean 91 days vs 120; $p=0.016$).

2.2.1 Bottom line results for the impact of diagnostic centres on waiting times

Evidence relating to the impact of diagnostic centres on waiting times appears to be mixed. There is evidence to suggest that the utilisation of diagnostic centres can reduce various waiting times, including time to surgical consultation and time from consultation to treatment. However, the evidence was mixed for other wait time outcomes including the time to first visit, time to diagnostic examination and time to diagnosis.

Reductions in waiting times were also reported for the time to biopsy, from cancer suspicion to treatment, from diagnosis to specialist consultation and from diagnosis to treatment, for patients attending diagnostic centres. However, these outcomes were reported by individual studies and as such firm conclusions cannot be made. Furthermore, the methodological limitations across included studies and variations in healthcare systems of the countries of origin of included studies, could limit the applicability of all findings.

2.3 Impact of diagnostic centres on capacity and pressure on secondary care

Thirteen studies reported a range of outcomes relevant to the impact of diagnostic centres on capacity and pressure on secondary care. These included outcomes such as the number of visits required to obtain a definite diagnosis, number of biopsies required to arrive at a diagnosis, onward referrals and referral patterns over time.

Number of visits required to receive a diagnosis

The number of visits to the diagnostic centre required to obtain a definite diagnosis was reported by four studies covering three diagnostic centres (two from Spain and one from the UK). The findings from the most recent studies are reported below for each diagnostic centre. Findings were unclear.

- Bosch et al (2021) investigated the costs incurred by two QDUs of tertiary and secondary hospitals and found that **significantly fewer visits were required to achieve a diagnosis at the secondary unit compared to the tertiary unit** (2.123

vs 3.098 visits; $p = 0.0064$). However, this study does not provide any non-QDU comparator data.

- Porter et al (2003) compared a newly established DDC to two existing clinical settings in the management of MS. They found **that patients attending the DDC required two visits** (one initial and one follow-up appointment) before receiving a definite diagnosis compared to one to four visits, and two to five visits respectively, for the other clinical settings.

Number of biopsies to arrive at a diagnosis

One study conducted in Canada reported the number of biopsies required to arrive at a definitive diagnosis.

- Nixon et al (2020) examining the effectiveness of a nurse-led LRDC, found **that significantly fewer patients required two or more biopsies to arrive at a diagnosis of lymphoma after institution of a LRDC compared with patients diagnosed prior to the implementation of the clinic** (40% vs 12%; $p < 0.001$).

Referral patterns over time and onward referrals

One study conducted in Spain reported referral patterns over time.

- Bosch, Jordán and López-Soto (2013) conducted a study to determine whether QDUs could be used to safely and efficiently avoid ED visits and hospitalisations. This study compared the referral trends over time of patients with suspected serious disease, from primary care and EDs to the QDU. **They found statistically significantly more direct referrals to the QDU (from 36% to 64%) and less to the ED (from 65% to 35%) respectively during the 25 month study period** ($p < 0.0001$). In addition, at least 84% of hospitalised patients were found to be stable and their hospitalisations might have been avoided.

Onward referrals after attending a diagnostic centre were reported by nine studies covering four diagnostic centres (three from Spain and one from UK). The findings from the most recent studies are reported below for each diagnostic centre. Two studies reported findings from the same diagnostic centre (Montori-Palacín et al 2017; Bosch et al 2018). However, Montori-Palacín et al (2017) compared the diagnostic performance of the diagnostic centre with that of another diagnostic centre of a different level of complexity, while Bosch et al (2018) combined two diagnostic centres into a single unit and compared outcomes with patients hospitalised in inpatient wards. Both are reported below.

- Bosch et al (2018) reported onward referrals for patients attending one of two QDUs and compared this to hospitalised patients. The study found the majority of QDU patients were referred to outpatient specialist clinics (95.1% and 96% respectively, compared to 92% of controls). Patients were also referred to primary care (3.1% and 3% respectively compared to 2.1% of controls) and to palliative care (1.9% and 1% compared to 6% of controls). **The patients attending the QDUs were significantly more likely to be referred to outpatient specialist clinics ($p = 0.046$) and were significantly less likely to be referred to palliative care ($p < 0.001$).** However, authors reported this significant difference is likely related to the fact that the inpatient cohort were generally older and likely to have more aggressive lymphoma subtypes than those attending the diagnostic centres.
- Montori-Palacín et al (2017) assessed the diagnostic performance of a QDU of a secondary hospital by assessing patients with potentially serious disorders and compared it with a tertiary hospital QDU. The study found that after diagnosis, **most**

secondary hospital QDU patients were referred to the outpatient clinics of the secondary hospital and primary care centres (42% each), and 8% referred to specialist outpatient clinics at the tertiary hospital. In contrast, 60% of the tertiary hospital QDU patients were referred onward to primary care centres and 35% to the hospital outpatient clinics. However, this study does not provide any non-QDU comparator data.

- Choudhury et al (2013) assessed the efficacy of a newly established RDC by conducting an audit of new referrals to a head and neck clinic during a six-month pre-RDC period and compared this with findings from the RDC period. The study reported an increase in the number of patients in whom a definitive outcome was reached (discharged or being listed for surgery) from the RDC. **In the pre-RDC period, one-third (33%) of patients reached a clear management plan including one of these two definitive outcomes, compared to almost one half (48 %) of all patients who attended the RDC, who were either discharged or scheduled for surgery.** Similarly, the number of patients that needed to be referred for an investigation fell by more than half, from 37 % in the pre-RDC period, to 15 % from the RDC period.

2.3.1 Bottom line results for the impact of diagnostic centres on capacity and pressure on secondary care

Evidence relating to the impact of diagnostic centres on capacity and pressure in secondary care appears to be unclear. There is evidence to suggest that diagnostic centres could reduce the number of visits needed to receive a definite diagnosis. The evidence also suggest diagnostic centres could reduce the number of biopsies needed to arrive at a diagnosis and reduce the number of stable patients being referred for hospitalisation overtime however, these outcomes were only reported by individual studies and as such firm conclusions cannot be made.

Onward referrals were made to a range of settings including primary care centres, palliative care, outpatient clinics and referrals for surgery. The evidence suggests onward referrals differed in diagnostic centres when compared with hospitalisation (however this is likely to be due to the differences of the patients who are able to attend a diagnostic centre and those who require hospitalisation). The evidence suggests that diagnostic centres can increase the number of patients reaching a clear management plan (discharged or scheduled for surgery) and reduce the need to be referred for further investigations. However, these findings were only reported by individual studies and as such firm conclusions cannot be made. Onward referrals appeared to differ between diagnostic centre patients and inpatients, possibly due to the fact that inpatients were generally older and more unwell than those attending diagnostic centres. The methodological limitations across included studies and variations in healthcare systems of the countries of origin of included studies could further limit the applicability of these findings.

2.4 Economic impact of diagnostic centres and other economic outcomes

Fourteen studies covering seven diagnostic centres (three from UK, three from Spain, and one from Canada) reported economic outcomes. Of these, three studies were economic evaluations: one cost-minimisation analysis (Sanclemente-Ansó et al 2016), one cost-effectiveness study (Sewell et al 2020), and one comparative cost analysis (Bosch et al 2021), while the other studies (11 quasi-experimental studies) reported more generic economic outcomes.

2.4.1 Economic evaluations

Bosch et al (2021) conducted a comparative cost analysis using micro-costing, to compare the costs incurred by two QDUs of different levels of complexity (tertiary vs secondary). The results showed that the mean total cost per patient of the tertiary unit was €577.50 ± 219.60, while the mean cost of the secondary unit was €394.70 ± 92.58 per patient (p value for difference between the two units = 0.0559). The mean cost per visit of both units was similar (€182.8 ± 41.47 in the tertiary vs €184.6 ± 29.41 in the secondary unit; p = 0.9056). An analysis of general costs revealed that direct and structural costs per patient of the two units were not significantly different. Conversely, indirect costs of the tertiary unit were significantly higher than those of the secondary unit (€49.93 ± 19.90 vs €12.42 ± 2.344, respectively; p = 0.0018). **The main driver of the cost differences between the two QDUs was found to be the total number of visits and successive/first visits ratio.** However, this study does not provide any non-QDU comparator data.

Sewell et al (2020) used patient-level DES and decision analytic modelling to estimate the cost-effectiveness of a pilot RDC in its first year of operation compared with standard clinical practice. The results showed that during the start-up phase of the service, the RDC was seeing a mean number of 2.78 patients per clinic and was more costly and more effective compared to standard clinical practice. However, **when run at near or full capacity (80% or higher, seeing a mean number of 4.65 patients/clinic), the RDC was found to outperform usual care, i.e. being less costly and more effective.**

Sanclemente-Ansó et al (2016) conducted a cost-minimisation analysis to assess the costs of the QDU approach compared with the costs of conventional hospitalisation for the diagnosis of cancer and severe anaemia. For this analysis, three groups of QDU patients (with a final diagnosis of severe anaemia, lymphoma, and lung cancer) were compared with hospitalised patients with the same final diagnoses. **The results showed a significant cost saving of care delivered by a QDU service compared with traditional inpatient care.** The QDU savings from hospitalisation for the three diagnostic groups were related to fixed direct costs of hospital stays (66% of total savings). Savings related to fixed non-direct costs of structural and general functioning were 33% of total savings. Savings related to variable direct costs of diagnostic investigations were 1% of total savings. Overall savings from hospitalisation of all patients were €867,719.31.

2.4.2 Generic economic outcomes derived from quasi-experimental studies

Eleven quasi-experimental studies reported a range of generic economic outcomes including patient costs (such as the mean cost per visit to the diagnostic centre, cost of diagnostic test per patients and the mean costs per patient), costs associated with running a diagnostic centre (such as the average cost per process, staffing costs and direct, indirect and structural costs) and cost savings.

Patient costs

Cost per visit to the diagnostic centre

Nine studies covering three different diagnostic centres (two from Spain and one from the UK) reported the mean cost per diagnostic centre visit. The findings from the most recent studies are reported below for each diagnostic centre. Two studies reported findings from the same diagnostic centre (Bosch et al 2020; Bosch et al 2018), however Bosch et al 2018 combined the cohort of patients in this centre with another diagnostic centre to form a single unit, and as such both studies are reported below. The findings were generally unclear.

- Bosch et al (2020) compared the costs of outpatients (QDU patients) and inpatients and found **the cost per hospital stay was less expensive than cost per visit to the QDU at the same hospital** (€154.72 vs €340.90).
- Bosch et al (2018) compared the associated costs of outpatient (QDU) and inpatient (hospitalised) settings and found **the total cost per one day stay as an inpatient was less expensive than the cost per visit to outpatients** (€328.42 vs €432.05). However, it is worth noting that two QDUs were combined and analysed as a single unit in this study.
- Porter et al (2003) compared a newly established DDC with two existing clinical settings in the management of MS. They found that **the cost per appointment to the DDC was £395, compared to £95 per visit to another outpatient clinic. For inpatients, the length of stay ranged from one to five days and patients in this group also attended outpatient appointments on two to five occasions before receiving a definite diagnosis. The collective price of admission and outpatient visits ranged from £1940 to £2700.**

Cost of diagnostic test per patient

Three studies covering three diagnostic centres (two from Spain and one from the UK) reported the cost of diagnostic tests per patient. Two studies reported findings from the same diagnostic centre (Bosch et al 2020; Bosch et al 2018), however the latter combined the cohort of patients from this centre with another diagnostic centre to form a single unit, and as such both studies are reported below. The findings indicate costs of diagnostic tests may be cheaper in diagnostic centres situated within hospital grounds. Findings for mobile-based diagnostic services are unclear.

- Bosch et al (2020) compared the costs incurred by outpatient (QDU) and inpatient (hospitalised) settings and reported **the total cost of diagnostic examinations per patient to be significantly cheaper for patients attending the QDU** compared to hospitalised patients (€231.88 vs €280.60; $p < 0.001$).
- Bosch et al (2018), compared the associated costs of outpatient (QDU) and inpatient (hospitalised) settings and found **the total cost of diagnostic examinations per patient was significantly cheaper for patients attending the QDUs** compared to hospitalised patients (€713.19 vs €1,026.80; $p < 0.001$). Two QDUs were combined and analysed as a single unit in this study.
- Pallan et al (2005) compared a primary care-based mobile diagnostic ultrasound service to a NHS Trust diagnostic ultrasound service and found **the cost of diagnostic tests was more expensive per patient attending the mobile diagnostic ultrasound service in the community compared to the NHS Trust hospital service** (cost per ultrasound £30 vs £20.62 - £27.51 respectively).

Total cost per patient

Three studies conducted in Spain reported on the total cost per patient for two diagnostic centres. The findings from the most recent studies are reported below for each diagnostic centre. Two studies reported findings from the same diagnostic centre (Bosch et al 2020; Bosch et al 2018), however the latter combined the cohort of patients from this centre with another diagnostic centre to form a single unit, and as such both studies are reported below. Both studies identified statistically significant reductions in cost per patient attending a QDU compared to hospitalisation.

- Bosch et al (2020), reported that **the total cost per patient at a QDU was significantly less than the total cost per hospitalised patient** (€347.76 [SD 48.69] vs €634.36 [SD 80.56]; $p < 0.001$). Total cost per QDU patient included 66.7% being attributable to diagnostic tests, 18.2% to ambulatory visits, and 13.7% to salaries, and total cost per hospitalised patient included 46.4% being attributable to personnel salaries and 44.2% to diagnostic tests.
- Bosch et al (2018) reported that **the total cost per patient was significantly less for outpatients (QDU patients) than the cost per hospitalised patient** (€1,408.48 [197.32] vs €4,039.56 [513.02]; $p < 0.001$). Two QDUs were combined and analysed as a single unit in this study.

Costs of running a diagnostic centre

Average cost per process (from admission to discharge)

Five studies covering one diagnostic centre reported the average cost per process. All five studies were conducted in Spain. The findings of the most recent study is reported below.

- Bosch, Jordán and López-Soto (2013) compared patients attending a QDU with hospitalised patients and found **the average cost per process was more expensive for hospitalised patients compared to patients attending the QDU** (€3,241.11 [standard deviation (SD), 915] vs €726.47 [SD, 617] respectively).

Direct, indirect and structural costs

Two studies conducted in Spain (Brito-Zerón et al 2014; Bosch et al 2020) reported on the direct, indirect and structural costs of one diagnostic centre. Therefore, only the findings from the most recent study is reported below.

- Bosch et al (2020) described mean **non-direct costs per patient** in QDU and hospitalised patients. These costs mainly corresponded to structural and general functioning costs such as costs related to maintenance (€0.05 [SD, 0.01] vs €0.66 [SD, 0.07]), laundry (€0.26 [SD, 0.02] vs €5.17 [SD, 0.36]), cleaning services (€0.73 [SD, 0.05] vs €8.36 [SD, 0.67]), administrative costs (€0.02 [SD, 0.01] vs €0.37 [SD, 0.03]), as well as depreciation of fixed costs (€3.10 [SD, 0.61] vs €4.43 [SD, 0.89]). All were found to **cost significantly less for patients attending the QDU** compared to hospitalised patients ($p < 0.001$).

Staffing costs

Two studies conducted in Spain covering two diagnostic centres, reported on staffing costs. The two studies covered the same diagnostic centre (Bosch 2020; Bosch 2018) however one study combined the findings for this centre with another diagnostic centre and as such, both studies are reported below. Both studies identified a statistically significant reduction in staff costs compared to controls.

- Bosch et al (2020) reported that **the mean staff wages per patient attending the QDU was significantly lower than the staff wages for hospitalised patients** (€47.71 [SD, 4.15] vs €294.50 [SD, 18.26] respectively; $p < 0.001$).
- Bosch et al (2018) reported that **the mean staff wages per patient attending the QDU was significantly lower than the staff wages for hospitalised patients** (€262.50 [SD, 22.92] vs €2,806.49 [SD, 174]; $p < 0.001$). Two QDUs were combined and analysed as a single unit in this study.

Cost saving from hospitalisation

One study conducted in Spain reported on the cost saving from hospitalisation.

- Bosch et al (2018) compared associated costs of outpatient (QDU) and inpatient (hospitalised) settings and found that **the total cost saving from hospitalisation** was €2,631.08 per patient. However, two QDUs were combined and analysed as a single unit in this study.

2.4.3 Bottom line results for the economic effectiveness of diagnostic centres

There is evidence to suggest that diagnostic centres are cost-saving and a more cost-effective resource than traditional inpatient care. However, it appears that overall cost-effectiveness may be dependent on whether or not the diagnostic centre is running at full capacity. Factors that could determine the costs incurred by a diagnostic centre include the diagnostic and clinical complexity of the patients managed at the unit, as well as the characteristics of the unit including the number of staff and contribution of staff time. Additionally, there is evidence to suggest that utilisation of diagnostic centres can reduce staffing costs, costs incurred per patient, and the costs of diagnostic tests. However, the methodological limitations across included studies and variations in healthcare systems of the countries of origin of included studies could limit the applicability of these findings.

Figure 1. Outcomes matrix of included studies as reported in the RR (all outcomes reported by each study can be seen in the rapid evidence map (REM)).

Authors in Bold denote cancer diagnostic centres	Arnaout et al 2013	<i>Bosch et al 2011</i>	<i>Bosch et al 2012a</i>	Bosch et al 2012b	<i>Bosch et al 2012c</i>	<i>Bosch, Jordán and López-Soto 2013</i>	Bosch et al 2018	Bosch et al 2020	<i>Bosch et al 2021</i>	<i>Brito-Zerón, et al 2014</i>	Choudhury et al 2013	Harcourt et al 1998	McKevitt et al 2017	<i>Montori-Palacín et al 2017</i>	Nixon et al 2020	<i>Pallan et al 2005</i>	<i>Porter et al 2003</i>	<i>Sanclemente-Ansó 2016</i>	Sethukavalan et al 2013	<i>Sewell et al 2020</i>	Total no of studies (n=20)
Performance outcomes																					
Wait time from confirmation of BI-RADS 5 status of abnormal diagnostic mammogram to biopsy	X																				1
Time from biopsy to pathology verification	X																				1
Time to first visit		X	X	X	X	X	X	X			X			X			X				10
Number of visits required to receive diagnosis						X			X					X			X				4
Number of biopsies to arrive at diagnosis															X						1
Time to diagnostic examination					X		X							X		X					4
Time to surgical consultation/assessment	X												X								2
Time from consultation to treatment	X										X		X		X				X		5
Time from cancer suspicion to treatment																			X		1
Time to diagnosis		X	X	X	X	X	X	X	X	X				X	X			X	X	X	14
Time from diagnosis to treatment																			X		1
Time from diagnosis to specialist consultation																			X		1
Referral patterns over time						X															1
Onward referral		X	X	X	X	X	X			X	X			X							9
Economic outcomes																					
Mean cost per hospital stay		X	X	X	X		X	X		X							X	X			9
Mean cost per visit to the diagnostic centre		X	X	X	X	X	X	X	X	X							X				10
Average cost per process (from admission to discharge)		X	X	X	X	X															5
Total cost per patient							X	X	X	X								X		X	6
Cost of diagnostic tests per patient							X	X								X					3
Cost saving related to diagnostic investigation																		X			1
Cost saving from hospitalisation							X											X			2
Cost saving per patient related to structural and general functioning costs of hospitalisation																		X			1
Mean cost saving per patient																		X			1
Overall cost saving																		X			1
Staffing costs							X	X	X									X			4
Costs of catering/ cleaning/laundry/ travel/maintenance/ administrative/depreciation/consultation								X													1
Cost-effectiveness												X								X	2
Direct, Indirect and structural costs								X	X	X								X			4

Table 1: Summary of included studies

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
Diagnostic centre vs usual care				
Canada				
Lymphoma Rapid Diagnosis Clinic (LRDC) at Princess Margaret Cancer Centre, Toronto, Ontario				
Nixon et al (2020). Evaluation of lymphadenopathy and suspected lymphoma in a lymphoma rapid diagnosis clinic . JCO Oncology Practice. 16(1). e29-e36	<p>Study Design: Cross-sectional post-test only quasi-experimental</p> <p>Intervention/comparator: Nurse-practitioner-led LRDC vs usual care at University Health Network (UHN) (i.e., care given at the centre before the LRDC was implemented.</p> <p>Aim: To investigate if wait times can be reduced for a definitive diagnosis of lymphoma and initiation of treatment by implementing a nurse practitioner-led LRDC in a tertiary care cancer centre</p> <p>Data collection methods and dates: Data were collected from patients referred to LRDC from June 1, 2015 to Nov 30, 2017. Pre-RDC data collected in 2008 and 2012.</p> <p>Outcomes reported: Number of biopsies to arrive at diagnosis Time from consultation to diagnosis</p>	<p>Sample size: 126 patients referred to the LRDC (no data on historical controls)</p> <p>Participants: Patients with lymphadenopathy on the basis of clinical assessment or imaging, biopsy results suspicious for lymphoma, or peripheral blood abnormalities.</p> <p>Setting: The LRDC at a tertiary cancer centre (Princess Margaret Cancer Centre), part of University Health Network (UHN), Toronto, Ontario, Canada.</p> <p>Staffing/facilities: The LRDC was led by a nurse practitioner, weekly operating room time was needed and commitments from surgeons and radiologists were needed to perform the biopsies.</p> <p>Services provided: Laboratory tests, peripheral blood flow cytometry, tuberculosis skin testing, abdominal ultrasound, CT scans, bone marrow biopsy, or fine-needle aspiration (FNA).</p>	<p>Of 129 patients referred to LRDC with suspected lymphoma, 126 were included in the current analysis. Median age was 55 years (range, 18 to 95 years), and 67 patients (53%) were female.</p> <p>Primary Findings: After evaluation, 66 patients (52%) had confirmation of a diagnosis of lymphoma - indolent (n = 34), aggressive (n = 18), Hodgkin lymphoma (HL) (n =14), acute leukaemia (n = 2), metastatic carcinoma (n =14), and non-malignant diagnoses (n = 44).</p> <p>Median time from initial assessment to lymphoma diagnosis was 16 days (9-24 days) for the patients assessed in LRDC and 28 days (19-48 days) for historical controls (P< 0.001). Median time from initial LRDC assessment to treatment of aggressive lymphomas and HL was 29 days (21-43 days) compared with 48 days (28-78 days) for historical controls (P< 0.001).</p> <p>Significantly fewer patients required two or more biopsies to arrive at a diagnosis of lymphoma after institution of the LRDC compared with patients previously diagnosed at UHN (40% v 12%; P<0.001, Fisher's exact test). Lymph node size greater than 3.4 cm and presence of mediastinal or abdominal adenopathy increased the likelihood of a diagnosis of malignancy, whereas younger age, being a non-smoker, and prior rheumatologic condition were associated with a non-malignant diagnosis.</p>	<p><i>Cancer-related study (lymphoma)</i></p> <p><i>Some of the included participants had a prior cancer diagnosis.</i></p> <p><i>The authors' acknowledge the small sample size used as a limitation of the study.</i></p> <p><i>This study does not give the patient characteristics of the controls or even the number of patients in the control group.</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	Time from assessment to treatment Predictive factors for benign diagnoses			
<i>A Rapid Access Breast Clinic (RABC) at Mount St Joseph Hospital, Vancouver</i>				
McKevitt et al (2017). Reduced time to breast cancer diagnosis with coordination of radiological and clinical care . Cureus, 9(12).	<p>Study Design: Cross-sectional post-test only quasi-experimental</p> <p>Intervention/comparator: RABC vs traditional system (TS) i.e., standard care</p> <p>Aim: To investigate if the RABC will decrease wait times to diagnosis and minimise duplication of services compared to usual care</p> <p>Data collection methods and dates: A retrospective review of a prospectively maintained breast clinic database was undertaken to look at diagnostic wait times, treatment times, and the number of preoperative diagnostic centres involved for consecutive patients seen by the three breast surgeons in November and December 2009.</p> <p>Outcomes reported: Time from presentation to surgical consultation/assessment</p>	<p>Sample size: 373 Patients</p> <p>Participants: Patients presenting with a new breast problem who were referred to the clinic with either an abnormal screening mammogram or were referred by their family physician for assessment of a breast symptom.</p> <p>Setting: The RABC at Mount St Joseph Hospital, University of British Columbia Vancouver, Canada</p> <p>Staffing/facilities: The clinic provided triple evaluation of patients with close collaboration between clinicians and radiologists, facilitated by clinical pathways and nurse navigation</p> <p>Services provided: Single site for coordinated clinical and radiological assessment of breast problems. Offers on-site mammography, breast ultrasound, ultrasound-guided biopsy, and mammographic</p>	<p>In the study group, 99% of patients were female with one male seen in the TS and two males seen in the RABC. In the RABC the surgeons saw 24 (38%) patients with a known cancer diagnosis and 40 (62%) patients with a benign or indeterminate diagnosis. In the office, 44 (25%) patients were referred with a known cancer diagnosis and 134 (75%) patients were referred with a benign diagnosis, indeterminate diagnosis, or an incomplete diagnostic workup.</p> <p>Primary Findings: Patients seen at the RABC had a decreased time to surgical consultation (33 vs 86 days, $p < 0.0001$) for both malignant (36 vs 59 days, $p=0.0007$) and benign diagnoses (31 vs 95 days, $p<0.0001$). Seventeen (13%) of the patients referred to the surgeon in the traditional system without a diagnosis were eventually diagnosed with a malignancy and waited a mean of 84 days for initial surgical assessment. Of the patients seen at the RABC, 5% required investigation at more than one institution compared to 39% patients seen in usual care ($p<0.0001$). Cancer patients had a shortened time from presentation to surgery in the RABC (64 vs 92 days, $p=0.009$).</p> <p>Additional Findings: For the patients presenting with breast cancer and having initial treatment with surgery, the time from surgical consultation to surgery was 33 days in usual care and 31 days in the RABC ($p=0.78$). However, the time from presentation to surgery for cancer patients was decreased for patients managed through the RABC (64 vs 92 days, $p=0.009$). For cancer patients that had a core biopsy prior to seeing</p>	<p><i>Cancer-related study (breast cancer)</i></p> <p><i>The study authors reported a total sample size of 373 patients, however there are disparities in the numbers reported for the intervention and control group</i></p> <p><i>The study authors acknowledge the retrospective nature of the data collected, as well as the inability to accurately determine the breast problem presentation date, as limitations for this study.</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	<p>Time from surgical consultation to surgery Time from presentation to surgery</p> <p>Number of diagnostic centres visited in order to obtain a diagnosis.</p>	and ultrasound-guided fine wire localisation.	<p>the surgeon, the time from presentation to core biopsy was shorter in the RABC (18 vs 38 days, $p=0.002$) as was the time from core biopsy to seeing the surgeon (15 vs 25 days, $p=0.01$).</p> <p>In the RABC, 61 (95%) patients had their diagnosis at one centre and three (5%) patients had diagnostic studies at other centres. In contrast, in the usual care group only 61% attended a single diagnostic centre with 39% attending two or more diagnostic centres ($p<0.0001$).</p> <p>A patient attending four diagnostic centres had a mammogram at one centre, an ultrasound at a different centre, an ultrasound-guided biopsy at a third centre, and a stereotactic core biopsy at a fourth centre. Of the patients having only mammograms, ultrasound, and ultrasound-guided biopsy in usual care, 31.5% of the patients attended more than one diagnostic imaging centre and were more likely to have attended one diagnostic centre for these tests in the RABC ($p<0.0001$). Patients referred with a breast cancer diagnosis were more likely to have been seen in a single diagnostic centre for mammogram, ultrasound, and ultrasound-guided core biopsy when seen at the RABC than in usual care ($p=0.021$).</p>	
<i>Rapid Access Diagnostic and Support (RADS) at The Women's Breast Health Centre, Ottawa Hospital, Ottawa, Ontario</i>				
<p>Arnaout et al (2013). Improving Breast Diagnostic Services with a Rapid Access Diagnostic and Support (RADS) Annals of surgical oncology, 20(10), pp.3335-3340.</p>	<p>Study Design: Cross-sectional post-test only quasi-experimental</p> <p>Intervention/comparator: RADS clinic vs pre-RADS period</p> <p>Aim: To pilot a rapid diagnosis and support clinic programme for patients</p>	<p>Sample size: 211 RADS patients and 225 historical controls</p> <p>Participants: Women referred to the breast centre with a high probability of breast cancer (i.e., patients with an initial diagnostic imaging classified as BI-RADS 5)</p>	<p>The mean age of patients enrolled in the RADS programme was 62 years. Fourteen percent (10 patients) of the biopsies performed on the RADS patients were benign. Overall, 91 % of the biopsies resulted in invasive (ductal or lobular) carcinoma or DCIS. An additional 2 % of the biopsies resulted in either lymphoma (1 %) or metaplastic carcinoma (1 %).</p> <p>Primary Findings: The mean wait time from abnormal imaging to biopsy decreased by 4.1 days (from 7.1 to 3 days; 58%</p>	<p><i>Cancer-related study (breast cancer)</i></p> <p><i>The authors acknowledge a limitation of the study was the inability to address whether or not the RADS program had an impact in the diagnostic wait times</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	<p>referred to the breast centre with a high probability of breast cancer</p> <p>Data collection methods and dates: Data for wait times and patient satisfaction was analysed before (for 1 year) and after 1 year of RADS clinic implementation (2011).</p> <p>Outcomes reported: Wait times from date of diagnostic imaging workup and confirmation of the BI-RADS 5 status to biopsy date Time from biopsy to pathological verification of malignancy Time from verification to initial surgical consultation Time from consultation to operative management Patient satisfaction Personnel costs</p>	<p>Setting: The RADS clinic, at the Women's Breast Health Centre of the Ottawa Hospital in Ottawa, Ontario, Canada (a university-affiliated tertiary care centre)</p> <p>Staffing/facilities: A multidisciplinary team of breast cancer specialists (five radiologists, five surgeons, two pathologists, one nurse manager, two nurse navigators, and a diagnostic imaging manager)</p> <p>Services provided: Routine screening mammography, initial diagnostic imaging workup (mammogram and/or breast ultrasound) for a breast problem (e.g., palpable mass, breast pain, nipple discharge), or additional diagnostic imaging and biopsy workup following an abnormal mammogram performed at another institution</p>	<p>reduction, $p < 0.01$), biopsy to pathology verification by 0.6 days (from 3.9 to 3.3 days; 15% reduction, $p < 0.01$), pathology verification to surgical consult by 10.1 days (from 16.1 to 5.9 days; 63% reduction, $p < 0.01$), and operative wait time from initial consultation by 7.5 days (from 31.5 to 24.1 days; 24% reduction, $p = 0.04$)</p> <p>Significant improvements in patient satisfaction was in the understanding of the diagnostic and treatment plan ($p = 0.03$), as well as timeliness of diagnostic tests ($p = 0.04$) and timeliness provision of results (0.04). There was a trend towards an improvement in overall satisfaction of the diagnostic testing experience but it was not statistically significant ($p = 0.16$).</p> <p>Additional Findings: There was an average of 4.5 RADS patients per week at the breast centre. The nursing cost was equivalent to a 0.2 FTE nurse annual salary (CAD \$20,730.80), and there were 10 additional biopsy days added in total (CAD \$6,100, including radiology technician time and equipment; not including fees for radiologist), which accommodated 70 of 234 diagnostic biopsies. The remaining 164 biopsies were fitted into previously routinely reserved biopsies slots in addition to last minute unused gaps in scheduling.</p>	<p><i>of breast cancer patients with BI-RADS 4 mammograms. However, findings for these patients will be reported in a future publication.</i></p>
Rapid Diagnostic Unit (RDU) at The Gale and Graham Wright Prostate Centre, North York General Hospital Toronto, Ontario				
Sethukavalan et al (2013). Improved wait time intervals for prostate cancer patients in a multidisciplinary rapid diagnostic unit compared to a community-based referral pattern . Canadian	<p>Study Design: Cross-sectional post-test only quasi-experimental</p> <p>Intervention/comparator: A multidisciplinary RDU vs a</p>	<p>Sample size: The study aimed to include 100 patients, however only 87 patients (44 RDU patients and 43 community patients) were included in the study</p>	<p>There were no significant differences between the RDU and community cohorts with respect to demographic (not all data shown) or tumour variables.</p> <p>Primary Findings: The median overall wait time interval from suspicion of prostate cancer to RT, the "overall interval," was</p>	<p><i>Cancer-related study (prostate cancer)</i></p> <p><i>The authors acknowledged that the retrospective nature of the data collected and the</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
Urological Association journal. 7;7, 244-250.	<p>community based referral pattern</p> <p>Aim: To document intervals between key wait time milestones within the prostate cancer care pathway from suspicion to the start of definitive therapy for patients referred to and treated with radical radiotherapy treatment (RT) at the Odette Cancer Centre, comparing patients diagnosed in the RDU versus the usual community process.</p> <p>Data collection methods and dates: The first 50 patients who were seen at the RDU and the first 50 patients from the community who consented were accrued to the study on a consecutive basis starting in October 2011. The RDU was not equipped to treat patients with radical radiotherapy treatment (RT), therefore the sample of patients that agreed to participate in this study was obtained at the Odette Cancer Centre at Sunnybrook Health Sciences Centre and not at the RDU.</p> <p>Outcomes reported:</p>	<p>Participants: A convenience sample of 100 consenting patients who were treated with radical radiotherapy at the Odette Cancer Centre at Sunnybrook Health Sciences Centre, in 2011 and 2012.</p> <p>Setting: RDU called The Gale and Graham Wright Prostate Centre, set up at the North York General Hospital (NYGH), Branson Site, Toronto, Ontario, Canada.</p> <p>Staffing/facilities: Staff include radiation oncology and urology specialists</p> <p>Services provided: Unclear</p>	<p>138 days for the RDU cohort and 183 days for the community cohort ($p = 0.046$). The median wait time interval from suspicion of prostate cancer to diagnosis, the “diagnostic interval,” for patients in the RDU and community cohorts was 49 days and 67 days, respectively ($p = 0.29$). The median wait time interval from diagnosis to radiation oncology (RO) consult for patients in the RDU and community cohorts was 27 days and 49 days, respectively ($p = 0.0019$). The median wait time interval from RO consult to start of therapy (RT), the “treatment interval,” for patients in the RDU and community cohorts was 46 days and 37 days, respectively ($p = 0.52$)</p> <p>There were statistically significant differences between the two cohorts, favouring the RDU cohort, for other key wait time intervals. These differences included suspicion to DTT ($p = 0.012$), urologist visit to diagnosis ($p = 0.0094$), diagnosis to DTT ($p = 0.018$), and diagnosis to treatment ($p = 0.016$).</p> <p>Additional Findings: Among all patients, there were 22 patients (25%) with perceived delayed treatment. Among those 22 patients, most of patients identified a systematic reason (64%) for the delay. There was no significant difference on the cause of perceived delay between the RDU and community cohorts ($p = 0.86$).</p> <p>Risk category and Gleason sum were independently predictive of longer intervals from diagnosis to DTT. Patients with Gleason sum of 6 or 7 disease had shorter diagnosis to DTT intervals compared patients with Gleason 8-9 disease (median 41 vs. 42 vs. 94 days, respectively, $p = 0.035$). Patients with low-versus intermediate- versus low-risk disease had median intervals of 67 vs. 41 vs. 38 days, respectively ($p = 0.011$). Conversely, patients with</p>	<p><i>use of a modest sample size over a limited timeframe, could limit the study findings.</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	<p>Participant characteristics, Overall wait time interval (time from suspicion of prostate cancer to radiation therapy) Diagnostic interval (time from suspicion of prostate cancer to diagnosis) Time from diagnosis to radiation oncology (RO) consult Treatment interval (time from RO consult to start of radiation therapy) Patient perceived delays</p>		<p>PSA ≥ 10, or with high-risk disease had shorter DTT to RT intervals: PSA ≥ 10 vs.</p>	
<i>Spain</i>				
<i>Quick Diagnostic Unit (QDU) at Hospital Clínic de Barcelona</i>				
<p>Bosch et al (2020). What is the relevance of an ambulatory quick diagnosis unit or inpatient admission for the diagnosis of pancreatic cancer? A retrospective study of 1004 patients. Medicine, 2020, vol. 99, num. 11, p. e19009.</p>	<p>Study Design: Cross-sectional post-test only quasi-experimental</p> <p>Intervention/comparator: QDU vs hospitalised (inpatient ward at same hospital)</p> <p>Aim: To investigate the effectiveness and associated costs of a hospital-based ambulatory QDU versus inpatient setting for the diagnosis of pancreatic adenocarcinoma.</p> <p>Data collection methods and dates: Clinical data were collected on QDU and hospitalised patients</p>	<p>Sample size: 1,004 patients comprising of 508 patients from QDU and 496 inpatients</p> <p>Participants: Patients aged ≥ 18 years with a diagnosis of pancreatic adenocarcinoma who had been referred to QDU or hospitalised between October 2005 and November 2018 were eligible.</p> <p>Setting: QDU based in the Adult Day Care Centre of Hospital Clínic, Barcelona, Spain</p> <p>Staffing/facilities: Staff at QDU includes a full-time consultant internist, a senior internal medicine resident, a full-time nurse, a part-time</p>	<p>The mean age of QDU patients and inpatients was 71.2 (12.8) and 72.5 (13.2) years, respectively, and there was a slight predominance of males in both groups. No significant differences were observed in the socioeconomic status.</p> <p>Primary Findings: Time to admission was significantly shorter than time to the first QDU visit (0.7 [0.2] vs 1.2 [0.3]) days; $P < 0.001$) and there were no differences between admission time to diagnosis and the QDU time to diagnosis (4.1 [0.8] vs 4.3 [0.6] days; $P = 0.163$). Three patients were admitted to inpatient wards during the QDU assessment: 2 had a quick deterioration of their performance status as well as increased jaundice and the other a pulmonary thromboembolism.</p> <p>The frequency of risk factors of pancreatic cancer (age, smoking status, history of pancreatitis, family history, BMI, Long standing Type II diabetes mellitus, heavy alcohol consumption) was slightly higher in</p>	<p><i>Cancer-related study (pancreatic cancer)</i></p> <p><i>potential QDU data overlap with Bosch 2021 (i.e. pancreatic ca data only between 2009 and 2017)</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	<p>between October 2005 and November 2018.</p> <p>Costs of all individual resource items were obtained from the institutional information system of the hospital</p> <p>Outcomes reported: Risk and prognostic factors of pancreatic cancer Presenting symptoms and signs <u>Wait times</u> Time to admission/first QDU visit (time between referral and appointment at QDU/admission of inpatients) QDU time to diagnosis (defined as time elapsed between the request of the decisive diagnostic procedure and the cyto/pathological diagnosis) Length of stay for inpatients Admission time to diagnosis (defined as time elapsed between the request of the decisive diagnostic procedure and the cyto/pathological diagnosis)</p> <p>Predictors of hospitalisation</p> <p>Mean number of visits during the QDU evaluation Cost per visit</p>	<p>nurse coordinator, and 2 part-time administrative assistants. The unit is open 5 hours a day, 5 days a week. Staff in each of the 3 medical wards includes 2 full-time consultant internists, 2 residents, a full-time nurse coordinator, 3 teams of 3 full-time nurses and 3 teams of 2 full-time nursing assistants (8-hours daily shifts), and a full-time administrative assistant.</p> <p>Services provided: Upper gastrointestinal endoscopic ultrasound (EUS), US/CT-guided biopsy, contrast-enhanced thin-slice CT scan of the chest, abdomen, and pelvis</p>	<p>inpatients than in QDU patients, but no significant differences were observed.</p> <p>Multivariate logistic regression analysis with adjustment for other variables, identified 4 significant independent predictors of hospitalisation: age ≥ 75 years (OR 4.40, 95% CI: 3.31 to 8.19; $p = 0.012$), thrombophlebitis (OR 2.07, 95% CI: 1.77 to 2.86; $p = 0.041$), jaundice (OR 9.12, 95% CI 6.58 to 16.03; $p < 0.001$), and an ECOG performance score ≥ 2 to 4 (1.304, 95% CI: 0.804 to 1.905; $p = 0.044$). Having jaundice was the strongest predictor of admission on multivariate analysis (OR 9.12, 95% CI: 6.58–16.03; $P < .001$).</p> <p>Cost analysis Considering that the mean admission time to diagnosis of inpatients was 4.1 (1.4) days and that the mean number of visits of QDU patients during the QDU time to diagnosis was 1.02 (0.3), the total cost per hospitalised patient was €634.36 (80.56), with 46.4% being attributable to personnel salaries and 44.2% to diagnostic tests, and the total cost per QDU patient was €347.76 (48.69), with 66.7% being attributable to diagnostic tests, 18.2% to ambulatory visits, and 13.7% to salaries. According to the analysis, the total saving with QDU was €286.6 per patient.</p> <p>67.7% of inpatients versus 62.6% of QDU patients had a tumour site of the head of the pancreas, Inpatients were also more likely than QDU patients to have a mean tumour size $> 2\text{cm}$ (77.0 vs 72.4%; $P = .048$), an N1 stage (75.6 vs 70.9%; $P = .049$), and a poorer grade of histological differentiation (26.2 vs 21.1%; $P = .031$). Moreover, 61.5 vs 59.1% of inpatients and QDU patients, respectively, had a metastatic stage on presentation ($P = .120$) and 29.4 versus 29.1% of inpatients and QDU patients, respectively, had an unresectable, locally advanced</p>	

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	<p>Total cost per QDU patient cost per day of hospital stay total cost per hospital inpatient total saving with QDU</p> <p>Charlson comorbidity index</p>		<p>tumour (P=.221). Regional lymph nodes could not be identified in imaging studies in 8.5% of QDU patients and 9.5% of inpatients. The histological differentiation in 7.9% of QDU patients and 8.5% of inpatients was unknown for the pathologist. There were several statistically significant differences regarding laboratory results. Inpatients were more likely than QDU patients to have higher serum levels of CA19.9, CEA, LDH, AST/SGOT, ALT/ SGPT, alkaline phosphatase, total bilirubin, creatinine, and CRP. The levels of albumin and haemoglobin were significantly lower in inpatients.</p> <p>Additional Findings: While both QDU patients and inpatients were more commonly referred from the ED, the QDU was more often used by PC physicians (31.7% of QDU patients versus 21.4% of inpatients were referred from PC; P<.001). The mean age of QDU patients and inpatients was 71.2 (12.8) and 72.5 (13.2) years, respectively, and there was a slight predominance of males in both groups. No significant differences were observed in the socioeconomic status. Compared with inpatients, QDU patients were less likely to live alone and more likely to live with a partner (21.3 vs 26.6%; P=.024 and 69.7 vs 65.0%; P=.042, respectively). Regarding symptoms and signs on presentation, admitted patients were significantly more likely than QDU patients to have weight loss, asthenia, anorexia, abdominal pain, jaundice, and palpable hepatomegaly of stony consistency. Whereas some symptoms (nausea/ vomiting, change in bowel habit, pruritus, and new-onset diabetes) never presented solitarily, the most frequent symptoms presenting solitarily were abdominal pain, jaundice, back pain, and the triad weight loss, asthenia, and anorexia. It is of note that 9 (1.8%) QDU patients and 6 (1.2%) inpatients (all of them with early-stage pancreatic adenocarcinoma) had no symptoms but their tumour was detected as an</p>	

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
			incidental imaging finding on medical check-up or during evaluation for other diseases.	
<p>Brito-Zerón et al (2014). Diagnosing unexplained fever: can quick diagnosis units replace inpatient hospitalization? European Journal of Clinical Investigation, 44(8), pp.707-718.</p>	<p>Study Design: Cross-sectional post-test only quasi-experimental</p> <p>Intervention/comparator: QDU vs hospitalised (internal medicine department)</p> <p>Aim: To analyse the main causes of fever as a key or isolated symptom of disease in a cohort of patients evaluated in the QDU of a tertiary university hospital, to examine the advantages and disadvantages of this unit for the diagnosis of fever and to compare the results with a cohort of hospitalised patients.</p> <p>Data collection methods and dates: Economic outcomes data collected from hospital information systems (bottom-up micro-costing)</p> <p>November 2008 and April 2011</p> <p>Outcomes reported:</p>	<p>Sample size: 344 patients, 176 from QDU and 168 controls (hospitalised).</p> <p>Participants: All participants were consecutive patients referred to the QDU due to fever of uncertain nature (FUN), defined as a temperature > 38 °C during at least 1 week and no diagnosis after a previous evaluation.</p> <p>Setting: QDU at Hospital Clínic de Barcelona, Spain</p> <p>Staffing/facilities: Staff in QDU includes a consultant internist, a full-time nurse and two part-time secretaries. Staff in each internal medicine ward includes two consultants internists, four residents, a nurse coordinator, three teams of three full-time nurses and three teams of two full-time nursing assistants (8-h daily shifts), and a full-time secretary.</p> <p>Services provided: Laboratory tests included, among others, acute phase reactants (C-reactive protein, erythron sedimentation rate), hemogram (total leucocytes, manual white blood cell count,</p>	<p>A total of 344 patients were finally evaluated, 176 QDU patients and 168 controls. QDU patients were predominantly women and had a lower mean age than controls. Both QDU and control patients were predominantly referred from the ED. However, more QDU patients than controls were referred from primary healthcare centres (PHC), and more controls than QDU patients were referred from the ED</p> <p>Primary Findings: Time-to-diagnosis of QDU patients was longer than length-of-stay of controls ((25.82 ± 26.14 vs. 12.89 ± 11.33 days, P < 0.001). The mean number of visits required to reach a diagnosis in QDU patients was 2.66 ± 1.25 (range: 1–10 visits). 56% patients required one or two visits, while 44% required three or more visits. Patients who required < 3 visits had a higher prevalence of infectious diseases, while those who required ≥ 3 visits had a higher prevalence of inflammatory diseases.</p> <p>QDU patients had a higher frequency of referrals in comparison with controls. QDU patients were more frequently referred to PHC physicians and less frequently to specialized outpatient clinics. Three QDU patients required admission in the internal medicine department for further evaluation of unresolved fever.</p> <p>One control patient died during hospitalisation, and there were no deaths among QDU patients Mean total costs per QDU patient was €644.59 ±120.18, while it was €4404.64 ±815.32 per hospitalised patient. Mean cost per QDU visit was €63.50, and mean cost per day in hospital was €117.00. Direct and Indirect costs varied but were generally less in QDU patients. The mean saving of</p>	<p><i>Unclear if controls are same wards as in Bosch 2020 and Bosch 2018.</i></p> <p><i>Potential QDU data overlap with Bosch 2021, i.e. FUN data only between 2009 and 2011</i></p> <p><i>As the setup may be different, the results and implications of this study cannot be directly applicable to other countries and generalized, which represents an intrinsic weakness. Specific QDU patients with potentially serious conditions including unexplained fever may be handled diversely elsewhere, with the contrast between hospitalisation and ambulatory care depending not only on local issues but also on the implementation and comprehension of clinical guidelines.</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	<p>Number of visits required to reach a diagnosis (QDU only)</p> <p>Time to diagnosis (from first visit to diagnosis) (QDU only)</p> <p>Length of hospital stay (hospitalised only)</p> <p>Death during evaluation</p> <p>Onward referrals</p> <p><u>Economic outcomes (micro costing):</u></p> <p>Indirect costs (general expenses, maintenance etc.)</p> <p>Cost per hospital stay (hospitalised only)</p> <p>Cost per day of stay (hospitalised only)</p> <p>Cost per visit (QDU only)</p> <p>Cost per patient (from first to last visit) (QDU only)</p>	<p>haemoglobin, haematocrit, platelets), liver function tests, serum lactate dehydrogenase, serum total proteins and protein electrophoresis, microbiological serologies [e.g. IgM and IgG for cytomegalovirus (CMV), Epstein–Barr virus (EBV), Toxoplasma gondii, human parvovirus B19], HIV testing, b2 microglobulin, specific serum tumour markers, specific serum autoantibodies, specific genetic studies (autoinflammatory diseases), including cultures, imaging studies, endoscopies and cytology/biopsy studies</p>	<p>€3760 for each QDU patient mostly reflects the differences in staffing and working hours and in number of investigations.</p>	<p><i>Time to diagnosis in QDU patients was compared to the length of hospital stay in hospitalised patients.</i></p> <p><i>Costs were adjusted for inflation to 2011 Euros, the last year of data gathering, using the Consumer Price Index</i></p>
<p>Bosch, Jordán and López-Soto (2013). Quick diagnosis units: avoiding referrals from primary care to the ED and hospitalizations The American Journal of Emergency Medicine, 31(1), pp.114-123</p>	<p>Study Design: Cross-sectional post-test only quasi-experimental</p> <p>Intervention/comparator: QDU vs hospitalised (internal medicine department)</p> <p>Aim: To determine whether quick diagnosis units (QDUs) can safely and efficiently avoid emergency department (ED) visits and hospitalisations.</p>	<p>Sample size: 4,170 QDU patients and 3,030 randomly selected hospitalised patients.</p> <p>Participants: QDU patients were consecutively selected, whilst hospitalised patients were retrospectively randomly selected with a diagnosis of anaemia (n = 851), cachexia-anorexia syndrome (n = 717), febrile syndrome (n = 485), adenopathies and /or palpable masses (n = 428), lung and/or pleural abnormalities (n = 278), and chronic diarrhoea (n =</p>	<p>Of the 4170 patients finally evaluated, 48% (n =2,001) were male, and the mean age (SD) was 61 (17.93) years. All patients were judged stable enough for an initial QDU assessment. Sixteen patients were lost to follow-up, 15 were hospitalised, and 12 died during the QDU evaluation before reaching a diagnosis.</p> <p>Primary Findings: Assessment of hospitalised patients concluded hospitalisation might have been avoided in between 84% and 91% of hospitalised patients.</p> <p>Referral sources varied. From December 2007 to December 2009, 1,304 (66%) of 1,963 QDU patients were referred from PC to the ED and 496 (25%) of</p>	<p><i>QDU data overlap with Bosch 2012a (2,000 consecutive patients evaluated between 2007 and 2010)</i></p> <p><i>One limitation of the study that makes it difficult to judge whether the use of QDUs alleviates ED crowding is the heterogeneity of patients included.</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	<p>Data collection methods and dates: Data collected from medical records QDU patients: December 2007 to December 2009 (n = 1963 patients) and January 2010 to January 2012 (n = 2207 patients). Hospitalised patients: September 2006 and January 2012 Telephone survey evaluated between December 2010 and December 2011</p> <p>Outcomes reported: Wait time for first visit (QDU only) Number of visits (QDU only) Time to diagnosis (time from first visit to ultimate diagnosis) (QDU only) Referral patterns over time (from ED to QDU vs hospitalisation) Onward referral/destination (hospitalised only) Length of hospital stay (hospitalised only) Future care preferences (QDU vs hospitalisation) – self reported Future preference on type of referral (QDU vs ED) – self reported</p> <p><u>Economic outcomes</u></p>	<p>271) admitted to the internal medicine service between September 2006 and January 2012.</p> <p>One month after evaluation, a telephone survey was conducted in 300 randomly selected QDU patients. Additionally, one month after discharge, a random sample of 200 patients from the random cohort were asked about care preferences and referral in future.</p> <p>Setting: QDU at Hospital Clínic de Barcelona, Spain.</p> <p>Staffing/facilities: The QDU has a dedicated consulting room and patient/family waiting room. It is open for 5 hours from Monday to Friday and is staffed by a consultant in internal medicine and a full-time nurse, with part-time support from 2 secretaries. In addition, consultations are provided by specialists from other services as required.</p> <p>Services provided: Not reported</p>	<p>1,963 QDU patients from PC to the QDU. In contrast, from January 2010 to January 2012, 774 (35%) of 2,207 QDU patients were referred from PC to the ED and 1,172 (53%) of 2,207 QDU patients from PC to the QDU (P < 0.0001).</p> <p>Analysis of the referral patterns from the ED over time for the 6 main reasons for consultation showed significant differences in the number of patients referred to the QDU vs hospitalisation. From December 2007 to December 2009, 683 (36%) of 1,876 patients were referred from the ED to the QDU, and 1,320 (65%) of 2,031 patients (retrospective cohort) were directly hospitalised from the ED. In contrast, from January 2010 to January 2012, 1,193 (64%) patients were referred from the ED to the QDU and 711 (35%) patients were hospitalised from the ED (P < 0.0001).</p> <p>The most common diagnoses were cancer in 1,264 (30.3%) of 4,170 patients and iron-deficiency anaemia not related to malignancy in 792 of (19%) 4,170 patients. The most frequent malignancies were colorectal cancer and lymphoma: the main reason for iron-deficiency anaemia was chronic gastrointestinal bleeding (325/4170 [7.8%] patients).</p> <p>Waiting times to first QDU visit from ED ranged from 0 to 3.5 days (mean 1.9 days) and from PHC ranged from 1 to 7 days (mean 3.6 days). Wait times for admission in hospitalised patients ranged from 0 to 2 days (mean 1.3 days) in those referred from ED and between 3 to 7 days (mean 4.9 days) in those referred from PHC.</p> <p>Each QDU patient had a mean of 3.13 visits and a mean (SD) time to diagnosis of 8.9 (2.35) days. The mean (SD) hospital stay of the retrospective cohort of hospitalised patients was 8.76 (2.18) days.</p>	<p><i>although the review of cases was conducted according to clinical parameters, we cannot exclude the possibility of some subjectivity when determining which hospitalised patients could have been worked up safely in the QDU.</i></p> <p><i>Because we did not describe the course of patients after an initial diagnosis was reached, we do not have an accurate picture of the overall costs involved.</i></p> <p><i>Time to diagnosis in QDU patients was compared to the length of hospital stay in hospitalised patients.</i></p> <p><i>Costs were assessed using the hospital costs and not overall Spanish National Health Service costs.</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	<p>Direct costs (diagnostic test, consumables, QDU visits and inpatient stay)</p> <p>Indirect costs (maintenance and general expense overheads)</p> <p>Cost per visit (QDU only)</p> <p>Cost per day (hospitalised only)</p> <p>Cost per hospital stay (hospitalised only)</p> <p>Cost per process (from admission to discharge)</p>		<p>Destinations of QDU and hospitalised patients, after diagnosis and hospital discharge, respectively. During the QDU evaluation, 125 (3%) patients were referred to the ED due to complications of the process under evaluation (e.g., worsening of anaemia). Overall, 15 patients were hospitalised and 12 died. In the remaining cases, the situation was resolved and the QDU evaluation proceeded. Review of these 27 cases showed that, at least initially, they were stable enough to start QDU evaluation.</p> <p>The mean cost per process was €3241.11 (SD 915) in hospitalised patients and €726.47 (617) in QDU patients. Mean cost of hospitalisation per day was €369.99 and mean cost per QDU visit was €232.1.</p> <p>Additional Findings: The response rate to the survey was 96% among QDU patients. If further diagnostic tests were required, 88% of patients would prefer the QDU care model to hospitalisation. In addition, 97% would prefer direct PC referral to the QDU without the need to attend the ED first. Finally, 182 (96%) of the 190 patients from the retrospective cohort who responded to the survey would prefer the QDU care model to hospitalisation should the diagnostic workup be performed again, and 98% would prefer direct hospitalisation from the QDU or PC without attending the ED first.</p>	
<p>Bosch et al (2012a). Quick diagnosis units versus hospitalization for the diagnosis of potentially severe diseases in Spain Journal of Hospital Medicine, 7(1), pp.41-47.</p>	<p>Study Design: Cross-sectional post-test only quasi-experimental</p> <p>Intervention/comparator: QDU vs hospitalised (admitted to the internal medicine department)</p>	<p>Sample size: 2,000 consecutive QDU patients and 1,454 control patients</p> <p>Participants: Consecutive QDU patients. Control patients (comprised of patients diagnosed with anaemia n = 548; cachexia-anorexia syndrome n = 458; febrile</p>	<p>Of the 2000 QDU patients finally included, of whom 1106 were female, with a mean age of 60 years (18.84).</p> <p>Primary Findings: The main sources of referral were the ED (1,022 patients) and PHC centres (942 patients). Waiting time for the first QDU visit ranged from 2 to 8 days (mean 3.9 days) in patients referred from PHC centres, and 0 to 4 days (mean 2.1 days) in patients</p>	<p><i>QDU data overlap with Bosch, Jordán and López-Soto 2013 (2,000 consecutive patients evaluated between 2007 and 2010)</i></p> <p><i>Time to diagnosis in QDU patients was</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	<p>Aim: To describe the functioning of a QDU in a Spanish public university hospital after evaluating 2000 consecutive patients. Authors intended to ascertain the utility and cost of the model compared to conventional hospitalisation and the degree of patient satisfaction.</p> <p>Data collection methods and dates: QDU data collected between December 2007 and July 2010 Hospitalised (control) data collected between September 2006 and June 2010</p> <p>Outcomes reported: Time to first QDU visit (QDU only) Number of visits (QDU only) Waiting time between visits (QDU only) Time to diagnosis (defined as the time from the first visit to a definitive diagnosis) (QDU only) Onward referral Charlson comorbidity index Length of hospital stay (hospitalised only) Hospital admissions avoided (defined as patients who would have been admitted)</p>	<p>syndrome n = 240 and adenopathies or palpable masses n = 208) randomly selected from 2,022 consecutive patients with these diagnoses. Participants were unmatched.</p> <p>A telephone survey was carried out in a random sample of 225 patients 3 months after the QDU intervention.</p> <p>Setting: QDU at Hospital Clínic de Barcelona, Spain</p> <p>Staffing/facilities: The QDU is composed of a specialist in internal medicine and a registered nurse who work in the QDU for 5 hours daily, 5 days a week (Monday-Friday), assisted by specialists from other specialties and receives administrative support from 2 secretaries shared with other units. It has a consulting room and a waiting room for patients and families, and functions daily.</p> <p>Services provided: Not reported</p>	<p>referred by the ED. The 2,000 first visits generated 4,260 successive visits (ratio first/successive = 2.13 visits). The average number of visits per patient was 3.11 visits. The mean length of hospital stay was 8.68 days.</p> <p>The most frequent diagnoses were cancer (both epithelial and hematological) in 526/2000 (26.3%) patients, and iron-deficiency anaemia (unrelated to malignancy) in 360 patients. The most common cancers were colon cancer and lymphomas, while the main cause of iron-deficiency anaemia was chronic gastrointestinal bleeding (148/2000 [7.4%] patients).</p> <p>Mean time to diagnosis was 9.4 days (1.78). After the diagnostic study was completed, 1,232 patients were referred to PHC centres, 712 to outpatients, and 56 required hospitalisation.</p> <p>Taking into account previously used criteria, authors estimated that 820 (41%) patients would have been candidates for conventional hospitalisation (for diagnostic studies) before QDU was created. Considering mean length-of-stay of the internal medicine department (50 beds) during 2009 for patients admitted for a diagnostic workup was 10.3 days, authors estimated that 12.5 beds per day during a year were freed up (i.e., 4563 bed-days saved in a year). On the other hand, 45 of 1000 (4.5%) patients required immediate or early hospitalisation due to their bad health status, which impeded further QDU diagnosis.</p> <p>In hospitalised patients, the total mean cost per day of hospital stay was €363.35, and the mean cost per process was €3,153.87 (910). In contrast, the mean cost per process in the QDU was €702.33 (610), and mean cost per QDU visit was €225.83. Mean direct and indirect costs were all less in the QDU visits.</p>	<p><i>compared to the length of hospital stay in hospitalised patients.</i></p> <p><i>Economic outcomes (micro costing) – sub-group analysis on a randomly selected cohort of 600 QDU and 600 QDU patients, each comprised of 150 patients with iron-deficiency anaemia, 150 patients with cachexia-anorexia syndrome, 150 patients with fever of unknown origin, and 150 patients with adenopathies and/or palpable masses. All costs analysed were hospital costs and not National Health Service costs.</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	<p>for a diagnostic workup if there no QDU)</p> <p><u>Self-reported outcomes</u> Degree of difficulty of travel to unit Overall satisfaction Preferential future care type</p> <p><u>Economic outcomes</u> Direct costs Indirect costs Mean cost per visit (QDU only) Mean cost per process (admission to discharge) Mean cost of daily stay (hospitalised only) Hospital bed days saved Cost per hospital stay Cost per process Cost per visit Patient satisfaction Patient preferences</p>		<p>Compliance with the patient survey was 94%. The results highlighted 3 main aspects: a) overall satisfaction with QDU care was high in 93% of cases; b) repeated travel to the hospital was not a major difficulty; and c) if further diagnostic tests were required, 84% of patients would prefer the QDU care model to hospitalisation. The same results were obtained analysing only patients with previous hospital admission. The remaining 16% indicated no preference for 1 type of care.</p> <p>Additional Findings: QDU patients with anaemia were significantly younger than hospitalised patients with the same diagnosis ($P < 0.0001$). Other parameters, notably age, time to diagnosis versus length-of-stay, and Charlson comorbidity index showed no statistically significant differences in any of the 4 main reasons for consultation.</p> <p>The type and mean number of complementary explorations in patients with the 4 main reasons for consultation was similar between QDU and hospitalised patients (2.27 vs 2.33, respectively).</p>	
<p>Bosch et al (2012b). Comparison of Quick Diagnosis Units and Conventional Hospitalization for the Diagnosis of Cancer in Spain: A Descriptive Cohort Study Oncology, 83(5), pp.283-291.</p>	<p>Study Design: Cross-sectional post-test only quasi-experimental</p> <p>Intervention/comparator: QDU vs hospitalisation (internal medicine department)</p> <p>Aim: To compare the diagnostic value and cost of a QDU and conventional hospitalisation in assessing patients with suspected and</p>	<p>Sample size: 169 QDU patients (62.8%), and 53 Hospitalised patients (control).</p> <p>Participants: Consecutive QDU patients with both initially suspected and ultimately confirmed (pathologically proven) cancer were evaluated for inclusion ($n=269$). Control patients evaluated from 164 hospitalised patients were newly diagnosed with cancer admitted to the internal medicine department.</p>	<p>Of the 169 patients, 20 were excluded due to associated conditions that made QDU management inappropriate. Of the 149 QDU patients finally included, 57% were males, with a mean age of 68.3 ± 14 years. Mean age of QDU patients were significantly younger than those hospitalised (68.3 vs. 74.7 years; $p < 0.05$).</p> <p>Primary Findings: Time to diagnosis among QDU patients compared to length of stay was not significantly longer 14.4 ± 11.3 days vs 10.6 ± 9.2 days respectively; $p > 0.05$).</p> <p>The main referral sources included 47% of QDU patients were referred from the ED, 37% from PHCs,</p>	<p><i>Cancer-related study</i></p> <p><i>Potential QDU data overlap with above studies by Bosch et al.</i></p> <p><i>Only participants with suspected and confirmed cancer diagnoses were included in this study.</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	<p>confirmed cancer in a Spanish tertiary public hospital.</p> <p>Data collection methods and dates: November 2008 and April 2010</p> <p>Outcomes reported:</p> <p>Wait time for first visit (QGU only) Number of visits (QDU only) Wait times between visits (QDU only) Time to diagnosis (from first visit to final diagnosis) Length of hospital stay (hospitalised only)</p> <p>QDU costs (per visit and per process) Hospital costs (per day and per process) Direct costs (unit costs of diagnostic procedures, consumables, QDU visits and inpatient stay) Indirect costs (overheads such as maintenance and general expenses)</p>	<p>Setting: QDU at Hospital Clínic de Barcelona, Spain</p> <p>Staffing/facilities: The QDU, which has a dedicated consulting room and patient/family waiting room, is open Monday to Friday for 5h and is staffed by a consultant in internal medicine, a full-time nurse, and two part-time secretaries. Consults are provided by other specialists on demand.</p> <p>Services provided: Not reported</p>	<p>7% from other hospital departments and 9% from other sources. Of hospitalised patients, 87% were referred from the ED, 9% from other hospital departments, 2% from PHCs, and 2% from other sources.</p> <p>The waiting time for the first QDU visit was 2 to 8 days in PHC referrals and 0 to 4 days in ED referrals. Waiting times for hospitalised patients were 0 to 2 days in ED referrals, 2 to 3 days in referrals from other departments, and 3 to 8 days in PHC referrals.</p> <p>Mean QDU visits were 2.37. The first 149 visits generated 199 successive visits (ratio first/successive = 1.335). Mean complementary tests per patient were 2.07 in QDU and 3.05 in hospitalised patients. Interconsultations per patient were 0.01 in QDU and 0.49 in hospitalised patients.</p> <p>The most common diagnoses were colorectal cancer (26%, n = 38) and lymphoma (22%) in QDU patients, and lymphoma (32%, n = 17) and colorectal cancer (23%) in hospitalised patients. There were significant differences between QDU patients and hospitalised patients in the source of referral ($p < 0.00001$) and destination ($p < 0.00001$) but not in the reason for consultation ($p > 0.26$) and diagnosis ($p > 0.34$).</p> <p>The Wilcoxon rank sum test showed a mean and median time to diagnosis of QDU patients of 14.4 ± 11.3 and 13 days (P25: 2.5, P75: 21.25), respectively, which was not significantly longer than the mean and median length of stay of hospitalised patients of 10.6 ± 9.2 and 8 days (P25: 2, P75: 12), respectively ($p > 0.05$).</p> <p>After diagnosis, 23% of QDU patients were hospitalised, 72% referred to outpatients [mainly oncology (36%) and haematology (17%)], 3% referred to PHCs, and 2% lost to follow-up. After</p>	<p><i>Authors acknowledged study limits including the prospective and retrospective nature of the two participant groups. Since the disease course after the initial diagnosis was not studied, authors were unable to provide a complete analysis of all costs.</i></p> <p><i>Time to diagnosis in QDU patients was compared to the length of hospital stay in hospitalised patients.</i></p> <p><i>Economic outcomes (micro costing) Costs were assessed using the hospital costs rather than Spanish National Health Service costs.</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
			<p>discharge, 63% of hospitalised patients were referred to outpatients [mainly oncology (26%) and haematology (25%)], 19% to home or specialized residential palliative care and 18% lost to follow-up.</p> <p>The mean cost per day of hospital stay was €382.96 in hospitalised patients. The mean cost per visit in QDU patients was €253.94. The mean cost per process was €4,059.37 8 987 in hospitalised patients and €601.84 8 502 in QDU patients.</p>	
<p>Bosch et al (2012c). Quick diagnosis units or conventional hospitalisation for the diagnostic evaluation of severe anaemia: A paradigm shift in public health systems? European Journal of Internal Medicine, 23(2), pp.159-164.</p>	<p>Study Design: Cross-sectional post-test only quasi-experimental</p> <p>Intervention/comparator: QDU vs hospitalised patients (internal medicine department)</p> <p>Aim: To investigate the utility and cost of a QDU for the evaluation of patients with severe anaemia (haemoglobin b8 g/l) compared with conventional hospitalisation in a tertiary public hospital in Spain.</p> <p>Data collection methods and dates: QDU data collected between 1 January and 31 December 2010 Hospitalised (control) patient data collected between September 2006 and June 2010</p>	<p>Sample size: 282 consecutive patients with severe anaemia attended by the QDU and 252 consecutive patients with the same diagnosis admitted to the internal medicine department</p> <p>Participants: Prospective cohort of all consecutive patients with severe anaemia (defined as a haemoglobin concentration lower than 8 g/l) attended by the QDU of the internal medicine department, and a retrospective cohort of all consecutive patients with same diagnosis admitted to the internal medicine department.</p> <p>A telephone survey was carried out in a random sample of 125 patients three months after the QDU intervention.</p> <p>Setting: QDU at Hospital Clínic de Barcelona, Spain</p>	<p>Of the 328 patients initially included for QDU evaluation 46 were excluded from the study due to associated conditions that made outpatient QDU management inappropriate. Therefore, 282 cases were finally included, of whom 182 were female (64.5%), with a mean age of 65.63 years (17.44). A total of 252 hospitalised patients were included, of whom 166 were female (65.9%), with a mean age of 76.11 years (12.68). QDU patients were significantly younger than hospitalised patients ($P < 0.0001$).</p> <p>Primary Findings: The main referral sources were the ED (186 patients) and primary healthcare centres (88 patients) in QDU patients, and the ED (170 patients) in hospitalised patients. Waiting time for the first QDU visit ranged from 2 to 8 days (mean: 3.9 days) in patients referred from primary healthcare centres and from 0 to 4 days (mean: 2.1 days) in patients referred from the ED.</p> <p>QDU patients generated 902 visits with a mean of 2.95 visits per patient (from first to last physician-patient encounter, once all the workup was completed and a diagnosis was achieved). Once a final diagnosis was made, 61.9% of QDU patients were referred to the original primary healthcare centre, 21.4% to internal medicine outpatients, 14.8% to gastroenterology outpatients, and only 1.9% were hospitalised in the internal medicine department,</p>	<p><i>Likely overlap of patient data with above studies</i></p> <p><i>Time to diagnosis in QDU patients was compared to the length of hospital stay in hospitalised patients.</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	<p>Telephone survey data collected three months after QDU intervention</p> <p>Outcomes reported: Charlson morbidity index</p> <p>Time to first visit (QDU only) Definitive diagnosis Time to diagnosis (defined as the time from first visit to a definitive diagnosis) (QDU only) Number of visits (QDU only) Length of hospital stay (hospitalised only) Referral source Onward referrals Diagnostic tests</p> <p><u>Self-reported outcomes</u> – Perception of the care process Degree of difficulty of travel to the unit Overall satisfaction, Preferential care type in the future Conditions of physical space</p> <p><u>Economic outcomes</u> – Cost per day of hospital stay (hospitalised only) Cost per visit (QDU only) Cost per process (time between first and last visit for QDU and admission to</p>	<p>Staffing/facilities: The QDU is composed of a specialist in internal medicine and a registered nurse, who are assisted by specialists from other specialities. It has a consulting room and a waiting room for patients and families, and functions daily. The QDU internist and nurse devote 5-hours daily, 5 days a week (Monday–Friday), to QDU work. QDU receives administrative support from two secretaries shared with other units.</p> <p>Services provided: Not explicitly stated but would include double endoscopy (colonoscopy, gastroscopy), duodenal biopsy, endoscopic capsule exam, imaging, laboratory or pathology tests</p>	<p>normally due to worsening of anaemia. Furthermore, 5 patients (1.8%) were temporally referred to the ED whilst being studied at the QDU for some acute complication (e.g., uncompensated heart failure) but all returned to the Unit to continue the study.</p> <p>The mean time to diagnosis in QDU patients was 7.82 days (1.36), which was not significantly different from the mean stay of 8.87 (4.45) days of hospitalised patients. Mean haemoglobin and haematocrit were 76.11 (21.8) and 25.03 (6.52), respectively, in QDU patients and 74.61 (21.1) and 24.11 (6.43), respectively, in hospitalised patients. The differences were not statistically significant.</p> <p>Mean length of hospital stay was 8.87 days among hospitalised patients.</p> <p>Total mean cost per day of hospital stay was €2,060.63 in hospitalised patients and €90.04 euros per QDU visit. The mean cost per process was €18,278.01 in hospitalised patients. In contrast, the mean cost per process in the QDU was €2,920.62.</p> <p>There was 92% compliance with the survey of patient opinion. The results highlighted three main aspects: a) overall satisfaction with QDU care was high in 93% of cases, b) repeated travel to the hospital was not a major difficulty, and c) if further diagnostic tests were required, 85% of patients would prefer QDU care to conventional hospital admission. The remaining 15% did not indicate a preferential type of care. The same results were obtained analysing only patients with experience of hospital admission.</p> <p>Additional Findings: One-hundred and eighty-six (65.9%) QDU patients were transfused before the first QDU visit, as were 162 hospitalised patients (64.3%), 131 from ED and 31 at the internal medicine ward. Furthermore, 5 of</p>	

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	discharge for hospitalised patients) Cost per length of stay (hospitalised only)		<p>the 186 QDU patients who had been transfused at the ED before the first visit were subsequently retransfused in the own Unit for re-augmentation of the anaemia during the study process. Likewise, 2 of the 131 hospitalised patients first transfused at the ED and 2 of the 31 first transfused at the internal medicine ward required a new transfusion at the ward. Overall, the mean number of blood units transfused was 2.0 for QDU and 2.1 for hospitalised patients.</p> <p>Definitive diagnosis among QDU patients included iron-deficiency anaemia (the commonest type of anaemia in the two cohorts), 94 patients (33.3%) had benign digestive lesions, 42 (14.9%) an unknown process, 40 (14.2%) gastrointestinal malignancies and 18 patients (6.4%) heavy menstrual bleeding. Benign digestive lesions were also the main aetiology of iron deficiency anaemia in hospitalised patients (n=90; 35.7%) followed by unknown process (50 patients; 19.8%). A gastrointestinal malignancy was found in 28 (11.1%) of 252 hospitalised patients with iron deficiency anaemia (Table 4). Multifactorial anaemia was the second major diagnostic group in QDU (n=34; 12.1%) and hospitalised patients (n=38; 15.1%).</p> <p>All these patients underwent a duodenal biopsy and a capsule endoscopy</p>	
Bosch et al (2011). Outpatient Quick Diagnosis Units for the evaluation of suspected severe diseases: an observational, descriptive study . Clinics, 66(5), pp.737-741.	<p>Study Design: Cross-sectional post-test only quasi-experimental</p> <p>Intervention/comparator: QDU vs hospitalised patients (internal medicine department)</p>	<p>Sample size: 1,000 consecutive patients evaluated in the QDU during time frame</p> <p>Subgroup analysis comprised of 50 randomly selected patients with iron-deficiency anaemia, 50 with fever of unknown origin and 50 with anorexia-cachexia syndrome</p>	<p>Median age of 60±18.84 years (range: 15 to 95 years), 447 men and 553 women and possibly 150 control patients</p> <p>Primary Findings: The first 1,000 visits generated 2,233 successive visits (ratio successive/first = 2.23).</p> <p>Waiting times for a first QDU visit ranged from 2 to 8 days (mean: 3.9 days) in patients referred from</p>	<p>Mean cost per hospital stay and mean cost per visit were directly compared</p> <p>Bed days saved – estimated from LOS and hospital admissions avoided)</p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	<p>Aim: To describe the functioning of a QDU in a Spanish public university hospital after evaluating 1,000 consecutive patients. Also aimed to ascertain the costs of the QDU model compared to conventional hospitalisation and the degree of satisfaction of QDU patients.</p> <p>Data collection methods and dates: Main data collected between November 2008 and January 2010 Subgroup analysis collected between September 2007 and September 2008 for Hospital data and during 2009 for QDU data collection Survey data collection three months after the QGU intervention</p> <p>Outcomes reported: Time to first visit - waiting time to first QDU visit from either PHC or ED Number of visits - calculated from first visit and successive visits (ratio successive/first) Time to diagnosis - time between first visit and definitive diagnosis (and usually coincided with the results of diagnostic test)</p>	<p>evaluated in the QDU / or patients who were hospitalised in the hospital's two Internal Medicine wards.</p> <p>Survey administered to 155 random patients attending the QDU (85% response rate)</p> <p>Participants: Patients with potentially severe diseases that would normally require hospital admission for diagnosis, or their general condition allows for outpatient treatment, and they do not have physical or psychological disabilities that would make traveling to the hospital several times difficult.</p> <p>Setting: QDU at Hospital Clínic de Barcelona, Spain.</p> <p>Staffing/facilities: staffed by a specialist in internal medicine and a registered nurse, with specialists from other fields assisting. It has a consulting room and a waiting room for patients and families, and it functions daily. The QDU physician and nurse devote five hours a day five days a week (Monday to Friday) to QDU work.</p> <p>Services provided: The main diagnostic tests (analytical and microbiological tests, simple radiology [X-ray], CT scans,</p>	<p>primary healthcare centres and from 0 to 4 days (mean: 2.1 days) in patients referred from the ED of the hospital.</p> <p>The most frequent diagnosis was cancer (either epithelial or hematological) in 188 patients, representing 18.8% of diagnoses, and iron-deficiency anaemia (unrelated to malignancy) in 180 patients (18%). The most common cancers were colon cancer and lymphomas, while the leading cause of iron-deficiency anaemia was chronic gastrointestinal bleeding (74 cases; 7.4% of all 1,000 patients). The mean time to diagnosis was 9.2±5.86 days (range: 1 to 19 days).</p> <p>After the diagnostic study was completed, 616 patients were referred to primary health care centres, 356 were referred to outpatient clinics and 28 required hospitalisation.</p> <p>Considering that the mean length of stay in the internal medicine department (50 beds) in 2009 for patients admitted for a diagnostic workup was 10.3 days, authors estimated that 12.5 beds/day were made available over the course of a year (i.e., 4,563 bed-days were saved in a year). However, 45 of 1,000 patients (4.5%) required immediate or early hospitalisation due to their bad health status, which impeded further QDU diagnosis.</p> <p>In hospitalised patients, the total mean cost per day of the hospital stay was €356.59 and the mean cost per process was €3,416.13. In contrast, the mean cost per process in the QDU was €735.65.</p> <p>Additional Findings: <u>Hospital admissions avoided</u> - 410 patients (41%) would have been candidates for conventional hospitalisation (for diagnostic studies) before the QDU was established</p>	<p><i>Looks like the only outcomes being compared between QDU and hospitalised patients are:</i> <i>Cost per stay/visit,</i> <i>cost per process</i> <i>Bed days saved</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	<p>Hospital admissions avoided - patients who would have been admitted for diagnostic workup if there were no QDUs (used to measure number of bed days saved)</p> <p>Appropriateness criteria for QDU assessment – based on predefined list of diseases</p> <p>Subgroup analysis – Length of hospital stay – no definition (used to estimate number of bed days saved) Cost per visit – mean cost per QDU visit Cost per hospital stay – mean cost hospital stay Cost per process (admission to discharge episode) Hospital bed days saved (mean LOS and cost per visit)</p> <p>Patient satisfaction Patient preference</p>	<p>echography, nuclear scintigraphy, digestive endoscopy, biopsies and lymph node fine-needle puncture aspiration [FNPA] are normally performed within 7 days after the first visit.</p>	<p><u>Appropriateness criteria for QDU assessment</u> – 84% of the 1,000 met the appropriateness criteria for QDU assessment according to the agreed-upon list of diseases. The remaining 16% either did not meet the established patient profile or did not have diseases suitable for QDU care.</p> <p>Survey response rate was 85% and highlighted findings included overall satisfaction with QDU was high in 95% of cases, repeated travel to the hospital was not a major difficulty for the patients, and if further diagnostic tests were required, 80% of patients would prefer the QDU care model over conventional hospital admission. The same results were obtained analysing only patients who had experience with hospital admissions. The remaining 20% did not indicate a preference for any one type of care.</p>	
Quick Diagnostic Unit (QDU) at Bellvitge Hospital				
<p>Sanclemente-Ansó et al (2016). Cost-minimization analysis favors outpatient quick diagnosis unit over hospitalization for the diagnosis of potentially serious diseases. Eur J Intern Med; 30:11-17. doi: 10.1016/j.ejim.2015.12.015</p>	<p>Study Design: Economic evaluation (cost-minimisation)</p> <p>Intervention/comparator: QDU vs hospitalised patients (internal medicine department)</p> <p>Aim: To evaluate the costs of QDU vs. conventional</p>	<p>Sample size: 195 QDU patients diagnosed with severe anaemia (n=94), lymphoma (n=63) and lung cancer (n=38) selected from 1,226 consecutive patients referred to the unit during timeframe and 237 control patients who were electively hospitalised at the Internal Medicine Department of the hospital for diagnostic</p>	<p>Primary Findings: There was no difference in the primary clinical outcome between QDU and hospitalised patients. For the three diagnostic groups, the overall average time to diagnosis at the QDU was 11.1 days, with a total of 195 first visits and 137 successive visits. LOS of comparable inpatients was 10.3 (+9.1) days (median, 8; range, 4–18).</p> <p>No significant differences in cost saving per patient according to each final diagnosis: mean cost saving</p>	<p><i>Potential QDU data overlap with Bosch 2018 (QDU2)</i></p> <p>Limitations <i>The results of the cost-minimization analysis might be biased in favour of QDU. In particular, a main criterion for</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	<p>hospitalisation for the diagnosis of cancer and anaemia using a cost-minimization analysis on the proven assumption that health outcomes of both approaches were equivalent.</p> <p>Data collection methods and dates: March 2008 and June 2012</p> <p>Medical records were retrieved from the institutional QDU database to identify the patient groups of interest. For hospitalised patients, the Minimum Basic Data Set (MBDS) complemented by medical records was used using codes of the Spanish version of the ICD-9-CM. Cost data obtained from the institutional information system implement in the Bellvitge hospital</p> <p>Outcomes reported: Health outcomes: mean time to diagnosis (QDU patients) mean length of stay (hospitalised patients) QDU Cost outcomes (actual): total cost per patient until reaching a diagnosis - calculated from the sum of</p>	<p>workup during the same period and who had the same final diagnoses.</p> <p>Participants: Three groups of QDU patients (severe anaemia; lymphoma and lung cancer) were compared with patients who were electively hospitalised for diagnostic workup.</p> <p>Setting: QDU at Bellvitge University Hospital in Barcelona, which is affiliated to the University of Barcelona, Catalonia, Spain. The QDU is integrated to the Internal Medicine Department of the hospital.</p> <p>Staffing/Facilities: The QDU is internist led and open 7 hours a day, 2 days a week (Tuesdays and Fridays). Analysis implies staff also included attending physician, registered nurse, caretaker.</p> <p>Services provided: Not explicitly stated, but to include blood and urine analysis, X-ray CT, simple X-ray, PET-CT, biopsy, bronchoscopy, cytology, microbial culture, scintigraphy, mammography, specialist consultation, ultrasonography, colonoscopy, electrocardiography, lower and upper gastrointestinal series,</p>	<p>per patient with a diagnosis of anaemia was €4422.91 (overall saving €415,753.54), €4481.41 per patient with a diagnosis of lymphoma (overall saving €282,328.83), and €4464.13 per patient with a diagnosis of lung cancer (overall saving €169,636.94).</p> <p>Greatest savings of specific cost items in all diagnostic groups were related to hospital stays. Taking into account the mean LOS and the mean cost per hospital stay, the mean cost saving per patient was €2956.41. Overall, the mean estimated saving per patient for the three diagnostic groups related to the costs of hospital stays represented 66% of the total cost savings per patient. Structural and general functioning costs also generated significant QDU savings from hospitalisation.</p> <p>Overall, the mean estimated saving per patient for the three diagnostic groups related to the structural and general functioning costs of hospitalisation was €1485.84, ranging from €1474.76 to €1494.26 depending on the diagnosis, which represented 33% of the total cost savings per patient.</p> <p>The estimated QDU savings from hospitalisation associated with the costs of diagnostic investigations were lower. The mean cost saving per patient across the three diagnostic groups ranged from €19.25 in patients with anaemia to €46.73 in patients with lung cancer to €58.25 in those with lymphoma. Overall, the mean QDU saving per patient for the three groups related to the costs of diagnostic investigations was only 1% of the total cost savings per patient. These findings suggested that, to reach a specific diagnosis of anaemia, lung cancer, and lymphoma in equivalent waiting times (i.e. time to diagnosis/LOS), the attending physician at the QDU ordered slightly fewer diagnostic tests than the two physicians assigned to every patient at the Internal</p>	<p><i>referral to and evaluation by the QDU is that patients must be well-enough and be able to attend several outpatient appointments [33]. Accordingly, there is a possibility that patients who were admitted were older and had more comorbidities, requiring more attendance and inpatient care leading to a potential selection bias. Although this would not likely change the results of the study or their interpretation, the actual cost savings of the QDU approach might thus be lower.</i></p> <p><i>By recruiting cases by diagnosis and not by suspicion of diagnosis, the cost of workup of patients who turn out to be negative for the suspected diagnosis are left out of the analyses, and bias might also result</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	<p>personnel, medical material, diagnostic tests, therapeutic procedures, structural and general functioning costs, and depreciation.</p> <p>Direct costs of QDU – included personnel, medical material, diagnostic investigations (unit cost for each type calculated according to officially established CHS fees), therapeutic procedures.</p> <p>Average outpatient consultation (unit cost calculated according to officially established CHS fees)</p> <p>Non-direct costs of QDU – structural and general functioning costs (administrative costs, maintenance costs, laundry and cleaning services, consultation costs, associated personnel, medical material and therapeutic procedures costs).</p> <p>Hospitalisation cost outcomes:</p> <p>Direct costs of hospitalisation – <u>cost of hospital stays</u> (comprising of personnel – nursing and caretaker staff only; medical material and therapeutic procedures) -</p>	<p>esophagogastroduodenoscopy, blood marrow aspiration, flow cytometry</p>	<p>Medicine Department (i.e. one attending physician and one resident physician). Physicians at the Internal Medicine Department ordered more blood and urine tests than the QDU attending physician did. Overall, for the three groups, the mean cost of blood and urine analysis per patient was 26% of the total costs of diagnostic investigations per patient in the QDU, and an estimated 33% of the total costs of diagnostic investigations per patient in hospitalisation. Taking into account the full sample of patients evaluated in the QDU (n=195), the total combined cost savings from hospitalisation were estimated at €867,719.31.</p>	<p><i>from attending more capable patients with better physical ('healthier') status at the QDU.</i></p> <p><i>Time to diagnosis in QDU patients was compared to the length of hospital stay in hospitalised patients.</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	<p>Costs based on an analytical cost performed internally by the Department of Economics of the Bellvitge Hospital and was based on admission in standard wards.</p> <p><u>cost of physicians</u> [attending and resident] - fraction of salary equivalent to 30 minutes per day</p> <p><u>cost of diagnostic investigations</u> - average of the unit costs for diagnostic tests in the hospitalisation approach, based on the same unit costs of the QDU.</p> <p>Non-direct costs of hospitalisation – structural, general functioning costs excluding consultations costs, personnel (attending and resident physician).</p> <p>Other outcomes: Number of visits</p>			
UK				
<i>Rapid Diagnostic Centre (RDC) at Neath Port Talbot Hospital</i>				
<p>Sewell et al (2020). Rapid cancer diagnosis for patients with vague symptoms: a cost-effectiveness study. British Journal of General Practice; 70 (692): e186-e192. DOI: https://doi.org/10</p>	<p>Study Design: Economic evaluation</p> <p>Intervention/ Comparator: Pilot RDC vs standard clinical practice</p> <p>Aim: To explore the cost-effectiveness of the RDC</p>	<p>Sample size: 1,000 (simulated based on real-life data for intervention and control group)</p> <p>Participants: Adults aged ≥18 years in the pilot area who were referred by their GP to the RDC at Neath Port Talbot Hospital (NPTH) for</p>	<p>Between June 2017 and May 2018, 189 patients attended the RDC. Of these patients, 46% were male and the mean age was 70 years (SD = 12.9 years; minimum = 26; maximum = 95).</p> <p>Primary Findings: Time to diagnosis</p>	<p><i>Cancer-related study</i></p> <p><i>Patient-level discrete-event simulation (DES) and decision analytic modelling were used to estimate the time from referral to</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
.3399/bjgp20X708077	<p>compared with standard clinical practice.</p> <p>Data collection methods and dates: Data collected between June 2017 and May 2018. Routinely collected, fully anonymised service data from the RDC provided model data inputs. NPTH records were manually searched for control patients.</p> <p>Outcomes reported: Time to diagnosis Quality adjusted life years (QALYs) Mean cost per patient Cost of diagnostic tests Personnel costs Cost-effectiveness</p>	<p>further investigation of non-specific and/or vague symptoms that could be due to cancer between June 2017 and May 2018</p> <p>Setting: RDC at Neath Port Talbot Hospital, Wales, UK</p> <p>Staffing/facilities: Consultant physician, a radiologist, a clinical nurse specialist (CNS), and a healthcare support worker (HCSW). Management and clinical guidance are provided by the RDC coordination manager and GP project lead. Two half-day clinics a week with five available clinic slots</p> <p>Services provided: Physical examination, CT scans</p>	<p>Mean time to diagnosis was 84.2 days (SD = 65.3) in the control group. This was reduced to 5.9 days (SD = 3.4) in patients who were diagnosed directly at the RDC clinic and to 40.8 days (SD = 30.0) if further investigations following RDC were warranted.</p> <p>Cost-effectiveness At between 80% and 100% capacity, the RDC produces more QALYs and is less costly, and thus outperforms standard clinical practice. Below 80% capacity, the RDC is not cost-effective at a £20 000 willingness-to-pay threshold.</p> <p>Additional Findings: Total staff costs per half-day clinic were calculated as £2640 with CT scan and other test costs amounting to £118.21 per patient</p>	<p><i>diagnosis and the cost-effectiveness of the RDC compared with standard clinical practice.</i></p> <p><i>According to the study authors, data used to populate the model were taken from the first year of the RDC pilot operation, and therefore unable to allow extrapolation of the longer-term impact of the RDC on healthcare resource use, patient outcomes, or survival. This could underestimate the cost-effectiveness of the RDC.</i></p>
Rapid Diagnostic Clinic (RDC) at St Barts Health NHS Trust				
<p>Choudhury et al (2013). A multidisciplinary audit of head and neck referrals: considerations for patients' timelines and outcomes. European Archives of Oto-Rhino-Laryngology, 270(12), pp.3121-3126.</p>	<p>Study Design: Cross-sectional post-test only quasi-experimental</p> <p>Intervention/ Comparator: Rapid Diagnostic Clinic (RDC period) vs head and neck clinics (pre-RDC period)</p> <p>Aim: To critically appraise the efficacy of a RDC with respect to its impact on</p>	<p>Sample size: A total of 212 new patients were seen during the pre-RDC period, with complete data on 197 new patient episodes. A total of 313 new patients were seen during the RDC period, with complete data on 299 patient episodes.</p> <p>Participants: All new target referrals for patients that were seen in weekly head and neck clinics</p>	<p>Primary Findings: During the pre-RDC period, the mean time taken for patients referred via the 2WW referral system was 11.2 ± 0.6 day (range 1–37 days). The mean time taken for all other target referrals (non-2WW) was 33.5 ± 3.3 days (range 2–145 days). During the RDC period, the mean time taken for patients referred via the 2WW referral system was 9.2 ± 0.4 day (range 1–27 days), and for non-2WW referrals was 23.3 ± 1.9 days (range 1–105 days).</p> <p>A comparative data analysis for the timelines from referral to the patients being seen between the pre-RDC and RDC period confirmed a statistically significant reduction in the time from referral to</p>	<p><i>Cancer-related study (Head and neck cancer)</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	<p>patients' timelines and outcomes</p> <p>Data collection methods and dates: Retrospective audit of all new target referrals for patients that were seen in weekly head and neck clinics between 1 October 2009 and 31 March 2010 (pre-RDC period), and a prospective audit the RDC during a similar time period, from 1 October 2010 to 31 March 2011</p> <p>Outcomes reported: Time to first visit Number of visits Time from consultation to treatment</p>	<p>Setting: A RDC within the ENT department of Barts Health NHS Trust, London, UK</p> <p>Staffing/facilities: ENT head and neck specialist, either a consultant or specialist registrar, consultant head and neck radiologist, consultant histopathologist.</p> <p>Services provided: Ultrasonography, and fine needle aspiration cytology (FNAC)</p>	<p>patients first clinic consultation, between the two study periods [referred via the 2WW referral system 11.2 to 9.2 days ($P = 0.0002$); all other referral sources 33.5 to 23.3 days ($P = 0.0015$)].</p> <p>Additional Findings: During the RDC period, over one-third of patients utilised the provision of ultrasound \pm FNAC, and consequently, the majority reached a definitive outcome (discharged or scheduled for surgery) following their first consultation.</p>	
<i>Community Diagnostic Service in the West Midlands</i>				
<p>Pallan et al (2005). Evaluation of an independent, radiographer-led community diagnostic ultrasound service provided to general practitioners. Journal of Public Health. 27 (2) 176-181</p>	<p>Study Design: Cross-sectional post-test only quasi-experimental</p> <p>Intervention/ Comparator: Radiographer-led community diagnostic ultrasound service vs local NHS Trust diagnostic ultrasound service</p> <p>Aim: To assess the benefits and disadvantages of a radiographer delivered, primary care-based mobile</p>	<p>Sample size: Random samples of 200 and 193 adult patients who underwent diagnostic ultrasound in 2001/2002 with the community and NHS Trust services respectively</p> <p>Participants: Random samples of 200 and 193 adult patients who underwent diagnostic ultrasound in 2001/2002 with the community and NHS Trust services respectively</p>	<p>The response rates for the surveys were 52.9 per cent for the community service patient survey (100/189, 11 patients had died or moved address), 44.6 per cent for the hospital service patient survey (82/184, nine patients had died or moved address), and 80.6 per cent for the GP survey (29/36). There was little variation between the two groups that responded to the patient surveys with regard to gender, age profile, or ethnicity.</p> <p>Primary Findings: Mean waiting time for an ultrasound scan appointment was 17.44 (95% CI 15.86–19.02) and 44.53 days (95% CI 38.83–50.23) for the community and NHS Trust services respectively.</p>	<p><i>The study authors reported the likelihood of biases in the study findings including recall bias and observer bias. Similarly, due to the retrospective design of the study, the patients were not randomly allocated to the two services, so it is possible that there were inherent differences in the</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	<p>diagnostic ultrasound service by comparing it to an NHS Trust diagnostic ultrasound service.</p> <p>Data collection methods and dates: Data was collected on adult patients who had undergone diagnostic ultrasound following referral by their GP between April 2001 and March 2002. Data on time between referral and appointment for the community service study sample were collected from GP referral forms, and for the NHS Trust service sample, data on time from receipt of referral to appointment were collected from the computerised patient management system. Postal surveys were designed to evaluate patient and GP access to the two services, patient and GP satisfaction with the services, and some aspects of service quality.</p> <p>Outcomes reported: Time to examination Diagnostic investigation costs Average cost per abnormality detected Patient satisfaction Patient preferences</p>	<p>Setting: Community based, mobile diagnostic ultrasound service, in a primary care area in the West Midlands, England, UK</p> <p>Staffing/facilities: The service is staffed by an independent radiographer</p> <p>Services provided: Ultrasound scans included abdominal, pelvic, transvaginal, renal, and prostate</p>	<p>Additional Findings: Location of ultrasound appointment was reported as convenient by 93 (93 per cent) of community service respondents and 78 (95.1 per cent) of hospital service respondents. Time of appointment was reported as convenient by 95 (95 per cent) and 76 (92.7 per cent) of community service and hospital service patients respectively.</p> <p>Patients were highly satisfied with both services. GPs were markedly less satisfied with the NHS Trust service compared to the community service. Quality of stored ultrasound images and reports were comparable for the services. Cost per abnormality detected was higher for the community service (£107.69 compared to £77.35 for the NHS Trust service, not statistically significant).</p>	<p><i>two patient study groups.</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	Physician satisfaction Service quality			
<i>Demyelinating disease diagnostic clinic (DDC) at University College London</i>				
Porter et al (2003). Diagnosis of MS: a comparison of three different clinical settings Multiple Sclerosis Journal, 9(5), pp.431-439.	<p>Study Design: Cross-sectional post-test only quasi-experimental</p> <p>Intervention/ Comparator: DDC vs general neurology clinic (GNC) vs inpatient investigation unit (IIU)</p> <p>Aim: To compare a newly established diagnostic clinic with two existing clinical settings in the management of the diagnostic phase of MS</p> <p>Data collection methods and dates: An audit questionnaire was designed and used in a retrospective review of patients' case notes, identified from the DDC, GNC and the IIU over a 12-month period (April 1999 – April 2001)</p> <p>Outcomes reported: Time to first visit Number of visits Time to examination Time to receiving results Length of hospital stay Mean cost per visit Mean cost per patient</p>	<p>Sample size: 50 patients (DDC = 20, GNC = 10, IIU = 20)</p> <p>Participants: Patients with written evidence of a confirmed diagnosis of MS during the period April 1999 – April 2001</p> <p>Setting: DDC at the National Hospital for Neurology and Neurosurgery, University College London Hospitals, UK</p> <p>Staffing/facilities: The clinic is staffed by a consultant neurologist and a MS nurse specialist</p> <p>Services provided: Evoked potential (VEP) testing, magnetic resonance imaging (MRI), and blood screening</p>	<p>The profile of the 50 patients in this study was representative of the general MS population; the majority of patients in each group were Caucasian, the age ranged from 21-68 years and there was a female predominance.</p> <p>Primary Findings: The time between referral and first appointment favoured the DDC with a mean time of 5.9 weeks, compared to 7.7 weeks for the GNC and 10.0 weeks for the IIU. The mean times between the first appointment and receipt of results were 4.7 weeks (DDC), 18.8 weeks (GNC) and 21.2 weeks (IIU). The price per patient ranged from £395 to £790 (DDC), £95 to £380 (GNC) and £1940 to £2700 (IIU).</p>	<i>The study authors highlighted the potential of bias and a retrospective methodology as limitations of this study.</i>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
<i>One-stop breast lump clinic at The Breast Care Centre, Bristol</i>				
Harcourt et al (1998). Evaluation of a one-stop breast lump clinic: a randomized controlled trial. The Breast, 7(6), pp.314-319.	<p>Study Design: RCT</p> <p>Intervention/ Comparator: One-stop breast lump clinic (providing same-day diagnosis) vs two-stop clinic (conventional system involving two appointments)</p> <p>Aim: To compare the impact on patients of a one-stop clinic with conventional clinic arrangements involving a minimum of two separate clinic appointments and a delay of several days or weeks before test results are provided.</p> <p>Data collection methods and dates: Data were collected via semi-structured interviews and questionnaires. Dates data were collected is unclear.</p> <p>Outcomes reported: Time to diagnosis Support offered after diagnosis Cost-effectiveness Patient satisfaction Patient anxiety and depression Quality of life</p>	<p>Sample size: 791 (One-stop clinic = 416, Two-stop clinic = 375)</p> <p>Participants: Women with no previous diagnosis of breast cancer, living within a reasonable travelling distance of the hospital and whose GP referral letter stated the presence of a breast lump were eligible for inclusion.</p> <p>Setting: One stop clinic in a hospital (location not given but likely to be study author's centre - The Breast Care Centre, Frenchay Healthcare Trust, Bristol, UK)</p> <p>Staffing/facilities: All clinics were conducted by the same two surgeons (one consultant, one staff grade)</p> <p>Services provided: Triple assessment (consisting of clinical examination, ultrasound scanning and cytology). Mammography, when needed, was then carried out by radiologists in the hospital's general X-ray department. Cytology specimens were analysed in the pathology department sited elsewhere in the hospital.</p>	<p>The mean age of the 791 women consenting to join the study was 42.75 years (SD = 12.90 years; range 16-85 years). No significant differences in demographic variables or baseline HADS scores existed between the two clinic groups or between women eligible and ineligible for randomisation.</p> <p>Primary Findings: Six days after first clinic attendance the one-stop group showed significantly lower levels of anxiety ($P < 0.05$). However, the sub-group who had breast cancer had become more distressed in both groups, more so in the one-stop group. A benign diagnosis in the one-stop group was associated with fewer symptoms of anxiety ($t = -5.47$; d.f. = 489; $P < 0.001$), depression ($t = -2.68$; degrees of freedom (d.f.) = 489; $P < 0.01$), improvements on VAS measures of worry about the breast problem ($t = 6.08$; d.f. = 481; $P < 0.001$), concern about future health ($t = 3.13$; d.f. = 474; $P < 0.01$), sleeping patterns ($t = -5.47$; d.f. = 481; $P < 0.001$), concentration ($t = -4.69$; d.f. = 481; $p < 0.001$), ability to carry on with normal daily activities ($t = -3.62$; d.f. = 479; $P < 0.001$) and EORTC subscales of quality of life ($t = 2.39$; d.f. = 471; $P < 0.05$), emotional ($t = 4.93$; d.f. = 471; $P < 0.001$) and cognitive functioning ($t = 2.55$; d.f. = 470; $P < 0.05$).</p> <p>Eight weeks later, women receiving a speedier diagnosis of cancer reported higher levels of depression than women given this diagnosis in the two-stop system ($P < 0.05$).</p> <p>Additional Findings: Same-day diagnosis appears to reduce psychological distress for the 90% of clinic attenders diagnosed with a benign lump.</p> <p>There was no significant difference in the consumption of resources between the two clinic groups.</p>	<i>Cancer-related study (Breast cancer)</i>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
Diagnostic centre vs Diagnostic centre				
<i>Spain</i>				
<i>QDU of Hospital Clínic de Barcelona vs usual care vs the QDU of Bellvitge Hospital</i>				
<p>Bosch et al (2018). Time to diagnosis and associated costs of an outpatient vs inpatient setting in the diagnosis of lymphoma: a retrospective study of a large cohort of major lymphoma subtypes in Spain BMC cancer, 18(1), pp.1-15.</p>	<p>Study Design: Cross-sectional post-test only quasi-experimental</p> <p>Intervention/comparator: QDU1 (Hospital Clínic) patients vs inpatients at Hospital Clínic vs QDU2 (Bellvitge Hospital) patients</p> <p>Aim: To investigate the time to diagnosis of a hospital-based outpatient or inpatient setting in four major subtypes of lymphomas and the costs incurred by both clinical settings in the diagnostic process. A further goal was to investigate the frequency, clinical, and prognostic features of each lymphoma subtype according to an outpatient or inpatient diagnosis</p> <p>Data collection methods and dates: Data were collected between January 2006 and September 2016 for all groups.</p> <p>Outcomes reported: Time to first visit, number of visits, Time to examination, Time to diagnosis, Mean</p>	<p>Sample size: 688 patients from QDU 1, 589 patients from QDU 2, 535 inpatients</p> <p>Participants: Patients aged ≥ 18 years with classical Hodgkin lymphoma, large B-cell lymphoma, follicular lymphoma, and mature nodal peripheral T-cell lymphoma (comprising peripheral T-cell lymphoma, not otherwise specified [NOS], angioimmunoblastic T-cell lymphoma, and anaplastic large cell lymphoma, anaplastic lymphoma kinase [ALK] negative).</p> <p>Setting: The QDU of the Hospital Clínic (QDU 1), an adult day-care centre in a public 855-bed tertiary university hospital in Barcelona (Spain), the in-patient wards of the internal medicine department of this hospital, and the QDU of the Hospital of Bellvitge (QDU 2), a public 750-bed tertiary university hospital near Barcelona, Spain</p> <p>Staffing/facilities: QDU 1 staff included a full-time consultant internist, a senior</p>	<p>Patients had a mean age of 63.4 years and 55.4% were males. Inpatients were older and more likely to be males than outpatients. Nearly 65% of patients presented with lymphadenopathy, which was more frequent in outpatients than in inpatients. The main referral source of inpatients was ED (i.e. emergency admissions) (68.4%) and it was PCs in outpatients (75.5%).</p> <p>Primary Findings: Inpatients waited less than 24 h to be admitted, whereas time to first visit in outpatients was significantly longer (0.6 [0.3] vs 1.7 [1.1] days; $P < .001$). The admission time for diagnosis of inpatients was significantly shorter than the QDU time for diagnosis of outpatients (12.3 [3.3] vs 16.2 [2.7] days; $P < .001$).</p> <p>The mean time to biopsy was substantially longer in outpatients (7.4 [1.8] days) than in inpatients (3.5 [1.1] days) ($P < 0.001$).</p> <p>After diagnosis, most patients were referred to outpatient specialist clinics and inpatients more often received direct palliative care after discharge than outpatients.</p> <p>Considering that the mean admission time for diagnosis of inpatients was 12.3 (3.3) days and that the mean number of visits of outpatients (corresponding to the mean QDU time for diagnosis) was 3.26 (1.2). The total cost per hospitalised patient was €4039.56 (513.02), with 69.5% being attributable to personnel salaries and 25.4% to diagnostic tests, and the total cost per outpatient was €1408.48</p>	<p><i>Cancer-related study (lymphoma)</i></p> <p><i>The Author's acknowledge there were some missing data in the cost analysis, such as diagnostic tests, therapeutic procedures, pharmaceuticals and consumables, and consultations.</i></p> <p><i>QDU time to diagnosis was compared to admission time for diagnosis (instead of length of hospital stay) because length of stay may not be a precise reflection of the time needed to evaluate and diagnose a patient with lymphoma</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	cost per hospital stay, Mean cost per visit, Mean cost per patient, Cost of diagnostic tests per patient, Cost saving from hospitalisation, personnel costs.	<p>internal medicine resident, a full-time nurse, a part-time nurse coordinator, and two part-time secretaries. The unit is open 5 h a day, 4 days a week.</p> <p>QDU 2 staff included a part-time consultant internist and a part-time nurse. This unit is open 7 h a day, 2 days a week.</p> <p>In the inpatient setting (three wards) staff included two full-time consultant internists, three residents, a full-time nurse coordinator, three teams of three nurses and three teams of two full-time nursing assistants and a full-time secretary.</p> <p>Services provided: The full range of services provided may not be fully reported in the text but included laboratory tests, Fine needle aspiration cytology (FNAC), excisional biopsies, Positron emission tomography-computed tomography (PET-CT)</p>	<p>(197.32), with 50.6% being attributable to diagnostic tests, 29.5% to outpatient visits, and 18.6% to personnel salaries. According to the analysis, the total saving from hospitalisation was €2631.08 per patient.</p> <p>Additional Findings: An FNAC was performed in 935 (54.4%) patients (766 [64.7%] outpatients and 169 [31.6%] inpatients) yielding an overall suspicious/compatible lymphoma diagnosis in 65.3% with no false positive result in any patient after considering the biopsy findings</p>	
<i>QDU of Hospital Clínic de Barcelona vs QDU of Hospital Plató</i>				
<p>Bosch et al (2021). A comparative cost analysis between two quick diagnosis units of different levels of complexity. Journal of Comparative Effectiveness</p>	<p>Study Design: Economic evaluation (micro-costing analysis)</p> <p>Intervention/comparator: QDU of tertiary unit (Hospital Clínic) vs QDU of</p>	<p>Sample size: 407 consecutive patients evaluated at the Secondary Unit and a random sample of 407 from 6960 consecutive patients evaluated at the Tertiary Unit</p>	<p>More patients from the Secondary Unit were women and no significant differences were observed in mean age between the two units.</p> <p>Primary Findings: Patients from the Tertiary Unit were significantly more likely to be referred from the ED (61.2 vs 17.0%,</p>	<p><i>Overlap with Montori-Palacín 2017 comparing the same centres and the data collection period is completely covered by Bosch</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
Research, 10(5), pp.381-392.	<p>secondary unit (Hospital Plató)</p> <p>Aim: To compare by micro-costing the costs incurred by quick diagnosis units of tertiary and second-level hospitals.</p> <p>Data collection methods and dates: Data were collected on patients that attended both QDUs at least once between 1st January 2009 and 1st January 2017. Data were retrieved from computerised medical records stored in the information systems of both hospitals.</p> <p>Outcomes reported: Number of visits, Time to diagnosis, Diagnosis, Mean cost per visit, Mean cost per patient, Direct and structural costs, Indirect costs, Personnel costs, Diagnostic investigation costs.</p>	<p>Participants: All patients aged ≥ 18 years who attended the two QDUs at least once between 1 January 2009 and 1 January 2017 were potentially eligible to be included in the study.</p> <p>Setting: The Tertiary Unit is located in an adult daycare centre of the hospital (hospital Clínic).</p> <p>The secondary unit is located in a second-level district hospital (hospital Plató).</p> <p>Both QDUs were located in Barcelona, Spain.</p> <p>Staffing/facilities: Staff at the unit of the tertiary hospital included a consultant general internist, a senior internal medicine resident, nursing, and administrative staff. The unit is open 5 days a week and is equipped with armchairs and recovery rooms for procedures requiring sedation.</p> <p>Staff at the unit of the secondary hospital included two part-time general internists as well as administrative personnel.</p> <p>Services provided: The full range of services provided may not be fully</p>	<p>respectively; $p < 0.0001$), whereas patients from the Secondary Unit were mostly referred from primary care centres (69.0%). The rate of referrals for symptoms suggestive of cancer was 33.2% in the Tertiary and 26.0% in the Secondary Unit ($p = 0.0012$) and patients from the former unit were more likely to have a final diagnosis of malignancy (19.7 vs 14.3%, respectively; $p = 0.0020$).</p> <p>Although the total number of visits in the Tertiary Unit was significantly higher than that in the secondary centre unit (3.098 ± 0.6584 vs 2.123 ± 0.2171, respectively; $p = 0.0064$) (ratio of successive/first visits [2.07 ± 0.2241 vs 1.12 ± 0.1034; $p = 0.0070$, respectively]), the mean time to diagnosis was significantly shorter in the former (8 [IQR 4–13] vs 12 [IQR 1–28], respectively; $p < 0.0001$).</p> <p>Cost outcomes</p> <p>The mean total cost per patient of the Tertiary Unit was $\text{€}577.50 \pm 219.60$, varying from a minimum of $\text{€}353.2$ to a maximum of $\text{€}975.8$ per patient and year, while the mean cost of the Secondary Unit was $\text{€}394.70 \pm 92.58$ per patient, ranging from a minimum of $\text{€}289.6$ to a maximum of $\text{€}539.1$ per patient and year. The mean cost per visit of both units was similar ($\text{€}182.8 \pm 41.47$ in the Tertiary vs $\text{€}184.6 \pm 29.41$ in the Secondary Unit; $p = 0.09056$). An analysis of general costs revealed that direct and structural costs per patient of the two units were not significantly different. Conversely, indirect costs of the Tertiary Unit were significantly higher than those of the secondary centre unit ($\text{€}49.93 \pm 19.90$ vs $\text{€}12.42 \pm 2.344$, respectively; $p = 0.0018$).</p> <p>In both units, Direct costs accounted for the largest proportion of cost per patient without significant differences (79.13 percent [95% CI, 77.12–81.14] in the Tertiary vs 81.15 percent [77.53–84.76] in the Secondary Unit; $p = 0.3327$). In addition, no</p>	<p>2021 data collection period. This study also has economic outcomes and so offers more information.</p> <p>The authors acknowledged some limitations of the study, In addition to its retrospective nature, costs related to the miles driven by the patient or anyone accompanying them or the contribution of patients' and caregivers' time (i.e., a societal perspective) were not included in the cost estimates. An additional limitation of the study is the fact that study data were obtained from two urban medical centres in a single geographic region therefore limiting the generalisability of the findings</p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
		reported in the text but included endoscopies, ultra-sonographies, cytology/biopsy, CT scans, and MRI	<p>significant differences were found in the average contribution of structural costs to the cost per patient of both units. However, the contribution of indirect costs was significantly greater for the unit of the tertiary centre (8.595 [8.377–8.813] vs 3.284 percent [2.618–3.950], respectively; $p < 0.0001$)</p> <p>When looking at the mean share of each direct cost component relative to the mean total cost per patient, laboratory and pathology costs along with imaging and endoscopy costs accounted for the largest share, with a significantly greater contribution of imaging and endoscopy costs of the secondary versus tertiary centre unit. Whereas costs of biopsy and cytology techniques and specialist consultation and referral accounted for a tiny fraction of the cost per patient of both units without relevant differences, personnel or staff costs of the Tertiary Unit accounted, on average, for a significantly greater amount (12.58 percent [10.64–14.51] vs 9.746 percent [8.029–11.46], respectively; $p = 0.0373$)</p> <p>The overall average costs of the two units in both groups of patients were higher than those in the baseline population. Specifically, for referrals for symptoms suggestive of cancer, mean cost per patient of the Tertiary Unit was €782.52 ± 191.56 and it was €562.21 ± 94.55 in the Secondary Unit ($p = 0.0537$). For patients with a final diagnosis of malignancy, mean cost per patient of the Tertiary Unit was €1069.17 ± 218.64 while it was €827.65 ± 151.83 in the other unit ($p = 0.0871$). Consistent with the results of the principal analysis, both for patients referred for suspected cancer and those with an eventual cancer diagnosis, cost differences continued to lie in personnel and indirect costs with significant differences between the two units.</p> <p>Personnel costs per patient of the tertiary hospital unit were found to be significantly higher than those</p>	

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
			of the other unit (€68.75 ± 14.90 vs €36.90 ± 3.28 p = 0.0011). Laboratory and pathology costs were higher in the tertiary unit however this was not significant, and no significant differences were reported for other costs such as, imaging and endoscopy, biopsy and cytology techniques and specialist consultation and referral.	
Montori-Palacín et al (2017). Quick outpatient diagnosis in small district or general tertiary hospitals: A comparative observational study . Medicine 96 (22).	<p>Study Design: Cross-sectional post-test only quasi-experimental</p> <p>Intervention/comparator: QDU1(Hospital Plató) vs QDU2 (Hospital clínic)</p> <p>Aim: To comparatively describe the diagnostic performance of the QDU of an urban district hospital (QDU1) and the QDU of its reference general hospital (QDU2).</p> <p>Data collection methods and dates: Data from all the patients evaluated were recorded onto case report forms and codified in a database. Data were collected for patients referred to both QDUs between November 2009 and February 2016</p> <p>Outcomes reported: Time to first visit, Number of visits, Time to examination, Time to diagnosis,</p>	<p>Sample size: 336 consecutive patients referred to QDU1, 530 patients who were referred to QDU2 randomly chosen retrospectively.</p> <p>Participants: Patients aged ≥18 years with potentially serious diseases referred to both QDUs between November 2009 and February 2016</p> <p>Setting: The QDU of Hospital Plató (QDU1) integrated in the internal medicine department of this hospital. It is an urban district hospital in Barcelona providing care to a reference population of 140,000 and QDU2 is its reference centre. The QDU of Hospital Clínic (QDU2) integrated in the internal medicine department of this hospital and, in particular, in an adult day-care centre.</p> <p>Staffing/facilities: QDU1 has 120 beds for acute patients. The attending physician in charge of the unit is a general internist who dedicates 4 hours</p>	<p>QDU1 patients were predominantly referred from PCCs (69%), and EDs were the main referral source of QDU2 patients (59%). The most frequent reasons for referral to QDU1 were unintentional weight loss (UWL) (21%), tests detected at referral sites (14%), anaemia (14%), abnormal peripheral lymphadenopathy and/or palpable masses (10%), and gastrointestinal symptoms (10%). In QDU2, the most common referral reasons were anaemia (21%), gastrointestinal symptoms (19%), UWL (16%), fever (12%), and adenopathies and/or palpable masses (11%).</p> <p>Primary Findings: The median time to first visit was longer in QDU1 than in QDU2 patients (5 [2–8] vs 3 [1–5] days; P=0.008) and the median number of visits was lower in QDU1 patients (2 [1–3] vs 2.5 [1.5–4], respectively; P=0.003). The 336 first visits in QDU1 generated 375 successive visits with a successive-to-first visit ratio of 1.12, which was lower than the QDU2 ratio 2.13 (P<0.001).</p> <p>At first visit, nearly all the patients underwent laboratory tests and plain X-rays (98 and 87%, respectively, in QDU1 and 97 and 90%, respectively, in QDU2). The QDU2 patients underwent significantly more ultrasonographies, endoscopies, and cytology/biopsy studies than the QDU1 patients. Furthermore, significant differences were observed in the waiting times to CT scan and cytology/biopsy studies, which were longer in QDU2 patients, and in</p>	<p><i>Overlap with Bosch 2021 comparing the same centres and the data collection period is completely covered by Bosch 2021 data collection period.</i></p> <p><i>The authors' acknowledged several limitations including the relatively small sample size, some relevant data from the QDU2 group might not have been fully captured, and the handling of patients referred to hospital-based outpatient clinics such as those reported here or hospitalised for evaluating similar conditions can be different in other clinical settings, a situation relying on factors such as the</i></p>

Citation	Study Details	Participants & Setting	Key findings	Observations/Notes
	Diagnosis, Diagnostic tests, Onward referral.	<p>per week to this clinical duty. QDU2 staff includes a consultant general internist full-time, a senior internal medicine resident, a nurse part-time, a nurse coordinator part-time, and 2 secretaries part-time. The unit is open 5 hours a day, 4 days a week.</p> <p>Services provided: CT scan, MRI, Ultrasonography, Endoscopy, Scintigraphy, Body FDG-PET, Cytology/biopsy, and Bone marrow aspiration</p>	<p>the waiting times to ultrasonography, endoscopy, scintigraphy, and body FDG-PET, which were longer in QDU1 patients.</p> <p>While QDU1 patients were more likely than QDU2 to require ≤ 2 visits to achieve a diagnosis (73 vs 57%; $P < 0.001$). the median time-to-diagnosis was longer in the former (12 [1–28] vs 8 [4–14] days, respectively; $P < 0.001$).</p> <p>Although a final diagnosis of no malignancy prevailed over malignancy in both QDU1 and 2 patients (83 and 79%) malignancy was more common among the latter (19 vs 13%, respectively; $P = 0.001$)</p> <p>After diagnosis, most QDU1 patients were referred to outpatient clinics of Hospital Plat� and PCCs (42% each), with 8% being referred to specialist outpatient clinics of the reference Hospital Cl�nic. In addition, 60% of QDU2 patients were referred onward to PCCs and 35% to the hospital outpatient clinics.</p>	<p><i>institution traditions, the available resources, or the type of centre. Consequently, the findings and potential implications of this study cannot be generalised. Lastly, although matching was indeed done, the resulting sample was too small to perform a logistic analysis.</i></p>

3. DISCUSSION

3.1 Summary of the findings

Our rapid review sought to identify community diagnostic centres, however our search only identified one diagnostic service located within the community, while the remaining studies covered diagnostic centres located in hospitals with direct access from primary care. There is evidence to suggest that diagnostic centres can be an effective alternative model of care, capable of reducing waiting times, and reducing pressure on hospitals by avoiding hospitalisations, reducing the number of visits required to receive a definite diagnosis, and increasing the number of patients in whom a definite outcome is reached. However, the costs incurred by a diagnostic centre can be impacted by the diagnostic and clinical complexity of the patients managed at the unit, as well as the characteristics of the unit including the number of staff and contribution of staff time. Overall cost-effectiveness of diagnostic centres may be dependent on whether or not the centre is running at full capacity.

However, much of the evidence was derived from quasi-experimental studies, with only three economic evaluations. We identified one RCT, however this study did not contribute to the evidence base used in this review because it was old and primarily focussed on patient anxiety. While it did report some economic outcomes these were superseded by more recent studies. Considerable methodological limitations across included studies, as well as structural differences in healthcare systems across international studies, could limit the applicability of these findings. However, we did identify five studies that were conducted in the UK, three of which were specific to cancer diagnosis, one specific to the diagnosis of MS, and one assessed the effectiveness of a mobile diagnostic ultrasound service.

3.2 Limitations of the available evidence

This RR has highlighted several evidence gaps including the paucity of robust study designs in this area of research. The majority of study designs included in this review utilised weak methodologies that may not be appropriate for inferring effectiveness. This RR did not identify any studies exploring equity of access to diagnostic centres and only three economic evaluations were identified, one of which was conducted in the UK.

The quality of reporting in the included studies was oftentimes poor. Key details pertaining to outcome measures or information about diagnostic centres, were often lacking or poorly described. In addition, key statistical parameters, such as confidence intervals, were not reported in some study results, making it difficult to determine the magnitude of effect of some diagnostic centres.

Most of the evidence identified in this review were derived from diagnostic centres located within hospital sites. Only one study included in this review examined a diagnostic service located within the community (a mobile ultrasound service). Whilst siting a diagnostic centre within the hospital setting is likely to provide greater availability to already established and functioning diagnostic equipment and services, it may not be accessible to certain groups of patients, and further worsen health inequalities.

Only five UK studies were identified, with the remaining studies conducted in a variety of other countries. A large number of these studies were conducted in Spain, and these measured many of the relevant outcomes included in this RR. As a result, the generalisability of our findings to Wales could be limited due to differences in healthcare systems and healthcare provision between both countries.

Furthermore, many of the studies conducted in Spain reported data from the same set of diagnostic centres - some with similar data collection periods, thereby creating the potential for double counting (see Appendix 2 for details about the potential for data overlap). To reduce the likelihood of double counting, where multiple studies reported on the same diagnostic centre, we only reported findings from the most recent study in the narrative synthesis (if a comparison to usual care was provided) and highlighted whether any of the other studies identified any other relevant outcomes not reported in the more recent publication. Although this is not a usual approach to take, we believe this was a pragmatic approach, given the timescale.

The majority of included studies compared patients attending diagnostic centres with a range of comparators including hospitalised patients and historical controls. These comparisons may not be appropriate considering the fact that hospitalised patients are generally more acutely unwell and require more clinical input and longer care than those eligible to attend a diagnostic centre. In addition, unlike hospital wards, diagnostic centres are generally not open 24 hours a day, and the infrastructure and operational functioning of these centres were inconsistently reported.

3.3 Implications for policy and practice

This RR has highlighted possible benefits of diagnostic centres, particularly with regards to their impact on waiting times and pressure on secondary care. Although inferences around the effectiveness of community diagnostic centres cannot be made due to the paucity of evidence from diagnostic centres located outside of hospital settings, the information extracted from these studies provide valuable information into the potential benefits of establishing these centres within Wales.

In light of the paucity of robust evidence, further well-designed, higher quality research from the UK and similar countries is needed to better understand the effectiveness of community diagnostic centres within Wales. Research around diagnostic centres sited outside of hospital locations is particularly needed to investigate the impact on equity of access. In addition, further research is required to evaluate the effectiveness of diagnostic centres for conditions other than cancer, and full economic evaluations of these centres are also needed to better understand how diagnostic centres can be efficiently utilised.

Comparative impact evaluations should be incorporated into service development plans from the onset, to assess the effectiveness of newly opened diagnostic centres in the UK over time.

3.4 Strengths and limitations of this rapid review

The studies included in this RR were identified through an extensive search of electronic databases, trial registries, grey literature, as well as consultation of content experts in the field. Despite making every effort to capture all relevant publications and reduce the risk of bias, it is possible that additional eligible publications may have been missed or we may have introduced some biases to this RR through our inclusion criteria. Efforts were made to reduce this risk of introducing bias and have highlighted this where possible, for example in the investigation into the potential risk of multiple studies reporting the same data.

We identified a large number of studies during the initial stages of this review (prior Rapid Evidence Map), many of which were descriptive in nature. To overcome this potential limitation, we made the decision to include only studies that had some sort of comparator and utilised a study design algorithm developed by Leatherdale (2019), to assign an accurate description of the methods employed.

We made the pragmatic decision to report the findings from the most recent studies when multiple studies were reporting on the same diagnostic centre and outcome. However, this may have introduced some bias in the reporting as there is a potential that the studies could have had different aims and objectives and may also have been focussed on different health conditions. Therefore, the findings may have differed between studies, specifically for the economic evaluations.

As no date or country of study limits were set, and the data collection dates of included studies are wide ranging, it is possible that the diagnostic centres we have included here may not be the same as the proposed diagnostic centres within Wales. It is also possible that as many of the diagnostic centres included were from other countries where the healthcare system is different to that of the UK, the results may not be generalisable to the UK.

4. REFERENCES

- BBC News (2022) Rapid cancer diagnosis centre rollout in Wales a UK first. Available at: [Rapid cancer diagnosis centre rollout in Wales a UK first - BBC News](#) [Accessed 06 October 2022].
- Department of Health and Social Care (2021) Available at: [40 community diagnostic centres launching across England - GOV.UK \(www.gov.uk\)](#). [Accessed 13 July 2022].
- Health Education England (2022). 'Community Diagnostic Centres (CDC)'. Available at: <https://www.hee.nhs.uk/our-work/cancer-diagnostics/community-diagnostic-centres-cdc>. [Accessed 31 October 2022].
- Jensen H, Tørring M.L, Olesen F, et al. (2015). Diagnostic intervals before and after implementation of cancer patient pathways—a GP survey and registry based comparison of three cohorts of cancer patients. *BMC cancer*, 15(1), pp.1-10.
- Leatherdale S.T. (2019) Natural experiment methodology for research: a review of how different methods can support real-world research, *International Journal of Social Research Methodology*, 22:1, 19-35, DOI: 10.1080/13645579.2018.1488449.
- NHS England (2020) Diagnostic: Recovery and Renewal. Report of the Independent Review of Diagnostic Services for NHS England. Available at: <https://www.england.nhs.uk/wp-content/uploads/2020/11/diagnostics-recovery-and-renewal-independent-review-of-diagnostic-services-for-nhs-england-2.pdf> [Accessed 12 July 2022].
- NHS England (2022) One million checks delivered by NHS 'one stop shops'. News. Available at: [NHS England » One million checks delivered by NHS 'one stop shops'](#) [Accessed 12 July 2022].
- NHS (2022) Document 3 - Community Diagnostic Hub (CDH) Draft Qualification Specification. Available at: <https://www.ardengemcsu.nhs.uk/media/2585/document-3-cdh-framework-specification-v111.pdf> [Accessed 12 July 2022].
- The King's Fund (2022). 'Are community diagnostic centres really moving care closer to home?' Available at: <https://www.kingsfund.org.uk/blog/2022/10/are-community-diagnostic-centres-really-moving-care-closer-home>. [Accessed 03 November 2022].
- Welsh Government (2021) NHS activity and performance summary: July and August 2021. Statistics. Available at: <https://gov.wales/nhs-activity-and-performance-summary-july-and-august-2021-html> [Accessed 12 July 2022].
- Welsh Government (2022) Our programme for transforming and modernising planned care and reducing waiting lists in Wales. Available at: <https://gov.wales/sites/default/files/publications/2022-04/our-programme-for-transforming--and-modernising-planned-care-and-reducing-waiting-lists-in-wales.pdf> [Accessed 13 July 2022].
- StatsWales (2022) Waiting times by month. Available at: <https://statswales.gov.wales/Catalogue/Health-and-Social-Care/NHS-Hospital-Waiting-Times/Diagnostic-and-Therapy-Services/waitingtimes-by-month> [Accessed 24 October 2022].

5. RAPID REVIEW METHODS

5.1 Eligibility criteria

We searched for primary sources to answer the review question “What is the effectiveness of community diagnostic centres?”

The following eligibility criteria were used to identify studies for inclusion in the RR:

Table 2: Eligibility criteria

	Inclusion criteria	Exclusion criteria
Participants	Symptomatic patients, all conditions being referred to diagnostic centres via primary care settings	
Settings	Diagnostic centres in any setting	Exclude screening programmes, or where there is treatment undertaken but no diagnostics.
Intervention / exposure	Diagnostic centres/units/hubs and clinics accepting referrals from primary care (as a minimum)	Community diagnostic centres accepting referrals exclusively from other routes
Comparison (if applicable)	Usual care/other diagnostic centres	
Outcomes	All outcomes, with a focus on: <ul style="list-style-type: none"> - capacity - pressure on secondary care - waiting times - equity of access - and all economic outcomes 	
Study design	Any design that contains a comparison that can infer effectiveness	
Countries	All countries	
Language of publication	Studies published in English	Any study not published in English
Publication date	No date limits set	
Publication type	Published and preprint primary literature	All publication types other than primary literature

5.2 Literature search

The studies included in this RR were identified through the literature search conducted in our preliminary work. COVID-19 specific and general repositories of evidence reviews noted in our resource list were searched on 6th July 2022 by three reviewers and an updated search was conducted on the 3rd of August 2022 for the REM. An audit trail of the search process is provided within the resource list (Appendix 3). Searches were limited to English-language publications and included searches for primary studies. References of secondary sources

identified during preliminary work were scanned for relevant primary studies and forward and backward citation tracking was also conducted on the secondary sources.

Search concepts and keywords around diagnostic units, centres, hubs, and clinics were utilised. The searches combined free text words and descriptors when available. We deliberately kept our search strategy broad to capture as much evidence on diagnostic centres as possible. Resources searched are outlined in Appendix 3 and the search strategy used to search Medline is available in Appendix 4.

5.3 Study selection process

Our prior Rapid Evidence Map included 50 primary studies, all of which were screened for inclusion in the Rapid Review using the updated eligibility criteria in 5.1 by two independent reviewers.

5.4 Data extraction

One researcher performed the data extraction and a second researcher carried out consistency checks. Information extracted includes:

- Reference (author, year, country)
- Study design
- Intervention / comparator
- Aim
- Data collection methods (and dates)
- Outcome(s) measured
- Study participants (e.g., sample size, age range, sex, any other specifics)
- Setting
- Staffing/facilities
- Services provided (e.g. MRI, ultrasound, etc.)
- Key findings
- Additional notes/comments

An observations/notes column was added to report key information that was not captured above and to record any limitations of the included sources (see Table 1).

5.5 Study design categorisation

Studies were categorised by research design and additional analytic techniques if applicable, using the study design classification system developed by Leatherdale (2019) by a single reviewer, with verification of all judgements by a second reviewer (see Tables 3, 4 and 5). The Leatherdale tool includes a series of questions on the methodological characteristics of a natural experimental study to identify an accurate description of the research design, in particular the characterisation of designs by the frequency and points at which data is collected.

5.6 Quality appraisal

A range of JBI quality appraisal checklists (which were selected based on the study design used) were used to assess the methodological quality of each included study. Quality assessment was undertaken by a single reviewer, with verification of all judgements by a second reviewer. Any discrepancies were discussed and resolved amongst the review team. The results of the quality appraisals can be seen in Tables 3, 4, and 5.

5.7 Synthesis


The effectiveness of diagnostic centres was compared to a comparator (most often usual care) on a range of outcomes including, pressure on secondary care, capacity, wait times and cost-effectiveness. Following on from the REM, a narrative synthesis was conducted reporting the results of selected studies that included diagnostic centres accepting referrals from primary care and that had a comparative element. Stakeholders highlighted the importance of finding out if diagnostic centres can impact waiting times and current pressures on secondary care, as well as the economic impact. With this in mind, we categorised the outcomes identified into 'impact on waiting times', 'impact on pressure' and 'economic outcomes' and reported findings using these categories. In an attempt to highlight the more robust methodological studies (economic evaluations), we reported these findings first. Where multiple studies reported outcomes on the same diagnostic centre, we chose to report only the findings from the most recent study to avoid the risk of double counting.

6. EVIDENCE

6.1 Study selection

Due to the large number of studies identified it was decided, in conjunction with stakeholders, to include only studies that included a diagnostic centre accepting referrals from primary care as a minimum and included a comparator group. Of the initial 50 studies screened 42 included diagnostic centres that accepted referrals from primary care and of these, 21 were comparative and 20 reported on our outcomes of interest. The study selection process is outlined below.

6.2 Study selection flow chart



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). *Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement*. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

6.3 Quality appraisal tables

Table 3. Quality appraisal results for economic evaluations

Study	JBI Appraisal Items – Economic evaluations										
	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Q11
Bosch et al 2021	Y	Y	Y	U	Y	Y	Y	U	N	Y	N
Sanclemente-Ansó et al 2016	Y	Y	Y	Y	Y	Y	Y	U	N	Y	N
Sewell et al 2020	Y	Y	Y	Y	Y	Y	N	N	Y	Y	N

Key: Y=Yes, N=No, U=Unclear, N/A=not applicable

Q1. Is there a well-defined question?

Q2. Is there comprehensive description of alternatives?

Q3. Are all important and relevant costs and outcomes for each alternative identified?

Q4. Has clinical effectiveness been established?

Q5. Are costs and outcomes measured accurately?

Q6. Are costs and outcome valued credibly

Q7. Are costs and outcomes adjusted for differential timing?

Q8. Is there an incremental analysis of costs and consequences?

Q9. Was sensitivity analysis conducted to investigate uncertainty in estimates of cost or consequences?

Q10. Do study results include all issues of concern to users?

Q11. Are the results generalizable to the setting of interest in the review?

Table 4. Quality appraisal results for randomised controlled trials

Study	JBI Appraisal Items – Randomised Controlled Trial												
	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Q11	Q12	Q13
Harcourt et al 1998	Y	Y	Y	N	N	N	Y	Y	Y	Y	Y	Y	Y

Key: Y=Yes, N=No, U=Unclear, N/A=not applicable

Q1. Was true randomization used for assignment of participants to treatment groups?

Q2. Was allocation to treatment groups concealed?

Q3. Were treatment groups similar at the baseline?

Q4. Were participants blind to treatment assignment?

Q5. Were those delivering treatment blind to treatment assignment?

Q6. Were outcomes assessors blind to treatment assignment?

Q7. Were treatment groups treated identically other than the intervention of interest?

Q8. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analysed?

Q9. Were participants analysed in the groups to which they were randomised?

Q10. Were outcomes measured in the same way for treatment groups?

Q11. Were outcomes measured in a reliable way?

Q12. Was appropriate statistical analysis used?

Q13. Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?

Table 5. Quality appraisal results for quasi-experimental studies

Study	JBI Appraisal Items – Quasi-experimental studies								
	Q1.	Q2.	Q3.	Q4.	Q5.	Q6.	Q7.	Q8.	Q9.
Arnaout et al 2013	Y	U	Y	Y	N	N/A	Y	Y	Y
Bosch et al 2011	Y	U	Y	Y	N	N/A	Y	Y	N/A
Bosch et al 2012a	Y	N	Y	Y	N	N/A	N	Y	Y
Bosch et al 2012b	Y	N	Y	Y	N	N/A	Y	Y	Y
Bosch et al 2012c	Y	N	Y	Y	N	N/A	N	Y	Y
Bosch, Jordán and López-Soto 2013	Y	N	Y	Y	N	N/A	N	Y	Y

Bosch et al 2018	Y	N	Y	Y	N	N/A	Y	Y	Y
Bosch et al 2020	Y	N	Y	Y	N	N/A	Y	Y	Y
Brito-Zerón et al 2014	Y	N	Y	Y	N	N/A	N	Y	Y
Choudhury et al 2013	Y	U	Y	Y	N	N/A	Y	Y	Y
McKevitt et al 2017	Y	U	Y	Y	N	N/A	Y	Y	Y
Montori-Palacín et al 2017	Y	N	Y	Y	N	N/A	Y	Y	Y
Nixon et al 2019	Y	U	Y	Y	N	N/A	Y	Y	Y
Pallan et al 2005	Y	U	Y	Y	N	N/A	Y	U	U
Porter et al 2003	Y	N	Y	Y	N	N/A	Y	U	N/A
Sethukavalan et al 2013	Y	Y	Y	Y	N	N/A	Y	Y	Y
Key: Y=Yes, N=No, U=Unclear, N/A=not applicable									

1. Is it clear what is the cause and what is the effect?
2. Were the participants included in any comparisons similar?
3. Were the participants included in any comparisons receiving similar treatment/care, other than the exposure or intervention of interest?
4. Was there a control group?
5. Were there multiple measurements of the outcome both pre and post the intervention/ exposure?
6. Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analysed?
7. Were the outcomes of participants included in any comparisons measured in the same way?
8. Were outcomes measured in a reliable way?
9. Was appropriate statistical analysis used?

7. ADDITIONAL INFORMATION

7.1 Conflicts of interest

The review team declares no conflicts of interest.

7.2 Information available on request

The protocol for this RR is available on request from Hannah Shaw, Public Health Wales,
E-mail: Hannah.shaw@wales.nhs.uk.

7.3 Acknowledgements

The authors would like to thank Brendan Collins, Delia Ripley, Jennifer Morgan, Joanna Charles, Leon Wong, Rob Orford and Sally Anstey for their contributions during stakeholder meetings in guiding the focus of the review and interpretation of findings.

8. ABOUT THE WALES COVID-19 EVIDENCE CENTRE (WCEC)

The WCEC integrates with worldwide efforts to synthesise and mobilise knowledge from research.

We operate with a core team as part of [Health and Care Research Wales](#), are hosted in the [Wales Centre for Primary and Emergency Care Research \(PRIME\)](#), and are led by [Professor Adrian Edwards of Cardiff University](#).

The core team of the centre works closely with collaborating partners in [Health Technology Wales](#), [Wales Centre for Evidence-Based Care](#), [Specialist Unit for Review Evidence centre](#), [SAIL Databank](#), [Bangor Institute for Health & Medical Research/ Health and Care Economics Cymru](#), and the [Public Health Wales Observatory](#).

Together we aim to provide around 50 reviews per year, answering the priority questions for policy and practice in Wales as we meet the demands of the pandemic and its impacts.

Director:

Professor Adrian Edwards

Contact Email:

WC19EC@cardiff.ac.uk

Website:

<https://healthandcareresearchwales.org/about-research-community/wales-covid-19-evidence-centre>

9. APPENDIX

APPENDIX 1: Characteristics of included diagnostic centres

Reference	Location & setting	Aim of the centre	Staff & facilities	Investigative procedures/services conducted	Diagnosis of interest	Referral	Referral criteria	Key underpinning elements of diagnostic centre
Canada								
<i>Lymphoma Rapid Diagnosis Clinic (LRDC) at Princess Margaret Cancer Centre, Toronto, Ontario</i>								
Nixon et al (2020).	Lymphoma Rapid diagnosis clinic (LRDC) based in a tertiary cancer centre (Princess Margaret Cancer Centre), part of University Health Network (UHN), Toronto, Ontario, Canada.	The goal of the centre was to provide specialised comprehensive assessment and timely and appropriate investigations to reduce wait times to a definitive biopsy to establish histologic diagnosis and initiation of treatment.	The clinic was led by a Nurse practitioner ; however, it appears weekly dedicated operating rooms for lymphoma biopsies were used by head and neck, thoracic, and general surgeons, and biopsy material from outside facilities were reviewed by hemapathologists when available.	Laboratory tests, peripheral blood flow cytometry, tuberculosis skin testing, abdominal ultrasound, computed tomography scans, bone marrow biopsy, or FNA. Referral to surgical services for consideration of excisional lymph node biopsy or radiology for image guided core biopsy was requested based on location and size of lymphadenopathy.	Lymphadenopathy and suspected lymphoma	Primary care or medicine, ER, or community specialists	Lymphadenopathy on the basis of clinical assessment or imaging, biopsy results suspicious for lymphoma, or peripheral blood abnormalities. Patient symptoms included: symptoms of viral infection, "B" symptoms, new pain, pruritus, palpable lymph nodes, lymphocytosis (ALC > 4.0 X 10 ⁹ /L)	The clinic was Nurse practitioner-led The optimal approach to lymphoma diagnosis is multidisciplinary, and our data suggest that even a modest additional investment in personnel and resources would be expected to significantly improve delivery of care for patients with suspected lymphoma.
<i>The Gale and Graham Wright Prostate Centre, North York General Hospital Toronto, Ontario</i>								
Sethukavalan et al (2013).	Rapid diagnostic unit (RDU) called The Gale and Graham Wright Prostate Centre, set up at the North	The Wright Prostate Centre is a diagnostic assessment programme and multidisciplinary clinic where both radiation oncology and urology specialists see	Staff include radiation oncology and urology specialists	Unclear	Prostate cancer	Urologists or family physicians (primary care)	Patients with suspicion of cancer either (based on a prostate-specific antigen (PSA) test), because of symptoms , or an abnormal digital rectal exam (DRE) , which warranted further testing or	

Reference	Location & setting	Aim of the centre	Staff & facilities	Investigative procedures/services conducted	Diagnosis of interest	Referral	Referral criteria	Key underpinning elements of diagnostic centre
	York General Hospital (NYGH), Branson Site, Toronto, Ontario, Canada.	every patient on the same day after obtaining their biopsy results					referral to a specialist to definitively diagnose or rule out cancer	
<i>Rapid Access Diagnostic and Support (RADS) at The Women's Breast Health Center, Ottawa Hospital, Ottawa, Ontario</i>								
Arnaout et al (2013).	The Women's Breast Health Center of the Ottawa Hospital in Ottawa, Ontario, Canada (a university-affiliated tertiary care centre)	The Rapid Diagnosis and Support (RADS) Program initiative was a pilot programme which aimed to accommodate the increasing patient volume, reduce wait times, decrease fragmentation of care , and enhance a patient's overall experience.	A multidisciplinary team of breast cancer specialists (five radiologists, five surgeons, two pathologists, one nurse manager, two nurse navigators, and a diagnostic imaging manager)	Routine screening mammography, initial diagnostic imaging workup (mammogram and/or breast ultrasound) for a breast problem (e.g., palpable mass, breast pain, nipple discharge), or additional diagnostic imaging and biopsy workup following an abnormal mammogram performed at another institution	Breast cancer	Primary care	Patients are routinely referred to the breast centre for either: 1. Routine screening mammogram 2. Breast symptoms requiring diagnostic imaging workup 3. Abnormal outside imaging needing additional diagnostic workup/biopsy	Coordination of diagnostic imaging workup and nursing support were provided by a nurse navigator . The nurse navigator was assigned to track all patients within the programme to help expedite and inform them of additional diagnostic imaging workup appointments, provide psychosocial support to the patients during their diagnostic care, and provide a telephone hotline service for which patients can call if they had any questions or concerns. RADS program patients were labelled as such on imaging and pathology requisitions to help avoid delays. Interventions, such as coordinating same day tests and changing biopsy schedules and calling pathologists to accommodate faster access to pathology, were implemented as much as possible. Through this prospective pilot project, we have learned that we can efficiently triage patients at highest risk of having breast cancer and therefore initiate strategies to reduce diagnostic wait times for these patients and prevent fragmentation of care. Most of these interventions were aimed at tracking the diagnostic journey of these patients so that their workup can be appropriately expedited and unnecessary gaps in scheduling can be avoided.

Reference	Location & setting	Aim of the centre	Staff & facilities	Investigative procedures/services conducted	Diagnosis of interest	Referral	Referral criteria	Key underpinning elements of diagnostic centre
<i>Rapid Access Breast Clinic (RABC) at Mount St Joseph Hospital, Vancouver</i>								
McKevitt et al (2017).	Rapid Access Breast Clinic (RABC) at Mt St Joseph Hospital, British Columbia, Canada	The RABC was established to offer a single site for coordinated clinical and radiological assessment of breast problems	Clerical staff, radiologists, surgeons, nurse navigator and clinic family physician (FP)	Offers on-site mammography, breast ultrasound, ultrasound-guided biopsy, and mammographic and ultrasound-guided fine wire localisation. Patients requiring stereotactic core biopsy, MRI or MRI-guided biopsy have those investigations coordinated by the RABC at regional imaging sites offering those investigations.	Breast cancer	Family physician (primary care)	Abnormal screening mammogram or presenting with a new breast problem .	The Rapid Access Breast Clinic (RABC) was established following the guidelines for breast centres outlined by the European Society of Mastology (EUSOMA). The clinic provided triple evaluation of patients with close collaboration between clinicians and radiologists, facilitated by clinical pathways and nurse navigation. The development of the RABC in conjunction with the radiology department at the centre created a unique situation in which the breast surgeons saw patients managed by two separate diagnostic pathways.
Spain								
<i>Quick Diagnosis Unit (QDU), Hospital Clínic, Barcelona</i>								
Bosch et al (2020). Brito-Zerón et al (2014). Bosch, Jordán and López-Soto (2013). Bosch et al (2012a). Bosch et al (2012b). Bosch et al (2012c). Bosch et al (2011).	Quick Diagnosis Unit (QDU) based in the Adult Day Care Centre which is situated within the General Internal Medicine Department of a public tertiary university hospital (Hospital Clínic), Barcelona, Spain.	The QDUs implemented in Spain are mainly led by general internists and aim to provide patients with serious disease with the prompt and effective diagnosis and treatment they deserve and require	Staff at QDU includes a full-time consultant internist, a senior internal medicine resident, a full-time nurse, a part-time nurse coordinator, and 2 part-time administrative assistants. The unit is open 5 hours a day, 5 days a week. In addition, consultants from other services are provided as required. It has a consulting room and a waiting room for patients	Upper gastrointestinal endoscopic ultrasound (EUS), US/CT-guided biopsy, contrast-enhanced thin-slice CT scan of the chest, abdomen, and pelvis Laboratory tests included, among others, acute phase reactants (C-reactive protein, erythrocyte sedimentation rate), hemogram (total leucocytes, manual white blood cell count, haemoglobin, haematocrit, platelets), liver function tests, serum lactate dehydrogenase, serum total proteins and protein electrophoresis, microbiological serologies [e.g. IgM and IgG for cytomegalovirus (CMV),	Most studies were non-specific but including potentially severe diseases such as cancer and severe anaemia (some studies had a specific focus including severe anaemia, pancreatic cancer, unexplained fever).	Primary care and emergency department	The QDU evaluates stable patients with suspected serious disease who require expeditious workup and who, in many instances, would be admitted to hospital for diagnostic testing. Thus, patients must be physically and mentally capable of attending several outpatient appointments. Symptoms may include: Anaemia, cachexia-anorexia syndrome, febrile syndrome, adenopathies and/or	The operation of the QDU is based on an urgent first visit, followed by the preferential scheduling and coordination of complementary tests and subsequent visits until a diagnosis is made.

Reference	Location & setting	Aim of the centre	Staff & facilities	Investigative procedures/services conducted	Diagnosis of interest	Referral	Referral criteria	Key underpinning elements of diagnostic centre
			and families, and functions daily.	Epstein–Barr virus (EBV), Toxoplasma gondii, human parvovirus B19], HIV testing, b2 microglobulin, specific serum tumour markers, specific serum autoantibodies, specific genetic studies (autoinflammatory diseases), including cultures, imaging studies, endoscopies and cytology/biopsy studies The main diagnostic tests (analytical and microbiological tests, simple radiology [X-ray], computed tomography [CT], echography, nuclear scintigraphy, digestive endoscopy, biopsies and lymph node fine-needle puncture aspiration [FNPA]) are normally performed within 7 days after the first visit.			palpable masses, unexplained severe abdominal pain, chronic diarrhoea, recent severe constipation, rectorrhagia, jaundice, lung and/or pleural abnormalities, unexplained dyspnea, dysphagia, ascites, anasarca, bone pain with suspicion of malignancy, arthritis, hemogram abnormalities suggestive of primary hematologic disorder, splenomegaly and/or hepatomegaly, monoclonal paraprotein band with or without suspicion of multiple myeloma, neurologic disorders (central, spinal, and peripheral nervous system)	
<i>Quick Diagnostic Unit (QDU) at Bellvitge Hospital, Barcelona</i>								
Sanclément-Ansó et al (2016).	QDU at Bellvitge University Hospital in Barcelona, which is affiliated to the University of Barcelona, Catalonia,	Not stated	The QDU is internist led and open 7 hours a day, 2 days a week (Tuesdays and Fridays). Analysis implies staff also included attending physician,	Not explicitly stated, but to include blood and urine analysis, X-ray CT, simple X-ray, PET-CT, biopsy, bronchoscopy, cytology, microbial culture, scintigraphy, mammography, specialist consultation, ultrasonography, colonoscopy,	Non-specific but including potentially serious diseases	Primary care and the emergency department	Anaemia, cachexia-anorexia syndrome, febrile syndrome, adenopathies and/or palpable masses, unexplained severe abdominal pain, chronic diarrhoea, recent severe constipation,	Hospital-based QDUs are normally led by internists and are a distinct model of outpatient care delivery almost exclusively reported in Spain, most notably in Catalonia. The driving reason explaining the important role of internists leading QDUs is the common presence of nonspecific symptoms such as weight loss, fatigue, malaise or fever of unknown origin in patients referred to

Reference	Location & setting	Aim of the centre	Staff & facilities	Investigative procedures/services conducted	Diagnosis of interest	Referral	Referral criteria	Key underpinning elements of diagnostic centre
	Spain. The QDU is integrated to the Internal Medicine Department of the hospital.		registered nurse, caretaker.	electrocardiography, lower and upper gastrointestinal series, esophagogastroduodenoscopy, blood marrow aspiration, flow cytometry			rectorrhagia, jaundice, lung and/or pleural abnormalities, unexplained dyspnea, dysphagia, ascites, anasarca, bone pain with suspicion of malignancy, arthritis, hemogram abnormalities suggestive of primary hematologic disorder, splenomegaly and/or hepatomegaly, monoclonal paraprotein band with or without suspicion of multiple myeloma, neurologic disorders (central, spinal, and peripheral nervous system)	<p>these units. The versatility of these physicians for the diagnosis of a wide range of serious disorders together with their integral, global view of the patient contrast with the more specialized approach of physicians at other units such as the UK one-stop diagnostic clinics.</p> <p>The requirements for evaluation by the QDU at Bellvitge Hospital are: 1) clear referral criteria based on a pre-established list of suspected serious disorders; 2) the first visit has to occur as soon as possible after referral (≤ 15 days); 3) patients must have preferential access to a wide range of diagnostic tests; and 4) patients should be able to attend several appointments for outpatient visits and diagnostic tests.</p>
<i>Quick Diagnosis Unit (QDU), Hospital Plató</i>								
Bosch et al (2021). Montori-Palacín et al (2017).	QDU of a second-level district hospital (Hospital Plató) with 160 beds and providing healthcare for a population of 140,000 inhabitants.	The unit works as an ambulatory clinic evaluating patients with suspected severe conditions whose physical performance allows them to travel from home to hospital and back for visits and examinations.	The unit is staffed with two part-time general internists each working 4 hours per week, as well as administrative personnel.	Not described but appear to include CT scan, MRI, ultrasonography, endoscopy, scintigraphy, body FDG-PET, cytology/biopsy, bone marrow aspiration.	Suspected severe conditions	Primary care, emergency department, outpatient clinics, and inpatient wards.	Not described in detail, but included unintentional weight loss, adenopathies and/or palpable masses, anaemia, fever, gastrointestinal symptoms, test abnormalities, osteoarticular symptoms, respiratory symptoms, unexplained tiredness, neurological	The general working protocol of the unit consists of a rapid first appointment after referral from primary care centres or the emergency departments of the hospitals (usually within 5 days), followed by preferential programming of diagnostics tests and subsequent visits until a diagnosis is made.

Reference	Location & setting	Aim of the centre	Staff & facilities	Investigative procedures/services conducted	Diagnosis of interest	Referral	Referral criteria	Key underpinning elements of diagnostic centre
							disorders, ascites and other reasons (not defined).	
United Kingdom								
<i>The Breast Care Centre, Bristol</i>								
Harcourt et al (1998).	One stop clinic in a hospital (location not given but likely to be study author's centre - The Breast Care Centre, Frenchay Healthcare Trust, Bristol, UK)	Not stated	All clinics were conducted by the same two surgeons (one consultant, one staff grade)	Triple assessment (consisting of clinical examination, ultrasound scanning and cytology) and mammography, when needed.	Breast cancer	GP (primary care)	Women with no previous diagnosis of breast cancer, living within reasonable travelling distance of the hospital and whose general practitioner (GP) referral letter stated the presence of a breast lump	Triple assessment of each woman was conducted by either member of staff in the initial appointment. Mammography, when needed, was then carried out by radiologists in the hospital's general X-ray department. Cytology specimens were analysed in the pathology department sited elsewhere in the hospital. This system was constant over the course of the study.
<i>Rapid Diagnostic Clinic (RDC) at St Barts Health NHS Trust, London</i>								
Choudhury et al (2013).	A ' Rapid Diagnostic Clinic ' (RDC) within the ENT department (of Barts Health NHS Trust, London)	The RDC provides multi-modality specialist assessment for new referrals, with on-site sonography and cytology.	ENT head and neck specialist, either a consultant or specialist registrar, consultant head and neck radiologist, consultant histopathologist. This clinic is run on a weekly basis.	Ultrasonography, and fine needle aspiration cytology (FNAC)	Head and neck cancer	GPs and other specialities within the hospital	Not clearly stated. (Targeted referrals included patients referred via the 2WW scheme and non-2WW referrals)	The RDC in this study was established based on National Institute of Clinical Excellence (NICE) recommendations for improving healthcare services for head and neck cancers. The RDC is a one-stop diagnostic service where all new target referrals for patients with suspected malignancy can receive multi-modality specialist assessment .
<i>Demyelinating disease diagnostic clinic (DDC) at University College London</i>								
Porter et al (2003).	Demyelinating disease diagnostic clinic (DDC) at the National Hospital for Neurology and Neurosurgery, University	The DDC aims to minimize the time between referral and completion of tests by carrying out tests on the same day and	The clinic is staffed by a consultant neurologist and a multiple sclerosis nurse specialist	Evoked potential (VEP) testing, magnetic resonance imaging (MRI), and blood screening	Multiple sclerosis	GP or another neurologist	GPs tend to refer patients with new neurological symptoms , lasting days or weeks with no obvious explanation . Neurologists refer difficult diagnostic	The DDC was modelled on the UK multiple sclerosis Society standards of healthcare set for the diagnostic phase. The structure of the DDC provides an appropriate setting and experienced professional support to deal with the initial psychological impact of the diagnosis and offers ongoing support through patient/family

Reference	Location & setting	Aim of the centre	Staff & facilities	Investigative procedures/services conducted	Diagnosis of interest	Referral	Referral criteria	Key underpinning elements of diagnostic centre
	College London Hospitals	providing follow-up within four weeks.					cases including suspected primary progressive disease, those with an atypical presentation and those with nonorganic symptoms	health promotion and self-management programmes. The clinic is designed to allow a 45-minute new patient appointment with the consultant neurologist and MS nurse, followed by access to visual evoked potential (VEP) testing, magnetic resonance imaging (MRI) and blood screening, as appropriate. Follow-up appointments to all patients are scheduled to allow 30 minutes with the neurologist and MS nurse followed by a further 30 minutes with the MS nurse in a quiet room. All newly diagnosed are followed up with one to one appointments with their families and have access to a structured educational programme entitled 'Working together to understand MS'.
<i>Rapid Diagnostic Centre (RDC) at Neath Port Talbot Hospital, Neath, Wales</i>								
Sewell et al (2020).	Rapid diagnostic centre (RDC), Neath Port Talbot Hospital, Wales, UK	Not stated	Consultant physician, a radiologist, a clinical nurse specialist (CNS), and a healthcare support worker (HCSW). Management and clinical guidance are provided by the RDC coordination manager and GP project lead. Two half-day clinics a week with five available clinic slots	It is unclear if the full range of investigative procedures available at the centre was reported but includes physical examination and computed tomography (CT)	Cancer	GP (primary care)	Patients with vague and/or non-specific symptoms suspicious of cancer, who do not meet criteria for referral under an urgent suspected cancer (USC) pathway	This pilot rapid diagnosis centre (RDC) allows GPs within targeted clusters to refer adults with vague and/or non-specific symptoms suspicious of cancer, who do not meet criteria for referral under an urgent suspected cancer (USC) pathway, to a multidisciplinary RDC clinic where they are seen within a week. Patients leave the clinic with either a diagnosis and management plan or further investigations booked.
<i>Community Diagnostic Service throughout the West Midlands</i>								

Reference	Location & setting	Aim of the centre	Staff & facilities	Investigative procedures/services conducted	Diagnosis of interest	Referral	Referral criteria	Key underpinning elements of diagnostic centre
Pallan et al (2005).	Community based, mobile diagnostic ultrasound service , in a primary care area in the West Midlands, England, UK	Not stated	The service is staffed by an independent radiographer	Ultrasound scans included abdominal, pelvic, transvaginal, renal, and prostate	Not specified	GP (primary care)	Not stated	The mobile diagnostic ultrasound service was radiographer-led and was provided to GPs by an independent radiographer.

Appendix 2: Potential overlap of data for the studies conducted in Spain

Spanish Studies: Includes 11 individual studies investigating four diagnostic centres NB: Groupings are by hospital site					
Reference	Study duration	Population	Outcomes	Study comparison details	Information on potential data crossover
Hospital Clínic de Barcelona – Barcelona - described as an 885 bed tertiary hospital with a reference population of around 550,000. Earlier sources describe it as a 840 bed tertiary hospital with a reference population of around 540,000					
Bosch et al (2021). A comparative cost analysis between two quick diagnosis units of different levels of complexity. Journal of Comparative Effectiveness Research, 10(5), pp.381-392.	2009 to 2017	Aged ≥18 years attending the two QDUs between January 2009 and January 2017 Sample size: 407 patients from each unit (the tertiary unit sample were randomly selected from 6,960 consecutive patients)	Participant characteristics Referral source Referral reason Number of visits Time to diagnosis Diagnosis Mean cost per visit Mean cost per patient Direct and structural costs Indirect costs Personnel costs Diagnostic investigation costs	QDU of Hospital Clínic (tertiary unit) vs QDU of Hospital Plató (secondary unit)	Unclear
Bosch et al (2020). What is the relevance of an ambulatory quick diagnosis unit or inpatient admission for the diagnosis of pancreatic cancer? A retrospective study of 1004 patients. Medicine, 2020, vol. 99, num. 11, p. e19009.	2005 to 2018	Aged ≥ 18 years with diagnosis of pancreatic adenocarcinoma referred to both settings Sample size: 508 patients from QDU and 496 inpatients	Participant characteristics Referral source Time to first visit Time to diagnosis Risk factors for cancer Predictors of hospitalisation Mean tumour size Tumour site Cancer stage on presentation Charlson comorbidity index Surgical characteristics Mean cost per hospital stay	QDU of Hospital Clínic vs inpatient setting at same hospital	Potential QDU data overlap with Bosch 2021 (i.e pancreatic ca data only between 2009 and 2017)

			Mean cost per visit Mean cost per patient Cost of diagnostic tests Personnel costs Costs of catering/cleaning/laundry/travel/maintenance/administrative/depreciation/consultation		
Montori-Palacín et al (2017). Quick outpatient diagnosis in small district or general tertiary hospitals: A comparative observational study. Medicine 96 (22).	2009 to 2016	Aged ≥18 referred to both settings (chosen randomly) Sample size: 866 participants, 336 from QDU1 and 530 from QDU2	Participant characteristics Referral source Referral reason Time to first visit Number of visits Time to examination Time to diagnosis Diagnosis Diagnostic tests Onward referrals	QDU1 (Hospital Plató) vs QDU2 (Hospital Clínic)	Potential QDU1 and 2 data overlap with Bosch 2021 (i.e patient data between 2009 and 2016) – note that cases were chosen randomly
Bosch et al (2018). Time to diagnosis and associated costs of an outpatient vs inpatient setting in the diagnosis of lymphoma: a retrospective study of a large cohort of major lymphoma subtypes in Spain BMC cancer, 18(1), pp.1-15.	2006 to 2016	Aged ≥18 years with lymphoma (4 types) Sample size: 1,779 patients. 1,184 outpatients (688 from QDU1 and 496 from QDU 2) and 535 inpatients	Patient characteristics Referral source Time to first visit Number of visits Time to examination Time to diagnosis Diagnostic tests Diagnosis Onward referral Mean cost per hospital stay Mean cost per visit Mean cost per patient Cost of diagnostic tests Cost saving from hospitalisation Personnel costs	QDU1 (Hospital Clínic) vs inpatient wards (within Hospital Clínic) vs QDU2 of hospital of Bellvitge	Potential QDU1 data overlap with Bosch 2021 (i.e lymphoma data only between 2009 and 2016)
Brito-Zerón et al. (2014). Diagnosing unexplained fever: can quick diagnosis units replace inpatient hospitalization? European Journal of Clinical	2008 to 2011	All consecutive patients referred to the QDU between November 2008 and April 2011 due to undiagnosed fever Sample size: 344 patients, 176 from QDU and 168 controls (internal medicine department)	Participant characteristics Referral source Referral reason Number of visits Time to diagnosis Diagnosis Length of hospital stay	QDU (Hospital Clínic) vs internal medicine department (unclear if same wards as in Bosch 2020 and Bosch 2018)	Potential QDU data overlap with Bosch 2021, i.e FUN data only between 2009 and 2011

Investigation, 44(8), pp.707-718.			Diagnostic tests Death during evaluation Onward referrals Mean cost per hospital stay Mean cost per visit Mean cost per patient		
Bosch, Jordán and López-Soto (2013). Quick diagnosis units: avoiding referrals from primary care to the ED and hospitalizations The American Journal of Emergency Medicine, 31(1), pp.114-123	2006 to 2012	Consecutive patients attending the QDU and patients admitted to the internal medicine service (randomly chosen) between September 2006 and January 2012 Sample size: 4,170 QDU patients and 3.030 hospitalised patients	Participant characteristics Referral source Referral reason Referral appropriateness Time to first visit Number of visits Referral patterns over time Time to diagnosis Diagnosis Length of hospital stay Death during evaluation Onward referrals Mean cost per hospital stay Mean cost per process Mean cost per visit Patient preferences	QDU patients (Hospital Clínic) vs patients admitted to the internal medicine service	QDU data overlap with Bosch 2012a (2,000 consecutive patients evaluated between 2007 and 2010)
Bosch et al (2012a). Quick diagnosis units versus hospitalization for the diagnosis of potentially severe diseases in Spain Journal of Hospital Medicine, 7(1), pp.41-47	2006 to 2010	Consecutive QDU patients evaluated between December 2007 and July 2010 and patients diagnosed with anaemia (n = 548), cachexia-anorexia syndrome (n = 458), febrile syndrome (n = 240), and adenopathies or palpable masses (n = 208) admitted to the internal medicine department between September 2006 and June 2010. Sample size: 2,000 QDU patients and 1,454 patients admitted to the internal medicine department	Participant characteristics Referral source Referral reason Time to first visit Number of visits Time to diagnosis Diagnosis Length of hospital stay Charlson comorbidity index Hospital bed days saved Onward referrals Cost per hospital stay Cost per process Cost per visit Patient satisfaction Patient preferences	QDU patients vs patients admitted to the internal medicine department	QDU data overlap with Bosch, Jordán and López-Soto 2013 (2,000 consecutive patients evaluated between 2007 and 2010)

Bosch et al (2012b). Comparison of Quick Diagnosis Units and Conventional Hospitalization for the Diagnosis of Cancer in Spain: A Descriptive Cohort Study Oncology, 83(5), pp.283-291.	2008 to 2010	QDU patients with both initially suspected and ultimately confirmed (pathologically proven) cancer evaluated between November 2008 and April 2010. Also included patients newly diagnosed with cancer admitted to the internal medicine department Sample size: 169 (62.8% of 269 consecutive patients evaluated for inclusion) QDU patients, and 53 Hospitalised patients	Patient characteristics Referral source Reason for referral/consultation Time to first visit Number of visits Time to diagnosis Length of hospital stay Diagnosis Onward referral Mean cost per hospital stay Mean cost per visit Mean cost per process	QDU (Hospital Clínic) vs internal medicine department	potential QDU data overlap with above studies by Bosch et al.
Bosch et al (2012c). Quick diagnosis units or conventional hospitalisation for the diagnostic evaluation of severe anaemia: A paradigm shift in public health systems? European Journal of Internal Medicine, 23(2), pp.159-164.	2006 to 2010	Consecutive patients with severe anaemia attended by the QDU and consecutive patients with the same diagnosis admitted to the internal medicine department Sample size: 282 cases from QDU, 252 hospitalised patients	Participant characteristics Referral source Referral reason Time to first visit Number of visits Time to examination Time to diagnosis Diagnosis Length of hospital stay Charlson morbidity index Diagnostic tests Treatment received at unit Onward referrals Mean cost per hospital stay Mean cost per process Mean cost per visit Patient satisfaction Patient preferences	QDU (Hospital Clínic) vs internal medicine department	Likely overlap of patient data with above studies
Bosch et al (2011). Outpatient Quick Diagnosis Units for the evaluation of suspected severe diseases: an observational, descriptive	2008 to 2010	Consecutive patients evaluated in the QDU Sample size: 1,000 QDU patients and ?150 patients admitted to internal medicine department	Participant characteristics Referral source Referral reason Referral appropriateness Time to first visit Number of visits	QDU (Hospital Clínic) vs internal medicine department	Likely overlap of patient data with above studies

study . Clinics, 66(5), pp.737-741.			Time to diagnosis Diagnosis Length of hospital stay Diagnostic tests Hospital bed days saved Onward referral Mean cost per hospital stay Mean cost per process Mean cost per patient Patient satisfaction Patient preference		
Bellvitge Hospital – Barcelona - described as a 750 bed tertiary hospital with a reference population of around 350,000					
Sanclemente-Ansó et al (2016). Cost-minimization analysis favors outpatient quick diagnosis unit over hospitalization for the diagnosis of potentially serious diseases . Eur J Intern Med; 30:11-17. doi: 10.1016/j.ejim.2015.12.015	2008 to 2012	Patients diagnosed with severe anaemia, lymphoma, and lung cancer selected from consecutive patients referred to the unit between March 2008 and June 2012 and those electively hospitalised at the Internal Medicine Department of the hospital for diagnostic workup during the same period and who had the same final diagnoses. Sample size: 195 QDU patients and 237 Internal Medicine department patients	Referral source Number of visits Time to diagnosis Diagnosis Length of hospital stay Diagnostic test Mean cost per hospital stay Mean cost per patient Direct and structural costs Indirect costs Personnel costs Diagnostic investigation costs Mean cost saving per patient Overall cost saving Diagnostic investigation cost saving Hospitalisation cost saving Cost saving per patient	QDU (Bellvitge) vs internal medicine department	Potential QDU data overlap with Bosch 2018 (QDU2)

APPENDIX 3: Resources searched during Rapid Review Searching

Table 6: Resources searched

Resource	Success or relevancy of the retrieval
Priority COVID resources for reviews	
Cochrane COVID Review Bank (Browse list of titles) https://covidreviews.cochrane.org/search/site	Searched, nothing found
WHO Global Coronavirus Database - secondary evidence (Use filter options to limit search results to secondary evidence under "Type of Study" and English language under "Language") https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/	Searched, results found
L*OVE COVID - systematic reviews (Links to the systematic reviews section) https://app.iloveevidence.com/loves/5e6fdb9669c00e4ac072701d?population=5e7fce7e3d05156b5f5e032a&classification=systematic-review	Searched, nothing found
VA-ESP (Use "search this page" to limit to a concept. A second (or subsequent) concept can be applied to the results list by using "search this page" again.) https://www.covid19reviews.org/index.cfm	Searched, nothing found
Additional COVID resources for reviews (Tailor the list according to the topic and potential evidence base. In some cases, it may be preferable to scan the main (generic) source rather than COVID-19 specific product; listed under secondary research)	
LitCovid (Subset of PubMed. Abstracts do not download, but if using EndNote or Mendeley you can use the 'Find Reference Updates' feature to import the abstracts from PubMed. Covered by VA-ESP for reviews) https://www.ncbi.nlm.nih.gov/research/coronavirus/	Not searched, not relevant
EPPI-Centre - Living map of the evidence of studies on COVID-19 identified in MEDLINE and EMBASE, that groups the evidence into broad themes (Select "Access current version" below first picture) https://eppi.ioe.ac.uk/cms/Projects/DepartmentofHealthandSocialCare/Publishedreviews/COVID-19Livingssystematicmapofthevidence/tabid/3765/Default.aspx	Not searched, not relevant
EUnetHTA – COVID 19 response (Not a searchable database but lists of evidence reviews covering diagnostics and treatments) https://eunetha.eu/services/covid-19/	Not searched, not relevant
Trip – for guidelines (TripPro can be accessed by an institutional based subscription based via institution, otherwise use Trip) As a COVID-19 resource for guidelines – search for (covid-19 OR covid19 OR sars-cov-2 OR sars-cov2 OR sarscov2) and the topic/concept of interest, then filter by UK guidelines, covers NICE and SIGN. Can also filter for non-UK guidance. https://www.tripdatabase.com/	Not searched, not relevant
For topic specific / focused review questions	
COVID-END – Evidence summaries (McMaster Health Forum) (Incorporates multiple COVID-19 resources, including many listed here. May be useful for topic specific/focused questions; may not be useful for border questions) https://www.mcmasterforum.org/networks/covid-end	Not searched, not relevant
COVID-19 Evidence Alerts from McMaster PLUS™ Usefulness dependent on topic; may not be user friendly for broad/complicated questions https://plus.mcmaster.ca/COVID-19/	Not searched, not relevant
Additional COVID resources for primary studies	

WHO Global Coronavirus Database - primary studies (Use filter options to limit search results to primary evidence under "Type of Study" and English language under "Language") https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/	Not searched, not relevant
L*OVE COVID - primary studies https://app.iloveevidence.com/loves/5e6fdb9669c00e4ac072701d?population=5e7fce7e3d05156b5f5e032a&classification=primary-study	Not searched, not relevant
Cochrane COVID-19 Study Register https://covid-19.cochrane.org/	Not searched, not relevant
LitCovid (Subset of PubMed. Abstracts do not download, but if using EndNote or Mendeley you can use the 'Find Reference Updates' feature to import the abstracts from PubMed) https://www.ncbi.nlm.nih.gov/research/coronavirus/	Not searched, not relevant
Secondary resources for reviews relevant to local/UK context	
United Kingdom Health Security Agency (UKHSA) – COVID-19 Rapid Reviews https://ukhsalibrary.koha-ptfs.co.uk/covid19rapidreviews/	Searched, nothing found
NICE resources for COVID reviews https://www.nice.org.uk/guidance/conditions-and-diseases/respiratory-conditions/covid19/products?Status=Published <i>Any queries regarding ongoing or planned reviews contact Chris Connell:</i> Chris.Connell@nice.org.uk	Searched, nothing found
Healthcare Improvement Scotland – COVID-19: Evidence for Scotland (not a searchable database but a lists Once for Scotland guidance, rapid evidence reviews, NICE rapid guidelines evidence covering diagnostics and treatments) http://www.healthcareimprovementscotland.org/our_work/coronavirus_covid-19/evidence_for_scotland.aspx	Searched, nothing found
Ireland, HSE Library, COVID-19 Summaries of Evidence not a searchable database but a list of all summaries of evidence that HIQA have been asked to address) https://hselibrary.ie/covid19-evidence-summaries/	Searched, nothing found
HIQA Health Information and Quality Authority (Ireland) – Rapid reviews https://www.hiqa.ie/reports-and-publications/health-technology-assessments?tid_1=All&field_hita_topics_target_id=112	Searched, nothing found
SAGE (if relevant) https://www.gov.uk/government/organisations/scientific-advisory-group-for-emergencies	Not searched, not relevant
Secondary resources for reviews produced by key international organisations	
NCCMT COVID-19 rapid reviews (Canada) https://www.nccmt.ca/covid-19/covid-19-rapid-evidence-service	Searched, nothing found
ECDC European Centre for Disease Prevention and Control (COVID-19 outputs) https://www.ecdc.europa.eu/en/publications-data	Searched, nothing found
CDC centre for Disease Control and Prevention - Guidance for COVID-19 (US) https://www.cdc.gov/coronavirus/2019-ncov/communication/guidance.html	Searched, nothing found
AHRQ Agency for Healthcare Research and Quality (US) (Note: only 1 of these covid-19 reviews are actively being kept updated as a living review: "Antibody Response Following SARS-CoV-2 Infection and Implications for Immunity: A Living Rapid Review") https://www.ahrq.gov/coronavirus/health-systems-research.html	Searched, nothing found
NASEM The National Academy of Sciences Engineering Medicine - Coronavirus Resources Collection (US) https://www.nap.edu/collection/94/coronavirus-resources	Searched, nothing found

Australian National COVID-19 Clinical Evidence Task Force - Living Guidelines; mainly treatment https://covid19evidence.net.au/ (also incorporated in Trip)	Searched, nothing found
Secondary research resources for (non-COVID-19) reviews (Tailor the list according to the topic and potential evidence base, talk to stakeholder before proceeding with this type of search)	
Trip (TripPro can be accessed by an institutional based subscription based via institution, otherwise use Trip) https://www.tripdatabase.com/	Searched, results found
Cochrane Database of Systematic Reviews (CDSR) https://www.cochranelibrary.com/cdsr/reviews	Searched, results found
Campbell Collaboration https://www.campbellcollaboration.org/better-evidence.html	Searched, nothing found
JBIC (via OVID) (Subscription based service – WCEBC has a subscription)	Not searched, maybe relevant
Epistemonikos https://www.epistemonikos.org/en/advanced_search https://www.epistemonikos.org/ (for the simple search)	Searched, results found
International HTA database (INAHTA-HTA) (for technology & intervention questions only) https://database.inahta.org/	Searched, nothing found
PROSPERO https://www.crd.york.ac.uk/prosperto/	Searched, nothing found
PubMed/MEDLINE Filter by systematic reviews, reviews or meta-analysis once search undertaken https://pubmed.ncbi.nlm.nih.gov/	Searched, results found
Additional resources searched (Add in any additional resources that have been used, e.g. Scopus, HMIC, Social Care Online)	
Google Advanced Search https://www.google.co.uk/advanced_search	Not searched, maybe relevant
Google Scholar https://scholar.google.com/	Searched, results found
Google	Searched, results found
EMBASE	Searched, results found

Appendix 4: Search strategy used for MEDLINE

Set#	Searched for	Results
S1	((TI,AB("community diagnos* centre*")))	1
S2	((TI,AB("community diagnos* clinic*")))	1
S3	((TI,AB("community diagnos* hub*")))	1
S4	((TI,AB("community diagnos* unit*")))	0
S5	((TI,AB("rapid diagnos* unit*")))	16
S6	((TI,AB("rapid diagnos* clinic*")))	12
S7	((TI,AB("rapid diagnos* centre*")))	4
S8	((TI,AB("rapid diagnos* hub*")))	0
S9	((TI,AB("mobile diagnos* hub*")))	0
S10	((TI,AB("mobile diagnos* clinic*")))	0
S11	((TI,AB("mobile diagnos* centre*")))	0
S12	((TI,AB("mobile diagnos* unit*")))	8
S13	((TI,AB("multidisciplinary diagnos* unit*")))	0
S14	((TI,AB("multidisciplinary diagnos* hub*")))	0
S15	((TI,AB("multidisciplinary diagnos* centre*")))	4
S16	((TI,AB("multidisciplinary diagnos* clinic*")))	2
S17	((TI,AB("mobile healthcare unit*")))	2
S18	((TI,AB("accelerate coordinate evaluate")))	3
S19	S18 OR S17 OR S16 OR S15 OR S14 OR S13 OR S12 OR S11 OR S10 OR S9 OR S8 OR S7 OR S6 OR S5 OR S4 OR S3 OR S2 OR S1	52
S20	((TI,AB("diagnos* centre*")))	408
S21	((TI,AB("diagnos* clinic")))	282
S22	((TI,AB("diagnos* clinics")))	86
S23	((TI,AB("diagnos* hub*")))	7
S24	((TI,AB("diagnos* unit*")))	462
S25	S24 OR S23 OR S22 OR S21 OR S20 OR S19	1247°
S26	(MJMESH.EXACT("Diagnostic Services"))	1211°
S27	S26 OR S25	2436°